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ABSTRACT 
Premature cardiovascular disease (CVD) complicates chronic systemic inflammatory disease, 
and is initiated by endothelial dysfunction. Despite an ever-improving array of medications to 
treat these diseases, how to prevent CVD is not known. Studying the actions of endogenous 
mediators of endothelial cytoprotection and of disease-modifying drugs might establish how 
best to protect patients with systemic inflammatory diseases from atherosclerosis, if specific 
beneficial effects on vascular endothelium could be demonstrated.  
High flow laminar shear stress (LSS) and vascular endothelial growth factor (VEGF) are two 
well known endogenous drivers of endothelial cytoprotection. Both can induce expression of 
protective genes but it is not known how confluent endothelial cells (EC) respond to VEGF 
when conditioned with LSS. Methotrexate (MTX) is the most widely prescribed treatment for 
rheumatoid arthritis and clinical data suggests that it reduces CV mortality. Known mechanisms 
of action of MTX result in intracellular accumulation of activators of AMP-activated protein 
kinase (AMPK). AMPK regulates cytoprotective genes in EC and its activation is associated 
with diverse desirable effects.  
I hypothesised that EC conditioned with LSS would be primed to respond to VEGF, resulting in 
a synergistic induction of cytoprotective genes. Secondly I investigated whether MTX exerts 
beneficial protective effects on vascular endothelium via activation of AMPK, which enhance 
endothelial resistance to injury. 
Studies of human umbilical vein EC (HUVEC) exposed to LSS showed that responses to VEGF 
are not enhanced in these conditions. However, MTX phosphorylated AMPKαThr172 and induced 
expression of several cytoprotective genes, notably manganese superoxide dismutase (MnSOD). 
The addition of folic acid did not alter this; and it was also preserved when HUVEC were pre-
treated with TNFα to mimic dysfunctional endothelium. siRNA depletion of AMPK attenuated 
MTX-mediated MnSOD induction. MTX treatment led to AMPK-dependent phosphorylation of 
the transcription factor CREB
Ser133
. siRNA depletion of CREB also reduced MnSOD induction 
by MTX, and chromatin immunoprecipitation demonstrated binding of CREB to the MnSOD 
promoter in MTX-treated samples. Moreover, MTX protected HUVEC against apoptosis 
induced by glucose deprivation, demonstrating the functional importance of this pathway. 
Finally, treatment of the murine (BXSB x NZW)F1 SLE model of inflammatory vasculopathy 
with MTX improved the intramyocardial arterial vasculopathy and reduced end-organ damage, 
increased aortic MnSOD and phosphorylated AMPKαThr172, and reduced ICAM-1 expression.  
I have shown that MTX activates an AMPK-CREB pathway in vascular endothelium leading to 
enhanced expression of cytoprotective genes and protection against apoptosis in vitro and 
inflammatory vascular injury in vivo. This novel mechanism may explain its observed benefits 
in reducing CVD in chronic systemic inflammation. 
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1 INTRODUCTION 
1.1 Atherosclerosis 
1.1.1 Epidemiology 
Atherosclerosis is a chronic disease of arterial vessel walls, leading to complications including 
myocardial and cerebral infarcts and aortic aneurysms. It is the commonest cause of death worldwide, 
with ischaemic heart disease and stroke together responsible for 22% of deaths in the world in 
2011[1]. In the UK, according to the British Heart Foundation, cardiovascular disease (CVD) is 
responsible for more than a quarter of all deaths in the country each year: approximately 161 000. 
Coronary artery diease affects around 2.3 million people in the UK, and 103 000 have a myocardial 
infarct (MI) each year. The risk factors that determine the prevalence of atherosclerotic diseases were 
first demonstrated in the Framingham heart study and include cigarette smoking, hypertension, 
hypercholesterolaemia and diabetes mellitus[2-4]. More recently, it was discovered that chronic 
inflammation is also an important risk factor. Rates of CVD in the general population correlate with 
markers of systemic inflammation such as C-reactive protein (CRP)[5, 6], and an increased incidence 
of CVD is seen in many chronic inflammatory conditions[7]. 
1.1.2 Pathogenesis 
Atherosclerosis affects predominantly large and medium-sized elastic and muscular arteries. The 
disease is slowly progressive and develops over several decades, a fact which places limitations on 
what can be learnt from in vivo models of the illness. The initiating event is injury to the endothelium, 
the monolayer lining all blood vessels, leading to endothelial dysfunction (discussed in detail in 
Section 1.3)[8]. Features of endothelial dysfunction include expression of cell adhesion molecules and 
increased permeability. These changes promote the adhesion and migration of leukocytes, particularly 
monocyte/ macrophages and T-lymphocytes, and the accumulation of cholesterol in the form of low-
density lipoprotein (LDL) in the subendothelial intimal space, resulting in the earliest atheroma 
lesion: the fatty streak. Over the course of several years, activated macrophages engulf the LDL, 
which has been modified by oxidation, via their scavenger receptor. If macrophage cholesterol 
metabolism and efflux pathways become overwhelmed, foam cells are formed.  
A chronic inflammatory process is then established in the vascular wall, leading to a self-perpetuating 
cycle whereby leukocytes secrete pro-inflammatory cytokines and chemokines that induce further cell  
adhesion molecule expression and promote chronic endothelial dysfunction, leading to greater 
recruitment of leukocytes and lipid. Smooth muscle cells and fibroblasts are also induced to migrate 
into the lesion and form an extracellular matrix that becomes a fibrous cap to the lesion, thus 
producing an atherosclerotic plaque. This protrudes into the lumen, causing a stenosis. This may 
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progress to a critical point at which ischaemia of the downstream tissue occurs; or the plaque may 
rupture acutely resulting in thrombus formation, complete vessel occlusion and tissue infarction[9]. 
1.1.3 Aetiology 
As described above, atherosclerosis begins with injury to the endothelium, and thus it is factors that 
influence on endothelial cell (EC) biology that determine whether atheroma will develop. Three 
significant factors are hyperlipidaemia, pattern of blood flow and a chronic inflammatory milieu[10], 
although there are a plethora of others, comprehensively reviewed elsewhere[9]. 
Older theories of the causes of atherosclerosis emphasised lipid deposition within the plaque as the 
hallmark of the condition. Hyperlipidaemia is a key pre-requisite for the formation of atheroma; and 
evidence for this comes not only from the Framingham heart study, but also from the well known in 
vivo models of the disease such as the low density lipoprotein receptor (LDLR)
-/-
 and apolipoprotein E 
(ApoE)
-/-
 mice, which largely rely on hyperlipidaemia to drive atherogenesis. However, 
hyperlipidaemia cannot be the sole factor: 50% of MI occur in patients with normal serum cholesterol. 
It does not provide an explanation for the initiation of atherosclerosis, nor why intra-luminal lipid 
accumulates preferentially at branch points.  
Atheroma forms exclusively in arteries, and has a clear geographical distribution. It has a predilection 
for parts of the arterial tree exposed to disturbed flow, such as branchpoints (e.g. the carotid 
bifurcation) and tight curves (e.g. the aortic arch), while those areas exposed to pulsatile laminar flow 
are rarely affected[11]. This suggests that the blood flow patterns and the shear stress exerted on the 
vessel wall are critical for determining susceptibility to atherogenesis. As it is the endothelium that is 
exposed to and senses shear stress, it is thought to be the mediator of this phenomenon, which will be 
discussed in section 1.4. Thus, in the "response to injury" hypothesis of Ross, turbulent blood flow 
renders the endothelium susceptible to injury and less able to mount a protective response when 
exposed to harmful factors including LDL, hyperglycaemia, pro-inflammatory cytokines and 
hyperhomocysteinaemia[8]. Endothelial dysfunction, allowing the tracking of leucocytes and lipid 
into the subendothelial space, therefore predominantly occurs here. 
That inflammation is important for the initiation of atheroma and for the perpetuation of lesions is 
supported by a multitude of differing lines of evidence. Firstly, atherosclerosis is more common in 
people with raised markers of systemic inflammation such as CRP[5]. Secondly, atherosclerosis is 
more common in patients with other chronic systemic inflammatory diseases such as rheumatoid 
arthritis (RA) and systemic lupus erythematosus (SLE)[12]. Thirdly, a world-wide genetics 
consortium has shown that individuals with an interleukin (IL)-6 receptor polymorphism that reduces 
IL-6 signalling have a reduced incidence of coronary heart disease[13]. Finally, patients with raised 
CRP benefit more from aspirin in terms of cardiovascular risk reduction than those with normal 
values[5], while the JUPITER trial showed that  rosuvastatin reduced CV events in patients with 
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normal serum cholesterol but raised CRP, measured by high-sensitivity assay[14]. These two findings 
suggest that risk reduction is being achieved through a reduction in inflammation rather than solely 
through anti-platelet effects or reductions in serum cholesterol, and that reducing inflammation could 
itself be a useful strategy to tackle atherosclerosis.  
1.1.4 Current treatment paradigms 
Treatment for atherosclerosis involves two major strategies. Firstly, disease progression can be 
reduced by modification of risk factors such as smoking, hypertension, dyslipidaemia, treatment of 
diabetes, diet and exercise. Secondly, atherosclerotic plaques that have enlarged until they cause 
symptomatic restriction of blood flow, or those that rupture acutely, are dealt with by intervention to 
reopen the blocked vessel, through percutaneous coronary intervention or thrombolysis, or by bypass 
graft surgery if medical intervention is unsuccessful or not feasible. 
There is no treatment as yet specifically targetting the process of atherogenesis itself. However, given 
the strong evidence suggesting that atherosclerosis is a chronic inflammatory condition, two new trials 
have recently started recruiting patients. These are designed to test the hypothesis that atherosclerosis 
is a chronic inflammatory disease of large arteries, and will involve treating patients who have already 
suffered myocardial infarcts and who have raised CRP or the metabolic syndrome with methotrexate 
(MTX)[15] or canakinumab[16]. Canakinumab is a monoclonal antibody that inhibits IL-1β, an 
archetypal pro-inflammatory cytokine. MTX is a well-established treatment for RA and other chronic 
inflammatory diseases, with a wide variety of anti-inflammatory actions,and will be discussed in 
detail later in the chapter. The aim of these trials is to show whether direct targetting of inflammation 
can prevent complications of atherosclerosis, thus proving that atherosclerosis is a disease perpetuated 
by inflammation. 
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1.2 Atherosclerosis in chronic systemic inflammation 
As described earlier, atherosclerosis is an inflammatory condition, and it occurs more commonly in 
people with other chronic inflammatory diseases. This section discusses the increase in atherosclerosis 
associated with systemic inflammation, and the mechanisms underlying this in RA and SLE. 
1.2.1 Rheumatoid arthritis 
RA is a chronic systemic inflammatory condition characterised by symmetrical polyarticular synovitis 
that progresses to joint destruction. It affects approximately 0.8% of the general population in the 
UK[17]. Central to its pathogenesis is systemic and synovial synthesis of pro-inflammatory cytokines 
such as tumour necrosis factor (TNFα), IL-6 and IL-17, B and T-lymphocyte activation, and 
production of auto-antibodies including rheumatoid factor (RF) and anti-citrullinated peptide 
antibodies (ACPA)[18]. 
CVD is 50% more common in patients with RA than in age and sex-matched healthy controls and is 
the major cause of death in this illness[19]. In some studies the increased incidence is up to 4-fold, 
making RA equivalent to diabetes mellitus as a risk factor for MI and stroke[20, 21].  
The mechanisms underlying the increased incidence of CVD in RA are heterogeneous. Firstly, the 
traditional Framingham risk factors for atherosclerosis are more common in patients with RA, 
although this does not explain the extent of the increased incidence[22]. Tobacco smoking is a risk 
factor for the development of ACPA and of seropositive RA[23, 24], but smoking status does not 
precisely correlate with CV events in RA and thus cannot fully explain the increase (REF). Insulin 
resistance and the metabolic syndrome are also more prevalent in RA[25, 26], and may be related to 
high circulating levels of  pro-inflammatory cytokines[27]. Thirdly, RA is associated with a distinct 
pattern of dyslipidaemia, with low high-density lipoprotein (HDL) and LDL cholesterol and raised 
triglycerides[28, 29]. HDL in RA can be abnormal, with higher levels of oxidised pro-inflammatory 
HDL. This could promote atherogenesis through decreased reverse cholesterol transport[30] and 
decreased paraoxonase activity, an antioxidant enzyme present in HDL particles that normally 
prevents HDL and LDL oxidation[31]. 
In addition to the increased incidence of traditional risk factors for atherosclerosis, there are disease-
specific mechanisms at work that promote atherosclerosis in RA. These include the effects of long-
term pro-inflammatory cytokine exposure, autoantibodies and a T-lymphocyte subset specific to RA. 
The principal pro-inflammatory cytokines that are thought to be involved in vascular injury in RA are 
TNFα, IL-6 and IL-17. Serum TNFα levels are increased in RA and correlate with coronary artery 
calcification[32]. TNFα is likely to be important in the initiation and progression of atheromatous 
lesions in the general population as well as in RA, as its actions include induction of endothelial cell 
adhesion molecules and chemotactic proteins that promote mononuclear cell invasion of the sub-
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endothelial space, and macrophage scavenger receptor expression to promote foam cell formation[33]. 
RA serum can induce similar changes in macrophages and its effects can be partially reversed by anti-
TNFα or IL-6 antibodies, emphasising their importance for endothelial injury in RA[33]. 
IL-6 is the most abundant cytokine in rheumatoid synovium and an important contributor to disease 
pathogenesis. In RA, increased IL-6 correlates with increased CVD, independently of traditional 
variables[32]. It is also found in human atheromatous plaques in non-RA patients[34] and exacerbates 
atherogenesis in ApoE
-/-
 mice[35]. 
IL-17 is pathogenic in RA synovial inflammation and may also be important in RA-associated CVD. 
Levels of IL-17 are an independent predictor of poor microvascular endothelial function and 
macrovascular arterial compliance in RA patients with stable disease[36]. IL-17 blockade protects 
against atherogenesis in LDLR
-/-
 mice[37]. Mechanistically, the combination of IL-17 and TNFα 
together on EC appears to have a synergistic pro-inflammatory effect and induces pro-thrombotic 
gene expression[38]. 
Autoantibody production is a central feature of RA. The presence and titre of RF has been associated 
with CV mortality in the general population, after controlling for systemic inflammatory response 
markers such as erythrocyte sedimentation rate (ESR)[39]. A correlation between RF and ACPA and 
impaired endothelial function and carotid intima-media thickness has been reported but not all studies 
agree[40-42]. It remains unclear whether rheumatoid auto-antibodies have a direct role in 
atherogenesis or are solely markers of disease severity and thus correlate with development of CVD. 
Finally, the presence of a subset of T-cells (CD4+ve CD28-ve), which are associated with more 
aggressive disease in RA,  has been reported to correlate with endothelial function and carotid intima-
media thickness[43]. They have also been found in patients suffering unstable angina but not stable 
angina, possibly indicating a common pathology linking RA and vulnerable atherosclerotic 
plaques[44]. However, it is not known whether this T-cell population plays a direct role in 
atherosclerotic plaque development in RA patients. 
1.2.2 Systemic lupus erythematosus 
SLE is a multi-system autoimmune disorder with widely varying clinical features caused by immune-
mediated damage to internal organs. It occurs predominantly in pre-menopausal women, a population 
generally thought to be protected against CVD. Despite this, an increased incidence of CVD is a 
prominent complication of the condition[45]. However, active SLE is not strongly associated with 
increased canonical pro-inflammatory markers such as CRP that correlate in both RA and the general 
population with CVD risk. This suggests that the mediators of increased CVD in SLE differ from 
those that operate in RA and the general population[12]. 
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SLE in young women is associated with an up to 50 fold increased relative risk of CVD[46]. A bi-
modal distribution of mortality is reported in the disease, with the later peak thought to be due 
predominantly to atherosclerosis[47]. As with RA, increased risk of CVD is seen with longer disease 
duration, supporting the idea that long term exposure to the immune abnormalities of SLE promote 
atherogenesis[48]. Abnormalities in endothelial function can appear early in the course of disease[49] 
and a substantial proportion have evidence of subclinical atherosclerosis[50]. 
There are diverse reasons for the increased incidence of CVD in SLE. Traditional Framingham risk 
factors are important but do not account fully for the extent of atherosclerosis[51]. Smoking appears 
to be the traditional risk factor with the biggest contribution[52]; but there is also a high incidence of 
hypertension in SLE due to nephritis, and lipid profiles in SLE are frequently abnormal, with low 
HDL, raised LDL and raised pro-inflammatory HDL. The latter is more prevalent in SLE than RA 
and correlates with subclinical atherosclerosis[30]. In addition, microalbuminuruia, insulin resistance 
and hyperhomocysteinaemia may all contribute, being present with increased frequency in SLE than 
control populations[53]. 
Disease-specific factors promoting CVD in SLE include increased circulating interferon-α (IFNα) 
levels and autoantibody production. The classic pro-inflammatory cytokines such as IL-6 and TNFα 
are not so important in SLE pathogenesis as in RA, instead IFNα may play a role in driving SLE 
inflammation with increased levels seen in active disease[45]. Patients with increased IFNα-driven 
gene expression have more severe endothelial dysfunction and coronary artery calcification[54], and 
reducing Type I IFN levels in atherosclerosis-prone mice reduces plaque size[55]. This suggests that 
raised IFNα, as found in active SLE, promotes atherogenesis and that this plays a role in vascular 
injury. 
Three mechanisms have been suggested by which increased circulating IFNα may contribute to CVD 
in SLE, shown in animal and human studies. Firstly, IFNα reduces the numbers and function of 
circulating endothelial progenitor cells (EPC), thus damaging intrinsic mechanisms of vascular 
repair[55], possibly by affecting the angiogenic factors vascular endothelial growth factor (VEGF) 
and IL-1β[56]. Secondly, IFNα may have roles in plaque progression. IFNα signalling and 
plasmacytoid dendritic cells making IFNα are increased in atheromatous plaques[57]. IFNα can 
increase macrophage infiltration of vessel walls[58] and promotes foam cell formation by increasing 
oxidised LDL uptake and modfication of scavenger receptors[59]. Finally, it can also promote 
thrombosis by increasing platelet activation and platelet-leukocyte aggregation, in murine models of 
SLE[55]. 
Several groups of autoantibodies may be pertinent to the development of atherosclerosis in SLE. 
Firstly, anti-phospholipid antibodies are associated with the development of arterial thrombosis and 
titres correlate with carotid intima-media thickness[60]. However, a firm causal link with CVD has 
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not yet been shown. Secondly, antibodies to HDL and to apolipoprotein A1 (present in HDL particles) 
are found in serum from SLE patients[61]. These may interfere with the role of HDL in reverse 
choesterol transport, thus worsening plaque cholesterol deposition. Finally, titres of anti-Ro 
antibodies, one of the common antibodies to nuclear proteins found in SLE, correlate with EPC 
dysfunction, although it is not known if they have a direct pathogenic role[62]. 
1.2.3 Other chronic inflammatory disorders 
In addition to RA and SLE, an increased risk of atherosclerosis has been demonstrated in other 
chronic inflammatory conditions: either an increased incidence of coronary artery disease or of 
subclinical atherosclerosis. The relative rarity of many of these conditions means that the large 
population studies needed to show conclusively that rates of CVD are increased are difficult to 
perform, hence, in many cases, markers of subclinical disease such as carotid intima-media thickness 
have been studied. 
Both plaque psoriasis and psoriatic arthritis (PsA) increase the risk of ischaemic heart disease and 
coronary artery events in a recent meta-analysis[63] and systematic review[64]. However, the relative 
risk of CVD appears lower than that associated with RA, and neither study demonstrated an 
association with CV mortality. 
In ankylosing spondylitis (AS), a large retrospective cohort study involving 8600 Canadian patients 
demonstrated a small increase in disease-associated ischaemic heart disease and cerebrovascular 
disease. The difference between AS patients and the general population was most pronounced in 
young patients[65]. A more recent prospective study has since confirmed that ischaemic heart disease 
is more prevalent in AS compared to the general population[66]. 
A recent meta-analysis examining CVD in inflammatory bowel disease, which included 33 
observational studies containing more than 200 000 patients, showed an increased risk of ischaemic 
heart disease but not of CV mortality[67]. As with AS and PsA, the increased risk was small: a 
relative risk increase of 25-50%. 
Systemic sclerosis has recently been shown in two retrospective cohort studies to be associated with 
an increased risk of acute myocardial infarction, stroke and peripheral vascular disease[68, 69]. An 
approximate doubling in the risk was observed in both. 
Primary systemic vasculitis, particularly granulomatous polyangiitis (GPA), has been linked with 
premature atherosclerosis. Faurschou et al found a doubling in the expected rate of acute myocardial 
infarction among 200 patients with GPA[70]. 
Finally chronic infection, particuarly periodontal disease, is associated with increased rates of 
coronary atherosclerosis and carotid intima-media thickness[71, 72]. This observation also extends to 
chronic infections in general[73].  
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Thus, it can be seen that chronic inflammation, of widely differing origins, is associated with the 
development of atherosclerosis. As with RA and SLE, the mechanisms that contribute may be specific 
to each condition, but all converge on a common pathway of endothelial damage, leading ultimately 
to atherogenesis. 
1.2.4 Current strategies to reduce atherosclerosis in systemic inflammation 
Prevention of atherosclerosis in systemic inflammation is at present suboptimal. This is because the 
drivers of vascular damage in each disease are not fully understood and so cannot be specifically 
treated. Secondly, it is not clear whether the measures adopted in other chronic diseases including 
type II diabetes, modification of the Framingham risk prediction tables, can be straightforwardedly 
transferred. Finally, although treatments for SLE and RA are improving rapidly, it is not as yet clear 
whether effective treatment of the disease reduces CVD. With many of these conditions, the 
underlying immune abnormalities persist for many years longer than the overt disease phenotype[74], 
and so vascular damage could accrue even when there is outwardedly no active inflammatory disease. 
Current best clinical practice is to manage optimally the traditional risk factors for CVD. The 
European League Against Rheumatism (EULAR) recommendations in RA are to multiply the 
conventional risk prediction scores by 1.5 in patients with RA for more than 10 years or who are 
seropositive, so lowering the threshold for treatment; and to monitor modifiable risk factors such as 
dyslipidaemia on an annual basis[75]. Statins in RA reduce serum cholesterol and improve CV and all 
cause mortality in primary prevention[76]. In SLE the benefits of statins are less clear: they improve 
endothelial function in the short term, but at 2 year follow-up no improvement in coronary 
calcification score or carotid atherosclerosis was seen[77, 78]. 
Although management of RA in general has vastly improved over the last 20 years, there has as yet 
been no proof of an reduction in the rate of CV complications with improved disease management. 
However, specific medications used in the treatment of RA may be beneficial. There is good evidence 
that use of MTX is associated with a reduction in the rate of MI and of CV mortality[79]. 
Hydroxychloroquine (HCQ) improves lipid profile in RA and reduces carotid plaque in SLE [80, 81]. 
There is less conclusive evidence for other drugs, particularly leflunomide[82], probably because they 
are prescribed at lower frequency and thus research data on their effects in clinical practice is harder 
to obtain. The effects of anti-TNFα biologic agents on atherosclerosis have been studied but whether 
they lower risk or not remains unclear. A recent meta-analysis suggested a trend towards 
cardioprotection, but this was significant only in cohort studies and not in randomised controlled 
trials[83]. 
In SLE, effective disease treatment in general seems to reduce the progression of atherosclerosis. 
Lower cumulative doses of azathioprine, cyclophosphamide and prednisolone may be associated with 
more CVD in later life[48], and aortic atheroma is reduced in patients given cyclophosphamide 
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compared to those who have never received it[81]. Mycophenolate mofetil (MMF) may be beneficial: 
it reduces carotid plaque in patients with symptomatic carotid artery stenoses and reduces 
atherogenesis in LDLR
-/-
 mice crossed with lupus-prone mice[84, 85]. 
Certain other classes of drugs used to treat systemic inflammatory diseases may have harmful 
vascular effects. Non-steroidal anti-inflammatory drugs (NSAIDs) are thought to increase the risk of 
myocardial infarction in the general population, but so far have not been shown to do so in RA, 
suggesting that their anti-inflammatory effects predominate[86]. Gluocorticoid steroids have a long 
term adverse influence on glucose homeostasis and blood pressure that one would expect to worsen 
vascular risk, but are such good anti-inflammatory drugs that the overall effect on the vasculature 
remains unclear, despite decades of widespread use[12]. 
Although strategies do exist to limit CVD in inflammatory disease, these at present consist only of 
aggressively targetting the known modifiable risk factors. Although we have evidence that some 
immunosuppressive and disease-modifying drugs may reduce CVD, we have no good idea how and 
indeed whether this would be enough to lower risk to the backgound population level. There is 
therefore an outstanding need for a clinical strategy to protect the vasculature in chronic inflammatory 
disease, and given that atherogenesis begins with endothelial injury, understanding the mechanisms of 
endothelial injury and how these can be combatted would be a good place to start. 
  
 29 
 
1.3 Endothelial dysfunction 
1.3.1 Functions of normal endothelium 
The vascular endothelium forms a continuous monolayer lining the entire vasculature from 
endocardium to capillary bed, may weigh up to 1.5kg and covers between 1 and 7m
2
 in surface 
area[87]. It was originally thought simply to form a passive barrier between the bloodstream and the 
interstitium, allowing the diffusion of oxygen, nutrients and waste products. Research over the last 
few decades, however, has shown it to be a highly active tissue, central to the regulation of many 
physiological and pathological processes[88, 89]. The functions of the endothelium as they are now 
understood include:  
 Control of vasomotor tone through the secretion of vasoconstrictor (e.g. endothelin-1 and 
angiotensin II) and vasodilative (e.g. nitric oxide (NO) and prostacyclin) factors; 
 Maintenance of blood fluidity through roles in the coagulation cascade and fibrinolysis. The 
endothelium is normally coated in a glycocalyx mesh composed of heparan sulphate and 
hyaluronan which presents an anti-thrombotic surface to the bloodstream; 
 Formation of a selective barrier between bloodstream and interstitial space, permeable to 
oxygen, nutrients, waste products and other molecules as needed; 
 Angiogenesis, through the production of angiopoietin-1 (Ang-1), VEGF and platelet-derived 
growth factor (PDGF); 
 A key role in innate and adaptive immunity through regulation of leucocyte trafficking by the 
inducible expression of cell adhesion molecules including E-selectin, vascular cell adhesion 
molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1)[87-89]. 
1.3.2 Clinical features of endothelial dysfunction  
As discussed earlier, current theories of the aetiology of atherosclerosis postulate that the disease 
begins with endothelial injury, leading to endothelial dysfunction[8]. Endothelium is normally a 
quiescent tissue with low cell turnover, promoting vasodilatation through NO production and release, 
and resistant to the activation of inflammatory and thrombotic processes. Endothelial dysfunction 
denotes a change in phenotype to promote vascular inflammation, vasoconstriction and coagulation 
and its principal feature is a reduction in the bioavailability of NO, or an imbalance between NO and 
other factors that antagonise its actions[90]. It is also associated with increased reactive oxygen 
species (ROS), cell adhesion molecule expression and increased EC apoptosis[12, 91].  
Endothelial dysfunction not only precedes atherosclerosis, it is also intimately involved in the 
progression of plaque formation[8]. Importantly from a clinical perspective, it is detectable in 
asymptomatic individuals without clinically evident atherosclerosis[92], independently predicts 
ischaemic events[93], and is reversible[94]. Identifying successful ways to combat endothelial 
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dysfunction therefore holds promise as a way to retard the development and progression of 
atherosclerosis. 
The causes of endothelial dysfunction are essentially the same pathogenic processes that are known to 
be associated with the development of atherosclerosis, including hypertension, hyperlipidaemia, 
diabetes mellitus, tobacco consumption, obesity, and chronic systemic inflammation. Accordingly, 
mediators such as oxidised LDL, cigarette smoke, angiotensin II, hyperglycaemia and pro-
inflammatory cytokines such as TNFα, IL-1 and IL-6 have all been demonstrated to have adverse 
effects on EC in vitro and endothelial responses in vivo that are consistent with promoting a 
dysfunctional endothelium[8, 91].  
Individuals with endothelial dysfunction are essentially asymptomatic. Clinical detection is therefore 
difficult, and the techniques to do so are time consuming and relatively invasive so thus far have been 
confined to use as research tools. There are many different ways to assess endothelial function in 
patients, reviewed comprehensively by Khan et al[90]. These include non-invasive assessment of 
flow-mediated dilatation in the brachial artery; vasodilation of the coronary vessels to acetylcholine 
infusion during coronary angiography, and assessment of the microcirculation using Laser doppler 
flowmetry combined with iontophoresis of acetylcholine. In addition, analysis of plasma levels of 
endothelial proteins such as E-selectin, thrombomodulin and von Willebrand factor has been used. 
Given the importance of endothelial dysfunction for the initiation and perpetuation of atherosclerosis, 
it is likely that an increased incidence of it contributes to the increased rate of CVD in chronic 
inflammation. Several studies have shown that endothelial dysfunction is seen in RA, in patients 
without other risk factors for CVD or clinically evident disease[95], and in patients with recent 
disease onset[96, 97] and with ostensibly well-controlled disease[98]. Endothelial dysfunction has 
also been noted in SLE[99], PsA[100] and primary systemic vasculitis[101] and can be reversed or 
improved by treatment of the disease, at least temporarily[102]. Its presence at diagnosis and in 
otherwise well-controlled disease underscores the difficulty in successfully combatting it simply by 
treating the illness itself. 
1.3.3 Pathophysiology of endothelial dysfunction 
While normal endothelium has an anti-coagulant, anti-inflammatory phenotype and exerts a tonic 
vasodilatory effect, endothelial dysfunction denotes a vascular condition that is characterised by 
vasocontriction, inflammation and predisposes towards thrombosis. This section discusses the 
pathogenic processes that lead to this. The mechanisms underlying this change include reduced NO 
availability, expression of cell adhesion molecules, increased EC apoptosis and reduced mechanisms 
of EC repair (Figure 1.1). A common feature of many of these disordered processes is increased 
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oxidative stress, which will be addressed in the next section.
 
Figure 1.1 Pathophysiology of endothelial dysfunction. 
Reduced NO bioavailability 
As it is currently understood, the central pathological characteristic of endothelial dysfunction is 
reduced NO bioavailability. NO is synthesised and released by EC and is the most physiologically 
important vasodilatory factor. It also has multiple protective functions beyond its vasomotor role, 
which relate closely to the chacteristics of normal vascular endothelium. Loss of NO therefore, in 
addition to predisposing to hypertension through vasoconstriction, leads to increased platelet 
adherence and thus thrombosis, smooth muscle proliferation and migration and thus hypertension, as 
well as atherogenesis, leucocyte adhesion and oxidative stress[91]. 
NO is formed through metabolism of L-arginine into L-citrulline and NO, catalysed by endothelial 
nitric oxide synthase (eNOS)[87]. eNOS can be activated in two ways: firstly, by binding calmodulin, 
which occurs through rises in intracellular calcium, and secondly by phosphorylation on serine 1177. 
The reaction requires two co-factors: nicotinamide adenine dinucleotide phosphate (NADPH) and 
tetrahydrobiopterin (BH4). Vasodilator hormones raise intracellular calcium and thus increase eNOS 
activity; fluid shear stress affects eNOS activity through protein kinase A (PKA) or Akt-dependent 
phosphorylation, although a number of other kinases, including AMP-activated kinase (AMPK), are 
also capable of eNOS phosphorylation on serine 1177[91]. 
The best known function of endothelial NO production is vasodilation. This occurs through diffusion 
of NO from endothelium to smooth muscle cells in the arterial media, where it activates guanylate 
cyclase, leading to a rise in cyclic guanosine monophosphate (cGMP). This mediates smooth muscle 
relaxation[87].  
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A reduction in NO bioavailability may occur through multiple mechanisms in chronic inflammatory 
conditions. Inflammation can cause shearing of the endothelial glycocalyx mesh, thus impairing NO 
release and breaking down a barrier to leucocyte adhesion[103]. Inflammation reduces expression of 
eNOS or uncouples it from BH4, so that NO is no longer the product of its reaction and superoxide is 
produced instead, thus contributing to oxidative stress[104]. Pro-inflammatory mediators such as 
TNFα and IL-6 can reduce degradation of the natural eNOS inhibitor dimethylarginine, and oxidised 
LDL increases synthesis of caveolin-1, which inhibits eNOS activation. In addition, the superoxide 
radical can react with NO to form the reactive nitrogen species peroxynitrite, a highly rective 
molecule capable of damaging BH4[105]. 
Cell adhesion molecule expression 
Upregulation of cell adhesion molecule expression is another central feature of a dysfunctional 
endothelium. The principal inducible cell adhesion molecules are E-selectin, ICAM-1 and VCAM-1, 
and they are synthesised and expressed on the luminal EC surface in response to pro-inflammatory 
mediators such as TNFα and IL-1[87]. If it occurs in arteries, this results in monocyte and T-
lymphocyte recruitment into the subintimal space, a critical step in the formation of atherosclerotic 
fatty streaks[8]. VCAM-1 is particularly important for this process[106]. TNFα binds to its p55 
receptor on the EC surface and activates the signalling pathway c-Jun n-terminal kinase (JNK) which 
then activates NFκB, the central transcription factor co-ordinating responses to pro-inflammatory 
stimuli. Activation of NFκB leads to its translocation to the nucleus and binding directly to consensus 
sequences in the promoters of E-selectin, ICAM-1 and VCAM-1, resulting in rapid induction of gene 
expression. 
Endothelial cell apoptosis 
An increased rate of EC apoptosis is another feature of endothelial dysfunction[107].  EC apoptosis is 
increased in areas of the vasculature exposed to low shear stress or disturbed flow, which are prone to 
atherogenesis[108]. EC apoptosis promotes atherosclerosis because denudation of endothelium 
exposes the basement membrane and thus potentially pro-inflammatory and pro-coagulant factors 
such as collagen and tissue factor, thus pre-disposing toward thrombosis[109]. SLE patients have 
increased rates of EC apoptosis[110] and this may reflect reduced VEGF synthesis reported in both 
the kidney and serum[111]. 
Endothelial progenitor cell dysfunction 
To counteract the effects of EC apoptosis, circulating endothelial progentior cells (EPC) are capable 
of  instigating endothelial repair, and reduced numbers and function of EPC are also seen in 
individuals with endothelial dysfunction. EPC are a subset of haemopoietic progenitor cells and 
originate in the bone marrow. They display some EC characteristics, and are capable of locating sites 
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of endothelial injury and developing into fully functional EC and influencing repair[112]. Low EPC 
numbers correlate with a higher incidence of CV events[113]. 
Both SLE and RA have been associated with reduced numbers of circulating EPC[114]. Grisar et al 
found lower levels of EPC in RA patients with active disease compared to those whose disease was 
well controlled [115]. Levels of EPC in RA patients have also been shown to correlate with other 
markers of endothelial dysfunction[116]. In SLE, even patients with inactive disease have reported to 
have reduced levels of circulating EPC[117], while disease activity correlates with impaired EPC 
function[118]. 
1.3.4 Reactive oxygen species 
Oxidative stress, an imbalance between reducing and oxidative reactions such that elevated levels of 
ROS are produced[119], is a feature common to many of the pathophysiological processes seen in 
endothelial dysfunction[87]. It was once thought to be the defining cause of endothelial dysfunction, 
atherosclerosis and even of ageing in general, but the lack of success of clinical trials of anti-oxidants 
suggests this may be over-simplistic.  
Over-production of ROS is damaging to cellular components, such as lipids, proteins and nucleic 
acids, resulting in impairment of normal cell functions. Within EC, elevated ROS can cause a 
reduction in vascular NO bioavailability, increased expression of redox-sensitive pro-inflammatory 
genes such as VCAM-1 and, if levels are overwhelming, can precipitate apoptosis[104]. However, 
oxidative stress also stimulates and regulates many cellular functions including apoptosis, growth, 
proliferation, genomic stability and vascular tone, and increasing evidence now suggests regulated 
ROS production within a physiological range is important for intracellular signalling. Therefore a 
concept is emerging of an optimal range of ROS production required for cellular homeostasis[120]. 
ROS produced by EC 
ROS produced by EC include superoxide (O2
.-
), hydrogen peroxide (H2O2), peroxynitrite (ONOO
.-
), 
hydroxyl radicals (OH
.
) and  lipid peroxides.  
Superoxide is produced by a one electron reduction of oxygen, catalysed by a number of oxidases 
including NAD(P)H oxidases and xanthine oxidase as well as the mitochondrial electron transport 
chain[121]. O2
.- 
in picomolar ranges is metabolised by superoxide dismutase (SOD) into H2O2, a 
freely diffusable and stable form of ROS which can act as signalling molecule. H2O2 can then be 
removed by conversion to water by catalase or glutathione peroxidase[122]. Whether superoxide and 
H2O2  are harmful depends critically on the amounts produced: while low levels are necessary for 
signalling and may modulate such responses as smooth muscle cell proliferation, high levels are 
associated with DNA damage and can lead to EC apoptosis.  Examples of H2O2 signalling include 
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acting as a hyperpolarising factor in resistance vessels, activation of guanylate cyclase, stimulation of 
NO production and altering gene expression[120]. 
Peroxynitrite is formed by excess superoxide reacting with NO and its production thus leads to a 
decrease in NO bioavailability as well as increased oxidative stress. This results in impaired 
endothelium-dependent relaxation. Peroxynitrite is a potent oxidant whose production does not appear 
to have any useful role in normal EC physiology. Instead it can oxidise lipids and thiol groups on 
proteins and is an important mediator of LDL oxidative modification[122].  
Sources of ROS in EC 
The principal sources of ROS within EC are the mitochondrial electron transport chain, NADPH 
oxidases (Nox enzymes), uncoupled eNOS and xanthine oxidase (XO)[123]. NADPH oxidases and 
mitochondria are thought to be the major sources under physiological conditions, with XO and eNOS 
uncoupling producing significant levels of ROS only in pathological states[104]. 
The mitochondrial electron transport chain represents a significant source of ROS (Figure 1.2). 
During oxidative phosphorylation, adenosine triphosphate (ATP) is generated as electrons are 
transferred from nicotinamide adenine dinucleotide (NADH) or flavin adenine dinucleotide (FADH2) 
to molecular oxygen. This process occurs through a series of electron transport carriers located on the 
mitochondrial inner membrane: Complex I (NADH-ubiquinone oxioreductase); Complex II 
(succinate-ubiquinone oxioreductase); Complex III ( ubiquinol-cytochrome c reductase); and 
Complex IV (cytochrome c oxidase). The 5th complex, ATP synthase, uses the gradient formed to 
generate ATP. 
1-4% of the oxygen reacting with the respiratory chain is incompletely metabolised and forms 
superoxide, which is scavenged by manganese superoxide dismutase (MnSOD) and converted to 
H2O2[124]. Under certain conditions, the electron transport chain can become uncoupled, leading to 
increased superoxide production. This involves the actions of uncoupling proteins which are discussed 
later. This may have pathological consquences - for example, causing oxidative damage to 
mitochondrial DNA - but may also be important for intracellular signalling.  Complexes I, II and III 
can all generate superoxide but only III generates ROS in the intermembrane space to allow signalling 
to the cytosol[124].  
Excess mitochondrial ROS production is harmful: it damages mitochondrial proteins and DNA, 
promotes inflammation and reduces NO bioavailability. CV risk factors are associated with increased 
mitochondrial damage in CV tissue, and mitochondrial DNA damage correlates with the extent of 
atherosclerosis in mouse and human tissue[125]. Mitochondrial ROS have also been linked with 
Alzheimers dementia and have even been suggested as the cause of ageing[126].   
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Recent research however suggests that regulated mitochondrial ROS generation may be 
physiologically desirable in EC[120]. Energy requirements in EC are relatively low and are satisifed 
by ATP production through glycolysis and so mitochondria do not appear to be needed for ATP 
generation and may instead function primarily for signalling purposes[124]. Mitchondria make up 
only 2-8% of EC mass (rather than 30% in cardiac myocytes)[127, 128]. Mitochondrial H2O2, 
produced by MnSOD or Nox 4, can function in physiological signalling as well as being the source of 
harmful effects. H2O2 can play regulatory roles in shear-stress induced vasodilation, autophagy, and 
inflammatory activation[124]. In myocardial arterioles mitochondria tethered to the cytoskeleton 
release ROS in response to deformation by shear stress, resulting in NO production[129]. Meanwhile, 
in rat pulmonary arterial EC, perinuclear mitochondria release ROS that can diffuse to the nucleus and 
alter expression of hypoxia-sensitive genes[130]. 
 
Figure 1.2 Superoxide production and dismutation in mitochondria. Complexes I and III of the electron transport 
chain can produce superoxide, which is converted to H2O2 by MnSOD in the mitocondrial matrix. Further ROS 
regulation is achieved by the action of uncoupling proteins, which dissipate the proton gradient generated by the 
electron transport chain across the mitochondrial inner membrane. I-V: electron transport chain; MnSOD: 
manganese superoxide dismutase; UC: uncoupling proteins. 
There are several subtypes of Nox enzyme expressed in EC, in both the cytosolic membranes and 
within mitochondria. Nox 1 is present at low levels constitutively but is inducible while Nox 4 is most 
abundant and is constitutively expressed in EC. Nox expression and activity is modulated by 
vasoactive hormones such as angiotensin II, endothelin-1, by TNFα and by physical forces such as 
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disturbed flow[104]. Their role in atherogenesis was revealed by studies of Nox deficient mice 
crossed with ApoE
-/-
 animals,where the double knockouts developed fewer, smaller atheromatous 
lesions as well as lower levels of aortic superoxide[131].  
Uncoupling of eNOS occurs when it is deprived of either its substrate or its cofactor for NO 
production: L-arginine and BH4 respectively. In this setting, eNOS is unable to transfer electrons to 
L-arginine and instead uses O2 as a substrate to produce superoxide. The superoxide can then react 
with NO to produce peroxynitrite, which oxidises BH4 and thus further uncouples eNOS, reducing 
NO bioavailability[132]. In studies of the vasculature in the rat adjuvant arthritis model of RA, both 
Nox enzymes and eNOS uncoupling appeared to play a role in the observed endothelial 
dysfunction[133]. 
XO catalyses the conversion of xanthine, an end-product of purine metabolism, and oxygen into uric 
acid, H2O2 and superoxide. XO is induced by pro-inflammatory cytokines including TNFα and by 
oxidation of cysteine residues by peroxynitrite, and is likely only to be a significant source of ROS in 
pathophysiological conditions[104]. A study of diet-induced atherosclerosis in hypercholesterolaemic 
rabbits implicated XO-induced oxidative stress in the disease process[134]; while studies on patients 
with coronary artery disease demonstrate coronary artery activation of XO as well as NADPH 
oxidase[135]. 
Endothelial antioxidant detoxification systems 
For there to be a balance between physiological ROS levels for signalling and regulatory purposes and 
damaging over-production, antioxidant systems exist to metabolise ROS to less reactive molecules. 
Enzymatic antioxidant systems include SOD, catalase, the glutathione system, the thioredoxin system 
and NADPH quinone oxioreductase -1 (NQO-1), which catalyse reactions to convert ROS into more 
stable compounds or to reduce already oxidised proteins. Non-enzymatic systems include ascorbate 
and α-tocopherol. These generally act as sites to accept or donate electrons in order to stabilise ROS.  
Antioxidant defence enzymes are found in specific distributions within cellular compartments: 
peroxisomes (catalase), mitochondria (SOD, glutathione peroxidase; Figure 1.2) and within the 
cytosol (SOD, peroxiredoxins, glutathione peroxidase). This selective distribution supports the idea of 
regional ROS production, which can then signal to other parts of the cell and regulate cellular 
functions. SODs are discussed in detail later in the chapter. 
The major cytosolic system in EC is glutathione, a modified amino acid containing a thiol group. This 
present at very high concentrations intracellularly, up to 1mM, and 99% of cytosolic glutathione 
exists in a reduced state. Glutathione peroxidase catalyses the oxidation of reduced glutathione by 
H2O2 and lipid peroxides and eliminates them. Reduced glutathione is then regenerated via donation 
of electrons from NADPH, catalysed by glutathione reductase[136]. 
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A further important source of defence against oxidative stress is the thioredoxin (Trx) system, which 
is involved in the reduction of unwanted disulphide bonds on oxidised proteins in order to maintain 
the reducing environment of the intracellular space, in conjunction with the glutathione system. They 
also protect against oxidative and nitrosative stress. Trxs are ubiquitous small proteins found 
variously in the cytosol, mitochondria, nucleus, embedded in cell membranes and secreted 
extracellularly. There are two isoforms in mammalian cells: Trx I which is located in the cytosol and 
in the nucleus, and Trx II, located in mitochondria[137, 138]. Trxs contain two conserved cysteine 
residues as their catalytic site which break the disulphide bonds on oxidised proteins by passing 
electrons and forming a disulphide bond with each other. This is then reduced by Trx reductase via 
NADPH electron donation.  
NQO-1 is another cytosolic antioxidant enzyme that uses NADPH as an electron donor. It catalyses 
the reduction of quinones and thus detoxification. It is also inducible, with transcription controlled by 
Nrf-2 binding to antioxidant response elements in its promoter. NQO-1's functions in addition to 
reduction of quinone compounds include prevention of ROS formation and scavenging of superoxide 
anion radicals[139]. It is highly expressed in human vascular tissue and flow-inducible[140]. 
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1.4 Endothelial cytoprotection  
Endothelial cytoprotection refers to the activation of intrinsic protective pathways to counteract the 
effects of injurious stimuli that predispose to endothelial dysfunction. This results in limitation of 
vascular inflammation and oxidative stress by anti-inflammatory, anti-oxidant, anti-apoptotic counter 
regulatory mechanisms that collectively maintain the integrity and homeostasis of the vascular 
endothelium (Figure 1.3). Studying these pathways is important in order to work out how they might 
best be enhanced, in order to relieve endothelial dysfunction and thus prevent atherosclerosis. 
Endogenous external factors that promote endothelial resistance against injury include laminar flow 
with high shear stress[11], growth factors such as VEGF and Ang-1, anti-inflammatory cytokines 
such as TGFβ and IL-10, and HDL[141]. Pre-conditioning could also have a significant effect: a brief 
exposure to oxidant stress or pro-inflammatory cytokines may blunt EC responses to subsequent 
exposure to injurious stimuli[89]. 
A number of intracellular signalling pathways and transcription factors have been identified as being 
important in mediating endothelial cytoprotection. These include extracellular signal-regulated kinase 
5 (ERK5), ERK1/2, protein kinase Cε (PKCε) and PKCζ, and AMP-activated kinase (AMPK)[142]. 
Among the many important transcription factors, there has been recent interest in Kruppel-like factor 
2 (KLF2), nuclear factor (erythroid-derived 2)-like factor 2 (Nrf-2), cyclic AMP-responsive element 
binding protein (CREB), peroxisome-proliferator activated receptor γ (PPARγ), and in the 
mechanisms for inhibiting nuclear factor-κB (NFκB). 
Cytoprotection occurs through the induction of end-effector intracellular proteins and release of 
vasoactive substances, as well as the down-regulation of pro-inflammatory mediators. These include 
eNOS and release of NO, heme oxygenase-1 (HO-1), antioxidant enzymes such as SOD and 
uncoupling proteins and anti-apoptotic and complement-inhibitory proteins. 
 
Figure 1.3 Selected mechanisms of endothelial cytoprotection. 
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1.4.1 High flow laminar shear stress 
The geographical distribution of atherosclerotic plaques is powerful evidence that biomechanical 
forces exerted by blood flow on vessel walls are important in the pathogenesis of atherosclerosis.  
Shear stress is the perpendicular force per unit area exerted on a surface (such as endothelium) when it 
is exposed to a tangential force (such as blood flow). For Poiseuille flow (steady unidirectional 
laminar flow through a straight cylindrical tube of constant diameter) shear stress is directly 
proportional to the velocity of blood flow and inversely proportional to the cube of the arterial 
radius[143]. Pulsatile high flow laminar shear stress (LSS) is therefore experienced by EC situated 
along straight non-branching arteries, while EC at branch points are exposed to disturbed flow with 
low shear stress. Post mortem studies of the human carotid bifurcation and the distal internal carotid 
artery show a predilection for atheroma at the carotid bifurcation, a branch point, and not the internal 
carotid which is straight[144]. In addition, EC apoptosis, VCAM-1 expression and monocyte 
adherence, all features of a dysfunctional endothelium, are enhanced in regions exposed to low shear 
stress[108, 145].  
Much research over the last 20 years has been devoted to discovering why LSS protects against 
atherogenesis, and how this protection is achieved. One initial theory was that of mass transport, 
which proposed that disturbed blood flow resulted in prolonged exposure of the endothelium to lipids 
and other pro-atherogenic substances at branch points and curvatures[146]. However, it is now 
generally accepted that EC sense and react to the flow patterns that they are exposed to, and that shear 
stress pattern modulates gene expression and thus EC phenotype[143]. Microarray studies have been 
used to determine the changes in gene expression in EC triggered by different flow patterns. Despite 
differences in model and environment of the study, these consistently show that high flow LSS 
downregulates gene expression in EC, promoting a quiescent phenotype resistant to activation[11]. 
Expression is particularly affected of pro-inflammatory cytokines, adhesion molecules, apoptosis 
regulators and genes involved in proliferation and migration. Expression of these genes is by contrast 
increased in areas of disturbed flow and it is this differential regulation of expression that may 
underpin the localisation of atherogenesis. 
Mechanotransduction in EC occurs through a complex of platelet-endothelial cell adhesion molecule 
(PECAM; CD31), vascular endothelial (VE)-cadherin and VEGF receptor 2 (VEGFR2). PECAM acts 
as the mechanosensor, and VE-cadherin and VEGFR2, once activated, are able to stimulate a 
succession of downstream signalling pathways[147]. In EC exposed to high flow LSS, this results in, 
among a host of responses, enhancement of NO production and priming of anti-inflammatory, anti-
apoptoic and anti-oxidant responses. 
The primary mechanism by which LSS exerts a protective effect on vascular endothelium is through 
regulation of NO production, achieved by phosphorylating eNOS on serine 1177, an event dependent 
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on phosphoinositol-3-kinase (PI-3K)/Akt signalling[148]. PI-3K activation may occur directly 
following activation of the mechanosensory complex[147]. 
LSS also promotes an anti-inflammatory phenotype in EC, whereas disturbed flow is pro-
inflammatory. Prolonged exposure to laminar flow in vitro reduces ICAM-1, VCAM-1 and E-selectin 
expression, while oscillatory flow upregulates them and enhances monocyte adhesion[149]. 
Moreover, exposure to IL-1β in EC conditioned by LSS results in reduced VCAM-1 expression 
compared to that observed in static conditions[150]. VCAM-1 expression and NFκB activation are 
seen in vivo in aortic EC located in areas associated with a high probability of atherosclerotic lesion 
development[151].  
Thirdly, LSS is associated in EC with lower levels of oxidative stress. In vitro, atheroprotective flow 
patterns result in lower levels of intracellular ROS and enhanced resistance to external oxidative 
stress, an effect co-ordinated by Nrf-2 binding to the antioxidant response element (ARE) region of 
anti-oxidant genes including HO-1, glutathione reductase, NQO-1 and Trx reductase[140]. This may 
occur through an effect on cytosolic levels of reduced glutathione, which in LSS conditions is 
enhanced and with disturbed flow is depleted[123]. Hojo et al showed that steady laminar flow 
inhibits JNK activation by H2O2, and cell death mediated by TNFα or H2O2, partly through an effect 
on glutathione reductase[152]. In addition, the antioxidant enzymes copper/zinc SOD (Cu/ZnSOD; 
SOD1) and extracellular SOD (ECSOD; SOD3) are induced by LSS[153], while oscillatory flow is 
associated with reduced NO production and increased superoxide[154]. Thus, the flow patterns 
endothelium is exposed to can differentially regulate cellular redox balance. 
A further facet of the quiescent phenotype invoked by the action of LSS on EC is inhibtion of 
apoptosis and proliferation. In one recent study, human umbilical vein EC (HUVEC) exposed to LSS 
for up to three days reduced proliferation by 20% as well as a significant reduction in apoptosis 
compared to cells cultured under static conditions[155]. Other work has shown that LSS for 24h 
reduces EC proliferation through p53 expression and stabilisation via JNK-mediated 
phosphorylation[156]. Finally, shear stress has been shown to inhibit apoptosis induced by growth 
factor withdrawal, TNFα or H2O2[157, 158] 
In summary, LSS promotes a quiescent phenotype in EC, characterised by plentiful NO production, 
reduced oxidative stress, reduced gene expression and slow cell turnover. This state is anti-
inflammatory and anti-thrombotic and so atheroprotective. 
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1.4.2 Vascular endothelial growth factor 
The growth factor VEGF-A (VEGF) is a heparin-binding glycoprotein produced by EC and 
surrounding cells with paracrine effects[89]. It is part of a family of related growth factors, and has at 
least 5 isoforms ranging from 121 to 206 amino acids in length. The 165 amino acid form is the most 
biologically active and most abundant form[159]. 
VEGF is essential in the embryo for vasculogenesis and angiogenesis, and even heterozygous VEGF-
deficient mice die in utero with a severely mal-developed vasculature[160, 161]. More recent work 
has shown that it has an important maintenance role for the adult vasculature. Targetted disruption of 
VEGF in the endothelium of adult mice leads to severe vascular abnormalities[162]. In addition 
bevacizumab, an anti-VEGF monoclonal antibody used to treat metatstatic cancer and age-related 
macular degeneration, can cause hypertension and proteinuria in patients, thought to be due to its 
effects on NO production[163]. 
VEGF in the adult vasculature has three well-described functions: angiogenesis, EC proliferation and 
enhancement of vascular permeability [164, 165]. Although studying the role of VEGF in mature 
vessels in vivo is difficult because of its lethality if depleted, in vitro work has led to the idea that it 
has vascular protective functions in mature adult blood vessels, enhancing vasodilative, anti-
thrombotic and anti-apoptotic pathways independently of its effects on proliferation[159]. 
VEGF is required to form and sustain new vessels in adult organisms[164]. This is often a response to 
pathology, such as angiogenesis in rheumatoid proliferative synovitis, cancer, diabetic proliferative 
retinopathy, or collateral vessel formation after pathological blood vessel occlusion. Without a VEGF 
signal new vessels regress, but mature vessels mostly do not require it for survival. However, VEGF 
is important for the maintenance and function of certain mature vascular beds. For example, it is 
required to form and maintain fenestrations and so major sites of constitutive VEGF production in 
mature organs are the cells adjacent to fenestrated endothelium in the glomerulus, the brain choroid 
plexus and within endocrine organs. The importance of this is shown in a study of lupus nephritis, 
where loss of VEGF in the kidney correlated with worse renal outcome[111]. 
The vascular protective actions of VEGF relate to its abilities to enhance NO production, and effects 
on both prostacyclin synthesis and on EC survival. VEGF enhances eNOS expression and stimulates 
endothelial NO production through phosphorylation of eNOS[166, 167]. The mechanism for this 
involves ligation of VEGFR2, a receptor tyrosine kinase and the principal receptor for mediating 
VEGF intracellular signalling. Evidence that this has vascular protective effects comes from a study 
of perivascular VEGF gene transfer in a rabbit carotid artery injury model, where addition of VEGF in 
a carotid artery cuff reduced neointimal hyperplasia, an effect abolished by co-treatment with the 
eNOS inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME)[168]. Further support comes from a 
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study of leucocyte adhesion, where administration of VEGF attenuated thrombin or L-NAME-
induced leucocyte adhesion in rat mesenteric endothelium[169]. 
VEGF also stimulates endothelial production of prostacyclin, another potent vasodilator that also 
affects on vascular permeability and inhibits platelet aggregation and smooth muscle cell 
proliferation[170]. As with stimluation of NO synthesis, the mechanism involves ligation of VEGFR2 
and then initiation of a signalling cascade involving c-Src, phospholipase Cγ1 and release of 
intracellular Ca
2+
[171].  
The restricted spatial pattern of constitutive VEGF expression in most organs argues against a need 
for VEGF for mature vessel survival. However, inhibition of VEGF in adult mice caused regression of 
tracheal capillaries[172] and in fenestrated endothelium sites, although not in the heart and lung[173], 
and as described above, severe vascular abnormalities were seen in adult mice with a single allele 
deletion of VEGF, restricted to the vasculature. The effects of VEGF on EC survival may involve 
VEGF induction of Bcl-2-related protein A1 (A1) and B-cell lymphoma protein-2 (Bcl-2), anti-
apoptotic proteins from the Bcl-2 family discussed later in the chapter[174, 175]. 
Finally, VEGF can protect vascular endothelium against complement-mediated injury, by 
upregulating cell surface expression of decay-accelerating factor (DAF), a complement inhibitory 
protein[176, 177] 
1.4.3 Pre-conditioning and stress-response hormesis 
A further external stimulus for enhancing endothelial cytoptotection is pre-conditioning. When cells 
are exposed briefly to an adverse stimulus, this can lead to an enhanced ability to withstand a second 
insult. For example, Zahler et al briefly exposed cultured EC to a high concentration of H2O2, then 
stimulated them with TNFα for 4h. Exposure to this powerful oxidative challenge, which was 
sufficient to reduce the intracellular reduced glutathione concentration by 50%, significantly altered 
the ability of EC to respond to TNFα, with reduced synthesis and release of IL-6 and IL-8, reduced 
expression of ICAM-1 and E-selectin, and a reduction in NFκB p65 translocation. Moreover, these 
effects were antagonised by pre-treatment with n-acetyl cysteine (NAC), which would preserve the 
pool of reduced glutathione, showing that the reduction in response to TNFα was due to the oxidative 
challenge[178].  
Pre-conditioning has also been investigated in the field of ageing, where it is described as "stress 
response hormesis"[179]. Organism and cellular responses to stress are biphasic, with high-intensity 
or prolonged insults being lethal but low-intensity stressors induce a response that results in stress 
resistance[89]. This adaptive, defensive response, occurring through alteration in gene expression, 
improves the ability of the cell or organism to deal with the second stressor. At an organism level, 
supportive evidence is provided by experiments on Caenorhabditis elegans, showing for example that 
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brief exposure to very high O2 concentrations extends lifespan[180]. It is possible that a number of 
activators of AMPK such as metformin, discussed later in the chapter, evolved as mitochondrial 
poisons as they inhibit the mitochondrial electron transport chain, but at low dose can have beneficial 
metabolic effects via AMPK activation[181]. 
1.4.4 Cytoprotective signalling cascades and transcription factors 
Many intermediary signalling kinases and transcription factors have been identified as being 
important in mediating endothelial cytoprotection as a result of activation by LSS, VEGF or other 
endogenous mediators and only a selection are discussed here. Identifying these pathways allows 
investigation of how they may be manipulated pharmacologically. 
Protein kinase Cε 
Protein kinase Cε (PKCε) is one of the novel isoenzymes of PKC, a family of serine-threonine 
kinases. It was first discovered as a cell survival factor, and activation results in protection against 
apoptosis in cardiomyocytes and in EC following ischaemic pre-conditioning[182-184]. Activation of 
PKCε is an important mediator of the cytoprotective effects of VEGF in EC, mediating protection 
against apoptosis through induction of A-1 and Bcl-2, and protection against complement-induced 
injury through induction of DAF[176, 182]. Cytoprotection due to PKCε activity may occur through  
ERK1/2 and NFκB activation: PKCε overexpression induces cytoprotective gene expression via 
NFκB but not pro-inflammatory genes[175]. 
Kruppel-like factor 2 
Kruppel-like factor 2 (KLF2), one of a family of zinc finger transcription factors, was first identified 
by transcriptional profiling as being strongly induced by LSS in vitro[185]. To date, no other 
endogenous inducers of its expression have been found, although it is likely also to mediate many of 
the endothelial protective effects of statins[186, 187]. This, combined with its in vivo expression in 
sites protected against atherogenesis, has led to the suggestion that KLF2 underpins the molecular 
basis of flow-mediated atheroprotection[143]. Genome wide analyses of gene expression suggest that 
KLF2 could influence the expression of up to a third of shear responsive genes[188]. It regulates the 
shear-induced expression of eNOS, thrombomodulin, and CD59, indicating that it is responsible for 
shear-induced anti-inflammatory, anti-thrombotic, anti-oxidant and complement-inhibitory 
effects[188-190]. The MEK5-ERK5-MEF2 pathway appears to be the signalling pathway most 
important for the regulation of KLF2 expression[188, 189]. 
Regarding the basis for endothelial dysfunction caused by chronic inflammation, it is relevant that 
KLF2 expression may be reduced by IL-1β and TNFα. Conversely, over-expression of KLF2 reduces 
VCAM-1 and E-selectin expression and reduces leucocyte adherence to EC[191, 192]. 
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Peroxisome proliferator-activated receptors 
Peroxisome proliferator-activated receptors (PPARs) are also important for atheroprotection and may 
mediate some of the beneficial effects of LSS. PPARs are transcription factors belonging to the 
nuclear receptor superfamily, and there are three subtypes: PPARα, PPARβ/δ and PPARγ. PPARs 
activate transcription by forming heterodimers with the retinoid receptor RXR, and binding to specific 
PPAR-responsive elements within promoter sequences. Natural ligands of the PPARs are not fully 
elucidated but include fatty acid derivatives and prostglandins[141, 193]. However, both PPARα and 
PPARγ are ligands for drugs in clinical use: PPARα is the site of action of the lipid-lowering drugs 
fibrates, and the insulin-sensitising drugs thiazolidinediones act on PPARγ. 
Activation of PPARγ with thiazolidinediones reduces atheroma formation in atherosclerosis-prone 
mice[194]. In vitro studies show that PPARγ ligands reduce TNFα-induced VCAM-1 expression and 
thus have anti-inflammatory roles. PPARα activation can repress cytokine-induced activation of 
VCAM-1 in EC, and reduce monocyte adhesion[195], and aortae from PPARα-/- mice display a more 
exuberant response to pro-inflammatory stimuli, resulting in increased vascular IL-6 production[196]. 
PPARs also have anti-oxidant actions, and can regulate both catalase and HO-1 expression[197]. 
PPARs are also capable of acting as transrepressors and inhibiting pro-inflammatory transcriptional 
mechanisms. For example, PPARα can negatively interfere with NFκB and AP-1 transcription, 
through actions on c-Jun[196]. 
Nuclear factor (erythroid-derived 2)-like factor 2 
Nrf-2 appears to be the transcription factor responsible for mediating the anti-oxidant effects of 
LSS[140]. This transcription factor binds to the ARE  motif, which is found in the promoters of many 
anti-oxidant genes. Dai et al demonstrated, by conducting genome-wide transcriptome profiling on 
EC exposed to atheroprotective flow patterns with siRNA to Nrf-2, that the major differentially 
regulated genes were antioxidants including HO-1, ferritin heavy chain, NQO-1, Trx reductase and 
glutathione reductase. The major upstream kinase in their model was PI-3K/Akt[140]. It may also be 
possible to manipulate Nrf-2-mediated transcription pharmacologically: Hamdulay et al found that 
Nrf-2 translocation was required for HO-1 induction by celecoxib[198]. 
Cyclic-AMP Responsive Element Binding Protein (CREB) 
CREB is a phosphorylation-dependent transcription factor, part of a family of cAMP-responsive 
factors that also contains ATF-1 and cAMP response element modulator (CREM) that are all capable 
of binding to cAMP-responsive elements (CRE) in gene promoter regions and activating transcription. 
It is responsible for regulating a variety of cellular responses, predominantly cytoprotective in 
nature.These include cell proliferation, survival, adaptive responses and glucose homeostasis[199].  
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CREB is activated by phosphorylation on serine 133 in its transactivation domain, and several serine-
threonine protein kinases can do this, including AMPK, c-AMPK-dependent protein kinase A (PKA), 
PKC, particularly PKCε, and calmodulin kinases (CaMKs), which respond to calcium fluxes[199, 
200]. Once phosphorylated on Ser133, CREB interacts with the co-activators CREB-binding protein 
(CBP) or p300, or CREB-regulated transcriptional co-activators (CRTCs), to initiate transcription of 
genes containing CRE sites in their promoters. This will be discussed in more detail in the 
introduction to Chapter 6. 
There is evidence that CREB activation exerts protective effects on the vasculature. Vascular CREB 
protein levels are depleted in rodent models of a variety of conditions affecting the vasculature, 
including hypertension, ageing and insulin resistance[201]. This is partly due to exposure to oxidised 
LDL and to elevated levels of ROS, as exposure of rat VSMCs to these in vitro resulted in loss of 
CREB protein, and this could be blocked by pre-treatment with ROS scavengers. Second, cardiac-
specific expression of dominant-negative CREB leads to a dilated cardiomyopathy with increased 
mortality and mitcochondrial dysfunction in female mice, resulting in survival at 21 weeks of only 
17%[202].  
Most studies have examined the role of CREB in vascular smooth muscle or cardiomyocytes but it is 
physiologically important in endothelium too. Exposing HUVEC to oxidised phospholipids results in 
protective induction of HO-1, mediated by CREB[203]. Depleting CBP by RNA interference 
sensitises EC to apoptosis by serum starvation[204]. Thirdly, CREB can interact with NFκB to 
modulate ICAM-1 expression[205].  Finally, activation of CREB is important for the induction of 
DAF by atorvastatin and rapamycin combination[206]. 
The protective effects of CREB activation come from its ability to influence mitochondrial function. 
Mice harbouring cardiac dominant-negative CREB exhibit decreased PPARγ coactivator-1α (PGC-
1α; a transcriptional co-activator essential for mitochondrial biogenesis) and diminished 
mitochdondrial density and structure. They also have increased ROS levels and reduced mitchodrial 
antioxidant levels (MnSOD and glutathione peroxidase)[202]. In vitro studies confirm that CREB is 
capable of regulating PGC-1α expression and thus mitochondrial biogenesis, as well as exerting an 
anti-apoptotic effect via induction of Bcl-2 and A1, and contributing to antioxidant defence by 
inducing MnSOD and HO-1[202, 203]. 
Nuclear factor-κB 
Just as important as those transcription factors activated in cytoprotective pathways is inhibition of 
NFκB, the key transcriptional regulator of inflammation. Anti-inflammatory cytokines such as IL-10 
and TGFβ negatively regulate NFκB; as do many cytoprotective and anti-inflammatory drugs, 
including glucocorticoids, and several cytoprotective genes inhibit NFκB as one of their actions[141]. 
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In its resting state, NFκB is sequestered in the cytoplasm bound to its natural inhibitor, IκBα. 
Phosphorylation of IκBα by the IκB kinase complex leads to its disengagement from NFκB, followed 
by its ubiquitination and proteolytic degradation, leaving NFκB free to translocate to the nucleus and 
initiate transcription[141].  
There are several points at which inhibition of NFκB may operate. Firstly, NFκB itself induces 
synthesis of IkBa, forming a negative feedback loop which limits NFκB activation[141]. Formation of 
IκB is also enhanced by glucocorticoids. Intracellular redox state is important, as a reducing 
environment may prevent activation of the IκB kinase complex[207]. Finally, agents which block 
IκBα degradation and interfere with IκB kinase activation have been investigated as possible anti-
inflammatory agents. 
1.4.5 Effectors of endothelial cytoprotection 
All cells possess endogenous mechanisms to defend against injurious stimuli and limit activated 
states. Within EC these fall into several broad categories: anti-inflammatory, anti-apoptotic, anti-
oxidant, and metabolic changes. In terms of the blood vessel as a whole, vasodilatory and anti-
thrombotic actions are also important. Many of the effectors of endothelial cytoprotection discussed 
below have activities that fall into more than one group. 
Nitric Oxide 
NO is best known for its powerful vasodilatory effect, which occurs through stimulating production of 
cGMP to mediate vascular smooth muscle relaxation, and which is the hallmark of a normally 
functioning endothelium. However, it also acts within EC as a signalling molecule, and as such has 
physiologically important anti-inflammatory and anti-oxidant actions. NO production is up-regulated 
by LSS and VEGF, and inhibits leucocyte-endothelial interactions by reducing ICAM-1 and VCAM-1 
expression[208]. In in vivo models, NO blockade results in enhanced vascular monocyte infiltration 
and increased cell adhesion molecule and chemokine expression, mainly through effects on NFκB 
activation. These pro-inflammatory changes are associated with increased vascular superoxide 
production, and can be reversed with NAC. They can also be inhibited using angiotensin II receptor 
antagonists[209, 210]. These data suggest that NO is able to counteract the pro-inflammatory and pro-
oxidant effects of vasoactive mediators such as angiotensin II. 
Heme oxygenase-1 
HO-1 is a stress-responsive enzyme that catalyses the rate-limiting step in the degradation of heme 
into biliverdin (which is then further metabolised to bilirubin by biliverdin reductase), carbon 
monoxide and iron (which in turn induces expression of heavy chain ferritin). It is present at low 
levels in quiescent cells but is highly inducible, and has been shown in a variety of settings to have 
protective properties that promote restoration of homeostasis, in both the cell and the whole 
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organism[211]. The products of its reaction are anti-oxidant and anti-inflammatory and can 
additionally be involved in the regulation of cell growth and death. Its protective effects in vivo are 
demonstrated by the poor response to stressors shown by Hmox
-/- 
 mice: these are much more likely to 
die when challenged with endotoxic shock or autoimmune neuroinflammation[212, 213]; while 
induction of HO-1 protects against nephritis in murine lupus and reduces synovial inflammation[214, 
215]. 
In vascular endothelium, HO-1 induction exerts anti-apoptotic, anti-inflammatory and anti-oxidant 
effects that collectively result in endothelial cytoprotection and protection against atherogenesis. 
Induction of HO-1 is responsible for the protection against oxidative damage provided by atorvastatin 
treatment in EC, an effect dependent on KLF-2[186]. HO-1 is involved in the inducible cell-surface 
expression of DAF, and loss of HO-1 results in enhanced susceptibility to complement-mediated 
injury in EC[216]. HO-1 induction is associated with protection against apoptosis induced by TNFα 
and ceramide, through AMPK signalling and activation of HO-1 expression by Nrf2 binding to ARE 
sequences in its promoter[217]. Consistent with the distribution of atherosclerotic plaque in the 
vasculature, HO-1 is strongly induced by "atheroprotective" flow patterns, via activation of PI-3K/Akt 
and Nrf2[140]. HO-1 induction also retards the development of atherosclerosis in LDLR
-/-
 mice and is 
associated with stabilisation of vulnerable plaque in humans[218, 219]. Finally, in the only known 
case of human homozygous HO-1 deficiency, oxidative stress, extensive vascular endothelial damage 
and death in childhood was observed[220].  
Manganese superoxide dismutase 
Superoxide dismutase enzymes catalyse the conversion of superoxide to the more stable hydrogen 
peroxide.There are three isoforms of superoxide dismutase in the human genome: Cu/ZnSOD located 
in the cytoplasm, MnSOD, located in mitochondria, and ECSOD. SOD1 and SOD3 share substantial 
sequence homology but MnSOD differs significantly[221]. MnSOD is most pertinent to the work 
presented in this thesis and will therefore be the focus of this section.  
MnSOD is a 222 amino acid protein, including a 24 amino acid leader peptide that is necessary for 
mitochondrial targetting and is then cleaved to leave the active enzyme. It is located intracellularly 
within the mitochondrial matrix, where it scavenges superoxide produced by the electron transport 
chain. It is one of the major defences against mitochondrial-derived ROS, and control of MnSOD 
activity and expression levels is a major mechanism of control of signalling via mitochondrial ROS. 
MnSOD is induced by a wide variety of cellular stimuli.These include pro-inflammatory cytokines, 
including TNFα, IL-1 and IFNγ[222, 223], and other toxic stimuli such as ionising radiation. 
Induction of MnSOD under these circumstances is principally mediated via activation of NFκB[224]. 
The importance of MnSOD for vascular health was first shown in studies of MnSOD deficient mice, 
which exhibited a dilated cardiomyopathy and 100% neonatal lethality at 10 days. Although the 
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authors suspected that this was due to mitochondrial dysfunction, given the importance of 
mitochondria to cardiomyocytes and the subcellular localisation of MnSOD, they could not 
demonstrate a structural abnormality by electron microscopy[225]. Further evidence of MnSOD's 
importance to the vasculature comes from studies showing that ApoE
-/-
 mice also deficient in SOD2 
developed increased mitochondrial DNA damage and accelerated atherogenesis at arterial branch 
points[226], while heterozygous MnSOD deficient mice have impaired endothelium-dependent 
vasodilation[227]. Although some studies have found Cu/ZnSOD to be regulated by laminar flow, this 
has not been demonstrated for MnSOD, suggesting that, although it is cytoprotective, it is not part of 
the group of genes whose expression is regulated by Nrf2[140].  
In contrast, it is not clear if Cu/ZnSOD operates as a cytoprotective gene in the vasculature. Tribble et 
al showed that in mice overexpressing human Cu/Zn SOD, atherogenesis increased in direct relation 
to aortic Cu/ZnSOD activity[228]. 
BCL-2 family 
The BCL-2 family of proteins are involved in the regulation of the intrinsic or mitochondrial 
apoptosis pathway. There are approximately 12 family members in mammals, with either anti-
apoptotic (BCL-2, A1, BCL-XL) or pro-apoptotic (BAX, BAK) actions. BCL-2 itself was first 
discovered in B-cell follicular lymphomas as an oncogene, as its over-expression inhibits cell 
death[229]. They are essential for the regulation of cell death in normal and pathological tissue 
turnover, and for immune system activation and deactivation.  
The mitochondrial pathway of apoptosis is that which controls cell death in response to 
developmental or cytotoxic cues such as viral infection, DNA damage or growth factor deprivation. It 
is strictly controlled by the BCL-2 family, and leads to the activation via cytochrome c and apoptotic 
protease activating factor of caspase 9. The pro-apoptotic members BAX and BAK induce 
permeabilisation of the outer mitochondrial membrane, leading to release of proteins that normally 
reside in the inter-membrane space that promote apoptosis such as cytochrome c, which then initiate 
caspase activation. They also induce fragmentation of mitochondria. BCL-2, A1 and BCL-XL inhibit 
BAX and BAK, although exactly how they do so is not understood. Regulation of their levels, 
however, is an important way by which cells determine whether apoptosis proceeds[230]. 
BCL-2 and A1 are important for the regulation of EC apoptosis. Increased EC apoptosis is a feature of 
enothelial dysfunction in a number of settings, notably SLE. Induction of BCL-2 by a constitutively 
active PKCε virus protects against EC apoptosis[182]. BCL-2 and A1 may also act to limit 
inflammatory activation. A1 is rapidly induced by the pro-inflammatory cytokines TNFα and IL-1β 
[231], as well as by growth factors such as VEGF[175]. Their importance is shown by in vivo 
experiments involving xenografts: EC in hamster hearts transplanted into rats are rejected if they do 
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not express BCL-2. In contrast, BCL-2 over-expression inhibits VCAM-1 and E-selectin expression 
in EC, through inhibition of NFκB[232].  
Complement inhibitory proteins 
Complement activation may be important in the development and perpetuation of atherosclerosis as 
complement cascade proteins, such as C1q, C3a, C5a and the C5b-9 membrane attack complex 
(MAC), are capable of activating EC, inducing expression of cell adhesion molecules and cytokines, 
increasing leucocyte adhesion and generating a prothrombotic surface[233-236]. To combat this, EC 
express inducible complement inhibitory proteins on the cell surface. DAF regulates complement 
activation by preventing the formation and accelerating the decay of C3 and C5 convertases, thus 
interrupting the complement cascade and reducing MAC formation. DAF is induced by VEGF, via a 
mechanism that involves ligation of VEGFR2 and PKCε[176, 177]. It can also be induced by statins, 
particularly atorvastatin in combination with rapamycin[206, 237]. The mechanism involves 
activation of AMPK and CREB as well as HO-1[206, 216]. CD59, another complement inhibitory 
protein, acts by preventing C9 incorporation into the MAC, and is induced by LSS[189]. The clinical 
importance of complement inhibitory proteins is evident in the disease paroxysmal nocturnal 
haemoglobinuria, caused by mutations in the PIGA gene that results in loss of DAF and CD59 
expression. 
Uncoupling proteins  
Uncoupling proteins are mitochondrial proteins that uncouple ATP generation from oxidative 
phosphorylation. They are located on the mitochondrial inner membrane and act by dissipating the 
proton gradient generated by the cytochrome enzyme complexes thus making the membrane potential 
less negative and reducing ATP production by the electron transport chain. This action means they 
also reduce levels of mitochondrial ROS production, along with other inducible anti-oxidant enzymes, 
and may therefore be important for the regulation of ROS for signalling purposes[238]. 
Three uncoupling proteins have been identified in the human genome: uncoupling protein-2 (UCP2) is 
the primary isoform in EC. Epidemiological evidence that UCP2 is important for cardiovascular 
health comes from studies showing that SNPs associated with increased UCP2 expression are also 
associated with reduced cardiovascular events[239]. Furthermore, UCP2
-/-
 mice exhibit increased 
atherosclerosis and impaired endothelium-dependent vasodilation[240]. In EC, UCP2 is important for 
control of mitochondrial superoxide production, for signalling purposes in response to growth 
stimulation, and its absence may lead to cell senescence[241]. 
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1.5 Therapeutic conditioning of the vascular endothelium 
Endothelial dysfunction is the initial stage in atherogenesis. It is also reversible. Exercise, weight loss, 
dietary and lifestyle modifications, and drugs or combinations of drugs are all capable of improving 
functional markers of endothelial function, at least in the short term. In the setting of chronic 
inflammatory disease, if a clear pharmacological strategy could be identified to prevent or reverse 
endothelial dysfunction, it might be possible to reduce substantially progression to plaque formation. 
Identification of such a path for therapeutic conditioning of the endothelium is the main aim of the 
work presented in this thesis. 
A number of drugs can improve markers of endothelial function. In addition to statins which are the 
most widely studied, PPARγ and PPARα agonists and metformin also exert beneficial effects. 
Although these are in clinical use as cholesterol-lowering, anti-hypertensive and anti-diabetic drugs 
respectively, they have pleiotropic actions; and may act directly on the vascular endothelium in 
beneficial ways. The actions of metformin and others in activating AMPK will be discussed in the 
next section. 
Statin therapy was first shown to improve endothelial function in patients with hypercholesterolaemia 
in 1994, comparing pravastatin 10-20mg daily for 6 months with placebo[242]. Subsequent studies 
have shown that statins improve endothelial function very rapidly, with even short -term courses 
associated with improvements, and this is not necessarily dependent on the degree of cholesterol 
reduction[243]. The likely mechanism relates to increased endothelial NO production, principally via 
increasing eNOS availability and activity, as giving the eNOS inhibitor L-NMMA alongside statins 
blocks their effect on endothelial-dependent vasodilatation[244]. In vitro studies indicate that LDL 
can increase the inhibitory interaction between caveolin-1 and eNOS, and that atorvastatin decreases 
caveolin-1 expression and increases the eNOS and Hsp90 interaction[245]. In addition, statins 
activate Akt, which then phosphorylates and activates eNOS[246]. Lastly, statins may have an anti-
inflammatory effect on endothelium, as their use is associated with reduced levels of circulating P-
selectin and ICAM-1, and they also induce expression of cytoprotective genes such as HO-1 and 
DAF[237, 247, 248].  
Drugs activating PPARα and PPARγ are in clinical use as lipid-lowering and anti-diabetic 
medications respectively, although PPARγ agonists are treated with caution as there is evidence of 
cardiotoxicity with their use and one, rosiglitazone, has been withdrawn[249]. However, multiple 
lines of clinical, in vivo and in vitro evidence suggest that they may be a good pharmacological means 
of stimulating endothelial cytoprotection. Gemfibrozil, a PPARα ligand, was shown in the Veterans' 
Administration HDL Intervention Trial to reduce atherosclerotic events by more than would be 
expected by the observed reduction in LDL concentration[250]. Both PPARα and PPARγ ligands can 
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induce HO-1 and enhance endothelial cytoprotection, while the PPARα ligand fenofibrate can 
improve EC survival through AMPK activation[197, 251]. 
In RA, treatment with anti-TNFα can improve endothelial function as measured by flow-mediated 
dilatation[252], and can increase numbers of EPCs[253]. DMARDs can also reverse endothelial 
dysfunction[96], and so can rituximab[254]. In addition, other drugs known to be beneficial to the 
vasculature may also improve endothelial function in RA, including statins[255] and ACE 
inhibitors[256]. 
However, not all drugs in rheumatology practice have benign effects on the endothelium. COX-2 
inhibitors and NSAIDs may have damaging effects as a number have been linked with increased risk 
of MI, although it should be noted that this is not a universal class effect, and indeed some may be 
beneficial to the endothelium: for example, celecoxib can induce HO-1, at least in vitro[198, 257]. In 
addition ciclosporin may worsen endothelial function and pre-dispose to hypertension, although this 
has largely been studied in transplant patients[258]. However, in vitro studies have shown that 
ciclosporin antagonises the beneficial action of VEGF in inducing DAF expression, and also induces 
expression of the vasoconstrictor endothelin-1[176, 259]. This underscores the need for detailed 
knowledge of which anti-rheumatic drugs improve endothelial function, and how they do it. 
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1.6 AMP-activated kinase 
1.6.1 Structure of AMPK and regulation of activation 
AMPK is a ubiquitous serine/threonine signalling kinase originally discovered as a sensor of cellular 
metabolic status that responds to changes in the intracellular ratio of AMP: ATP[260]. It is conserved 
throughout all eukaryotes, and its function, and that of its homologue SNF1 in unicellular organisms 
such as yeast, is to co-ordinate the response to nutrient deprivation. When the ambient glucose 
concentration is low, AMPK and SNF1 activation leads to switching off of anabolic processes such as 
protein biosynthesis, cell growth and proliferation, and promotion of efficient generation of ATP 
through mitochondria rather than relying on glycolysis. In multicellular animals with hormonal and 
metabolic systems for controlling serum glucose concentrations, intracellular glucose deprivation is 
rarely experienced and the AMPK system has been adapted to respond to other stressors that disrupt 
homeostasis such as, in EC, pro-inflammatory cytokines, toxins and oxidative stress[261]. 
Structure 
The AMPK molecule is a heterotrimeric complex composed of a catalytic α subunit, scaffolding β and 
regulatory γ subunits. There are two or three genes encoding each subunit in the human genome and 
thus twelve possible AMPK complexes.  
There are two α subunit  isoforms, α1 and α2, both of which are present in EC, although α1 is much 
the more abundant[142, 262]. Both contain a phosphorylation site, threonine 172, that markedly 
enhances their catalytic activity, in addition to the kinase domain at their N-terminal end[263]. They 
also have slightly different distributions, with α1 being predominantly located in the cytoplasm, while 
α2 can translocate to the nucleus, suggesting it may be more important in the control of gene 
expression. α2 is also thought to be more sensitive to AMP binding than α1[264]. 
The γ subunit contains three sites, known as Bateman domains, for binding adenine nucleotides and 
which can bind AMP, two of which can also bind adenosine diphosphate (ADP) or ATP[265]. AMP 
or ADP binding promotes Thr172 phosphorylation in the α subunit, while ATP binding does not[181].  
The β subunits predominantly act as a bridge linking α and γ, but also contain a sequence for binding 
glycogen. The significance of this is not entirely clear, but it may be important for localising the 
AMPK complex with glycogen and with enzymes involved in glycogen synthesis and catabolism, 
which are targets for AMPK activity[181]. 
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Mechanism of activation 
AMPK activation occurs through  two different mechanisms: binding of AMP to the γ subunit, which 
increases activity about 5 fold, and phosphorylation at Thr172 in the α subunit, which increases 
activity approximately 100 fold[266, 267]. AMP binding to the three sites in the γ subunit results in a 
conformational change that renders Thr172 a better substrate for its upstream kinases. It also 
allosterically activates the enzyme and slows dephosphorylation by the protein serine/threonine 
phosphatases PP2a and PP2c[268]. Recent studies suggest that ADP also binds to the γ subunit, 
protects against dephosphorylation, and may promote phosphorylation[269]. ATP can also bind to the 
γ subunit, and this antagonises the effect of AMP. 
The upstream kinase responsible for Thr172 phosphorylation is liver kinase B1 (LKB1), a tumour 
suppressor gene that is the site of the mutation causing Peutz-Jeghers syndrome[266, 270]. LKB1 
itself is constitutively active and would permanently activate AMPK without a control mechanism. 
Therefore, it is AMP or ADP binding, rendering the AMPK complex receptive to Thr172 
phosphorylation and preventing dephosphorylation, that determines whether activation of the pathway 
occurs[267].  
There is a third mechanism of AMPK activation, which was discovered in neurones and tumour cell 
lines (such as the cervical cancer HeLa cell line) which lack LKB1. In these cells, AMPK activation 
can still occur, through increases in cytosolic Ca
2+
 concentrations, which result in AMPK 
phosphorylation by Ca
2+
/calmodulin-dependent kinase kinase-β (CaMKKβ)[271, 272]. This may be 
an important mechanism of AMPK phosphorylation in EC, where a number of stimuli, such as 
bradykinin and thrombin, are capable of causing rapid changes in intracellular calcium and equally 
rapid changes in AMPK activation state[273]. 
Regulation of activation by metabolic factors, hormones and cytokines 
Any metabolic stress that inhibits ATP production or increases its consumption will activate AMPK. 
Example of this include glucose deprivation or exposure to the glucose analogue 2-deoxyglucose, 
which depletes ATP through conversion to the non-metabolisable 2-deoxyglucose-6-phosphate, thus 
preventing generation of ATP through glycolysis or oxidative phosphorylation[261]. This is 
principally a research tool: physiologically, mammalian cells only stop producing ATP from glucose 
when glucose concentrations drop to profoundly low levels. However, more modest degrees of 
hypoglycaemia also activate AMPK in EC in vitro[274].  
Other stressors that interfere with oxidative phosphorylation also activate AMPK: for example 
hypoxia, ischaemia and poisons such as arsenite and dinitrophenol[275-277]. More physiologically, 
skeletal muscle contraction uses ATP and thus activates AMPK, and many of the desirable metabolic 
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effects of exercise may be mediated through AMPK signalling[278, 279]. Furthermore, although 
glucose deprivation is not usually a signal for AMPK activation in mammalian cells, it is used within 
the physiological range of glucose in certain specialised tissues: for example the β cells in the 
pancreatic islets of Langerhans responsible for insulin secretion; and in the hypothalamus, where 
AMPK activation appears to play a role in moderating feeding behaviour[280, 281]. 
Several hormones that operate through G-protein coupled receptors signal via AMPK, including 
adrenaline via α1 adrenoceptors in adipocytes, bradykinin in bovine aortic EC and thrombin in 
HUVEC[273, 282, 283]. These are all likely to activate AMPK via release of intracellular calcium 
and thus CaMKKβ-mediated phosphorylation[284]. In addition, the adipokines leptin and adiponectin 
activate AMPKα2  in skeletal muscle, where they stimulate glucose uptake and fatty acid 
oxidation[285, 286]. In the liver, adiponectin also activates AMPK, where the result is a reduction in 
gluconeogenesis[286]. 
1.6.2 Pharmacological activators of AMPK 
Experimentally, activation of AMPK is often achieved by treating cells or animals with AICAR, an 
adenosine analogue. AICAR is taken up by cells via adenosine transporters, then converted by 
adenosine kinase into the phosphorylated nucleotide 5-aminoimidazole-4-carboxamide ribonucleoside 
(ZMP), which mimics the effects of AMP on AMPK activation[287]. 
Metformin, a widely prescribed drug used to improve insulin sensitivity in type II diabetes mellitus, 
activates AMPK in vitro and in vivo[288]. It is activation of AMPK in the liver, leading to a reduction 
in hepatic gluconeogenesis, that is most likely responsible for its clinical efficacy[289]. Although 
metformin has been used in vitro to activate AMPK in other tissues,  including EC, the concentrations 
required are not achievable in patients other than in the portal venous system and liver, and thus it is 
unclear whether metformin activates AMPK in EC in patients [261, 262]. The mechanism by which 
metformin activates AMPK is thought to be through inhibition of complex I in the mitochondrial 
electron transport chain, leading to a change in the AMP:ATP ratio and thus allosteric activation[288]. 
Atorvastatin and simvastatin activate AMPK in EC and in the vasculature in vivo[290, 291], and this 
may be an important contributor to the pleiotropic vasculoprotective properties of statins. Although 
the mechanism is not clear, AMPK activation is linked to inhibition of HMG CoA reductase, which is 
the primary effect of statins, and both can increase vascular eNOS activity[245, 292, 293]. Statins 
may also alter LKB1 phosphorylation, through activation of PKCζ[291]. 
PPARα and γ agonists have also been used to activate AMPK in vitro, but there is as yet little 
evidence to suggest that this is an important facet of their mechanism of action in vivo. Fenofibrate, a 
PPARα agonist in clinical use to treat hyperlipidaemia, prevented apoptosis induced by serum 
deprivation in retinal EC through activation of AMPK and induction of VEGF mRNA[251]. This 
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effect appeared to be PPAR independent. More recently, it was demonstrated that rosiglitazone, a 
PPARγ agonist, can activate AMPK and thus have effects on NO production in EC[294]. 
It was recently discovered that salicylate can directly activate AMPK[295]. Salicylate is the active 
aspirin metabolite responsible for the majority of the pharmacological effects attributed to aspirin. 
Activation of AMPK by salicylate may be important for the anti-cancer, as well as anti-inflammatory, 
properties of aspirin, although the concentrations used in vitro are probably not achievable in patients 
taking conventional low dose aspirin for prevention of coronary artery disease[296]. For example, in 
order to demonstrate increased acetyl CoA carboxylase (ACC) phosphorylation in response to 
salicylate (a key AMPK target critical for its effects on fatty acid oxidation), Hawley et al used doses 
sufficient to generate plasma concentrations of 1-2mM in mice[295]. 
A wide variety of other drugs and herbal supplements have also been shown to activate AMPK, 
including resveratrol (found in red wine), epigallocatechin gallate (green tea), capsaicin (chillis) and 
curcumin (turmeric)[297-299]. All act in some sense as a mitochondrial poison, inhibiting the 
respiratory chain or ATP synthase and thus causing AMP or ADP concentrations to rise. In vitro work 
has demonstrated cytoprotective properties for all these compounds[181]. 
1.6.3 Targets and metabolic effects of AMPK activation 
A wide array of cellular processes are now known to be regulated by AMPK. These include 
carbohydrate and lipid metabolism; promotion of mitochondrial metabolism and biogenesis; 
autophagy; cell growth and proliferation; apoptosis; and anti-inflammatory pathways. In many cases 
AMPK directly targets and phosphorylates effector enzymes in the metabolic pathways under 
influence. This is the case with ACC, HMG CoA reductase and eNOS[260, 292, 293]. In other cases, 
AMPK activates transcription factors and co-activators to alter gene expression[142]. Finally, AMPK 
activation may have target effects via epigenetic regulation: AMPK has been reported to affect the 
action of histone acetylases and deacetylases, including sirtuin-1 (Sirt1)[300]. 
Metabolic effects 
AMPK is thought to operate as a sensor of cellular energy depletion that, when activated by a rise in 
AMP:ATP ratio, switches on catabolic pathways capable of generating ATP and turns off energy-
requiring processes that are not essential for cell survival. These changes have been explored most 
extensively in skeletal and cardiac muscle, and in the liver. The catabolic pathways affected by 
AMPK include upregulation of glucose transporter expression and activity, leading to increased 
cellular glucose uptake[301]; increased glycolysis via increased activity of 6-phosphofructo-2-
kinase[302]; increased fatty acid oxidation[303]; and autophagy[304]. The anabolic processes that are 
suppressed include glycogen synthesis and hepatic gluconeogenesis[305, 306]; fatty acid and 
cholesterol synthesis (via inhibition of HMG CoA reductase)[293, 307]; and protein synthesis (via 
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suppression of MTORC1)[308]. These changes occur both through direct actions on target enzymes 
and indirectly through activation or inhibition of transcription factors and co-activators and changes in 
gene expression. 
Mitochondrial metabolism 
A significant change in cell metabolism promoted by AMPK is increased mitochondrial oxidative 
metabolism: both by increasing expression of enzymes involved in oxidative phosphorylation, and by 
inducing mitochondrial biogenesis[266]. Mitochondrial biogenesis is a well-defined feature of 
activation of AMPK signalling in EC, and in energy-requiring tissues is orchestrated via the 
transcriptional co-activator PGC-1α[309].  
In HUVEC, AMPK activation using metformin or AICAR resulted in induction of PGC-1α, 
stimulated mitochondrial biogenesis, and increased mRNA expression of nuclear respiratory factor-1 
and mitochondrial DNA transcription factor A[262, 310]. These effects were associated with a 
reduction in mitochondrial ROS production. 
However, in EC, mitochondria are not the primary energy source; rather they rely mainly on 
glycolysis[124]. It is therefore not clear what the physiological function of enhanced mitochondrial 
biogenesis might be, if not to do with a response to increased ATP requirements. It has recently been 
proposed that mitochondrial biogenesis and PGC-1α activation in EC may be more important for 
orchestrating the cellular defence against oxidative stress, through the induction of mitochondrial 
antioxidants[262]. It is also possible that endothelial function depends on the whole process of 
mitochondrial turnover, both biogenesis and increased mitophagy/ autophagy, which is also regulated 
by AMPK[124]. 
Cell growth and proliferation 
Given that the principal stimulus to AMPK activation is nutrient deprivation, it is unsurprising that a 
further effect of AMPK activation is to inhibit cell growth and proliferation, in both normal and 
malignant cells. This is likely to be important in its anti-cancer effects. AMPK switches off the 
mammalian target of rapamycin (mTOR) - S6 kinase I pathway that is critical for regulation of cell 
growth and size, via phosphorylation of the upstream regulator tuberous sclerosis complex-2 (TSC2) 
[311]. Inhibition of mTOR results in the downregulation of proteins required for rapid cell growth, 
including the transcription factor hypoxia inducible factor 1α (HIF-1α)[312]. 
In addition, AMPK activation induces cell cycle arrest in G1, inhibiting transition to S-phase. This 
state is associated with accumulation of p53 and of the cyclin-dependent kinase inhibitors p21 and 
p27, which act downstream of p53[313]. 
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Apoptosis, senescence and lifespan 
The effect of AMPK on apoptosis is not uniform across all tissues. In most cases in normal, non-
activated cells, AMPK activation acts to protect against apoptosis[217, 277]. However, in malignant 
cells, AMPK activation may promote cell death[314, 315].  
AMPK activation may also contribute to cell senescence. Activation of AMPK and an increased 
AMP:ATP ratio are associated with senescence in fibroblasts after a high number of passages in 
culture[316].  
There is also evidence that AMPK orthologue signalling is important for senescence and thus lifespan 
in the nematode worm Caenorhabditis elegans. C. elegans senescence is associated with increases in 
cellular AMP:ATP. Environmental stresses such as starvation or heat shock that cause rises in 
AMP:ATP or mutations inactivating the C.elegans equivalent of the insulin/ IGF-1 pathway (that 
antagonises AMPK in mammalian tissues) can only extend the lifespan of worms expressing the full 
AMPK orthologue[317]. Furthermore, glucose restriction extends C.elegans lifespan through the 
induction of mitochondrial oxidative metabolism, an effect dependent on AMPK activation and 
sirtuins[318]. This raises the possibility that AMPK activation is implicated in the increase in life span 
induced by caloric restriction in mammals. Although direct evidence of a role for AMPK signalling in 
delaying ageing in humans is missing, there is evidence that long-term physical exercise improves 
mitochondrial metabolism and reduces the decline in mitochondrial function with age, and similar 
changes in mitochondrial metabolism have been attributed to AMPK activation in vitro and in 
rodents[262, 279, 319]. 
Anti-inflammatory effects 
There is increasingly good evidence that activation of AMPK results in limitation of inflammation. 
Partly this is due to its effects on cell metabolism: activated cells of the immune system rely on 
glycolysis for energy; whereas quiescent cells use primarily oxidative phosphorylation in 
mitochondria[266]. AMPK signalling favours mitochondrial metabolism and so tends to direct cells 
towards a more quiescent phenotype. For example, in dendritic cells, the switch to aerobic glycolysis 
following activation by ligation of toll-like receptors (TLRs) is associated with reduced AMPK 
Thr172 phosphorylation and can be inhibited by pharmacological activation of AMPK[320]. In 
macrophages, the pro-inflammatory M1 phenotype is associated with aerobic glycolysis while the 
anti-inflammatory M2 phenotype  uses more oxidative phosphorylation[321]. Studies of macrophages 
depleted of AMPK suggest that it normally lowers the expression of pro-inflammatory cytokines in 
response to lipopolysaccharide (LPS)[322]. Meanwhile, in mice with a genetic deletion of the AMPK 
β1 subunit, macrophages demonstrated increased JNK activation and hence a predominant M1 
phenotype[323]. 
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In addition, AMPK signalling is able to invoke anti-inflammatory effects through inhibition of NFκB 
signalling, and these actions are discussed in the later section on AMPK in EC. 
1.6.4 Actions of AMPK in EC 
In EC, AMPK activity has similar effects on metabolism as those described in other tissues, including 
effects on glucose and lipid metabolism and on mitochondrial biogenesis and function (Figure 
1.4)[142]. However, whether AMPK has as important a role in EC metabolism as it does in other 
tissues is less clear, particularly as EC are thought to rely on glycolysis with relatively little energy 
derived from glucose oxidation[124]. 
 
Figure 1.4 Targets and physiological consequences of AMPK activation in EC. Adapted from Fisslthaler and 
Fleming[142]. 
In vitro, as in other cell lines, AMPK can be activated in EC via AICAR, glucose deprivation, hypoxia 
and pharmacologically, resulting in diverse cytoprotective effects[262, 276]. Additionally, and more 
relevant to the natural physiological state, stimuli specific to EC such as LSS and VEGF activate 
it[290, 324].  
The mechanism by which LSS leads to activation is not clear, but it appears to differ from that by 
which LSS leads to the phosphorylation of other shear-responsive pathways such as Akt. The 
evidence for this comes from deletion of CD31, which forms part of the mechanotransduction 
complex in EC.This did not alter AMPK phosphorylation in response to shear stress[325]. One of the 
most important protective effects of AMPK in EC is direct phosphorylation of eNOS at both Serine 
1177 and Serine 633, leading to increased endothelial NO production [292] and this is likely to be 
closely linked to its activation by shear stress, given that blood flow powerfully activates eNOS. In 
addition, the forkhead transcription factor FoxO1a depends on AMPK for its phosphorylation by flow, 
leading to its export out of the nucleus and downregulation of expression, in turn leading to a 
reduction in HMG-CoA reductase and Ang-2 expression[326]. Lastly, flow-induced AMPK signalling 
may be important for the induction of KLF-2, as Young et al reported that blocking AMPK resulted in 
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abrogation of the flow-mediated induction of KLF-2 expression. This effect depended on downstream 
changes in ERK5/ MEF2 signalling[327]. 
Secondly, AMPK may be important for angiogenesis. Embryonic LKB1 knockouts die in utero with 
vascular abnormalities[328], and dominant negative AMPK virus infection of HUVEC inhibited their 
migration along a VEGF gradient and angiogenesis in in vitro and in vivo assays[329]. This effect 
may be mediated through AMPKα1, as inhibition with RNA interference reduced VEGF-induced 
angiogenesis in matrigel plug assays[324]. Of note, although VEGF is also a powerful stimulator of 
NO formation by eNOS in EC, this appears independent of its activation of AMPK, as inhibition of 
AMPK or its upstream kinase CaMKKβ did not affect VEGF-mediated eNOS phosphorylation[324]. 
Thirdly, AMPK activation in EC can protect against oxidative injury, through its effects on 
mitochondrial function and biogenesis. EC pretreated with AICAR or metformin were protected 
against injury and death induced by rising concentrations of H2O2. This effect involved abrogation of 
JNK pathway activity, reversal of changes in mitochodrial membrane potential and mitochondrial 
ROS production induced by H2O2, and enhanced mitochondrial biogenesis[262]. It also involved the 
transcriptional co-activator PGC-1α, which in muscle is a critical controller of mitochondrial 
metabolism through AMPK[330]. 
Part of the explanation for how AMPK protects against oxidative injury presumably derives from its 
ability to induce expression of anti-oxidant genes. Silencing AMPKα1 in human EC resulted in 
decreased expression of many anti-oxidant genes, including MnSOD, catalase, γ-glutamyl cysteine 
synthase and Trx[276]. These changes required PGC-1α, CREB and FoxO3a. AMPKα2 is important 
too however, despite being expressed at lower levels in EC. Wang et al demonstrated impaired 
endothelium- dependent relaxation in response to acetylcholine in aortae from AMPKα2-/- mice, 
which was improved by pre-treatment with a SOD mimetic, suggesting that increased oxidative stress 
was responsible. They also noted increased expression of NADPH oxidase subunits and superoxide 
production in HUVEC treated with DN-AMPK or AMPKα2 siRNA[331]. 
Fourthly, AMPK activation acts to prevent apoptosis induced by a variety of stimuli including TNFα, 
hyperglycaemia and oxygen and glucose deprivation[217, 277, 332].  When EC are subjected to 
oxygen and glucose deprivation, AMPK is activated, and pre-treatment with AICAR or CA-AMPK 
viral infection prolongs EC survival while inhibition exacerbates rates of apoptosis. The mechanism 
underlying this involves induction of Bcl-2 and survivin, through activation of NFκB, which in turn 
appears to rely on AMPKα1 signalling[277]. Induction of HO-1 is also important in this context. HO-
1 is induced by an Nrf2 interaction with the antioxidant response elements in the HMOX-1 promoter. 
AMPK-mediated cytoprotection against TNFα and ceramide was reduced by inhibition of HO-1[217]. 
Finally, AMPK activation in EC is also noted to have an anti-inflammatory action. Notwithstanding 
Liu et al's study suggesting that NFκB mediates AMPK's anti-apoptotic actions in EC, other work 
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suggests that AMPK activation with AICAR or viral over-expression attenuates NFκB activation in 
EC by TNFα[333], leading to suppression of VCAM-1 and E-selectin. This leads to reduced 
monocyte adhesion to the EC surface[334]. Reducing AMPKα2 signalling, by contrast, increases 
NFκB translocation and degradation of IκBα[331].  In bovine aortic endothelial cells (BAEC), 
AICAR treatment did not affect IκB degradation and nuclear translocation of the p65 subunit, while 
binding of NFκB to a κB consensus sequence oligonucleotide was reduced in AICAR-treated cells, 
suggesting that AMPK inhibtion of NFκB occurs at the level of interference with DNA binding[335]. 
1.6.5 Clinical conditions resulting from aberrant AMPK activation 
AMP kinase disease in people is an inherited condition caused by mutations in the gene encoding the 
AMPK γ2 subunit (PRKAG2), and was first described in 2001[336]. It is rare: eleven families are 
described in the literature[337] and analysis of 100 consecutive referrals to a dedicated heart muscle 
unit found only 1 additional case[338].   
Clinically the condition is characterised by left ventricular hypertrophy, mimicking hypertrophic 
cardiomyopathy, and by electrophysiological abnormalities including accessory conduction pathways 
and atrio-ventricular block[336, 339]. Later work has established that skeletal muscle is also 
abnormal, with proximal myopathy seen on electromyography (EMG), and a small number of patients 
also develop epilepsy with generalised tonic-clonic seizures[338].  
Both families in the original description and the subsequent cases identified harbour missense 
mutations leading to amino acid substitutions in evolutionarily conserved regions of the protein: the 
CBS domains responsible for binding AMP. Altering γ2 structure in this way does not affect the 
ability of the γ2 subunit to associate with α and β subunits and form the complete complex, but does 
appear to affect its sensitivity to AMP, such that sensing the AMP:ATP ratio and energy state of the 
cell is impaired[340]. Murine models of the disease have been created, and have established that 
deposition of amylopectin, a glycogen-like polysaccharide, in myocytes is fundamental to disease 
development. It has been proposed that glycogen accumulation may lead to AMPK inactivation, and 
that this is responsible for the disease phenotype[341]. Amylopectin accumulation is also seen in 
myocardial sections from patients with the disease. Histological examination of quadriceps biopsies in 
those patients who also had a proximal myopathy demonstrate ragged red fibres with increased 
numbers of mitochondria. A mild excess of glycogen deposition was described in a subset, 
occasionally seen within mitochondria[338]. 
Single nucleotide polymorphisms (SNPs) in the gene encoding the AMPKα1 subunit (PRKAA1) have 
been associated with an increased risk of developing gastric cancer in Chinese patients and with 
prognosis in colorectal cancer, but no association was seen with breast cancer [342-344]. The 
functional relevance of these SNPs is as yet unclear. Single nucleotide polymorphisms in PRKAA1 
have also been studied in the context of risk of coronary artery disease in patients with type II diabetes 
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in China, and an association seen between haplotype and protection from CAD but with increased 
CAD if the individual was also a smoker[345].  
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1.7 Methotrexate 
1.7.1 Methotrexate in clinical practice 
Methotrexate (MTX), an anti-metabolite drug that interferes with folic acid metabolism, is a well-
established and effective anti-inflammatory agent central to the current treatment paradigms for 
RA[346, 347]. It is also used as a disease-modifying drug in other forms of inflammatory arthritis 
such as psoriatic arthritis and juvenile idiopathic arthritis; and as a steroid-sparing drug in many other 
chronic inflammatory conditions, including primary systemic vasculitis, sarcoidosis and idiopathic 
inflammatory myositis. 
MTX was initially developed as a cancer-chemotherapy agent over 65 years ago. Following the 
discovery of folic acid and its role in cellular metabolism in 1946, effort went into developing anti-
metabolites that would block the folic acid cycle, and aminopterin, a methotrexate precursor that 
potently blocked folic acid metabolism, was discovered shortly after to be effective in inducing short 
remissions in acute leukaemia in children[348]. Aminopterin was first reported to be successful in 
treating RA by Gubner et al in 1951, who described 6 cases, 5 of whom improved[349]. However, 
this observation was not expanded upon until Hoffmeister reported success in treating 78 patients with 
intramuscular methotrexate in 1983[350]. Four randomised controlled trials were then conducted in 
the 1980s[351-354], which led to the widespread adoption of MTX as a treatment for RA. 
MTX is now used as the first-line disease-modifying anti-rheumatic drug (DMARD) in RA treatment. 
DMARD denotes those agents that, in addition to improving the clinical features of the disease such 
as joint pain, swelling and stiffness, prevent progression of the disease, most clearly seen in the 
development of joint erosions on X-ray that signify permanent joint damage. The DMARDs include 
sulphasalazine and leflunomide, and are distinguished from NSAIDs and glucocorticoid steroids, that 
provide powerful symptomatic relief but do not prevent disease progression. MTX is the central 
DMARD because it is thought to have the best efficacy-to-toxicity ratio, when taken and monitored 
correctly[355]. A meta-analysis on the original 4 trials of MTX for RA found that patients treated 
with MTX had 26% fewer inflamed joints and 39% greater improvement in pain than those treated 
with placebo. Adverse effects resulting in discontinuation occured in about one third of patients, but 
the vast majority of these were mild and less than 1% suffered serious adverse events[356]. These 
findings have led to a view of MTX as the benchmark treatment for RA against which all others, 
including biological agents, are measured. 
MTX can be taken orally or parenterally by subcutaneous or intra-muscular injection, and the doses 
used in modern rheumatology practice (typically 10 - 25mg per week) are several orders of magnitude 
smaller than those when used as a cancer chemotherapy agent. Absorption is not significantly 
different with any route, but higher doses may be tolerated better if taken parenterally. Once in the 
circulation, approximately 50% is protein-bound. Side-effects include oral ulceration, stomatitis and 
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nausea commonly, which can be mitigated by the co-prescription of folic acid. More serious but rare 
effects include bone-marrow suppression with subsequent cytopenias, transaminitis progressing to 
cirrhosis if liver function abnormalities are disregarded, and pneumonitis. These can largely be 
avoided with appropriate prescription and monitoring blood tests. 
1.7.2 Methotrexate and cardiovascular disease 
There was initial concern that MTX would increase rates of CVD in RA, as its use is associated with 
increased plasma homocysteine concentrations[357]. Hyperhomocysteinaemia is associated with 
increased rates of CVD[358] and has toxic effects on endothelium including reduced NO availability 
and increased ROS generation[359]. However, the prescription of folic acid reduces 
homocysteinaemia, as it is required for the methylation of homocysteine into methionine[360], and 
further work has since established that MTX use is associated with a reduction in CVD in RA. 
Although short case series and observational retrospective studies suggest that several DMARDs, 
including leflunomide and sulphasalazine, may reduce CVD, MTX is the drug for which the evidence 
is most secure[82]. Choi et al, in a retrospective study of over 1000 patients, found a 70% reduction in 
CVD mortality in RA patients taking MTX compared to other drugs; and more recent systematic 
literature reviews and a meta-analysis have confirmed this [79, 361, 362].  Moreover, MTX is also 
associated with improvement in functional markers of endothelial dysfunction[363]. Finally, MTX 
improved atherogenesis in the cholesterol-fed rabbit model. In this study, animals were treated with 
MTX 4mg/kg weekly by intravenous injection for 4 weeks, and a 75% reduction in atheroma area was 
reported, along with improvements in intima-media ratio and macrophage infiltration[364]. These 
findings have led to initiation of a trial of its use as a treatment to reduce atherosclerosis even in 
patients with no known inflammatory disease[15].  
1.7.3 Mechanism of action of methotrexate 
Despite its long history and widespread use the anti-inflammatory mechanism of action of MTX 
remains a subject of debate. Originally it was thought that antagonism of folate metabolism, which is 
the basis of its cancer killing actions, was also responsible for its anti-inflammatory effects. Other 
theories include accumulation and extracellular release of adenosine and increased intracellular 
oxidative stress. 
Inhibition of folate metabolism 
Inhibition of purine and pyrimidine synthesis is the established mechanism by which MTX kills 
malignant cells. Folates are co-enzymes derived from the diet and are essential for nucleotide 
synthesis, particularly purines and adenosine. Folate from the digestive tract is converted to 
dihydrofolate in the liver, and this enters cells via a folate transporter and is then converted 
intracellularly to tetrahydrofolate (TH4), the biologically active form, by dihydrofolate reductase 
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(DHFR). TH4 and its downstream metabolites are cofactors in many enzymatic processes, particularly 
those involved in purine synthesis. In addition, methyltetrahydrofolate promotes the conversion of 
homocysteine to methionine. 
MTX is an analogue of folate and can therefore enter cells in the same way, via the folate transporter. 
It has a higher affinity for DHFR than does TH4, and hence inhibits TH4 production. In turn this 
prevents purine nucleotide synthesis and so stops cell proliferation, and in rapidly dividing cells 
induces apoptosis. However, MTX can also bind to and inhibit a number of other genes in folate and 
purine metabolism, including thymidylate synthase, which is the enzyme it has most affinity for (this 
is inhibited at MTX concentrations of 1nM, while inhibition of purine synthesis requires at least 
10nM). Enzyme inhibition results in a cascade of effects, with build-up of metabolites leading to 
biological actions of their own. For example, MTX inhibtion of DHFR, reducing generation of TH4, 
then results in reduced methylTH4, and thus reduced promotion of the conversion to methionine of 
homocysteine, hence raised levels of homocysteine. 
As purine synthesis is essential for cellular proliferation, it seems reasonable that MTX, by reducing 
TH4 availability, could reduce disease activity in RA by inhibiting proliferation of activated T 
lymphocytes and macrophages in synovial tissue and elsewhere. Adverse effects such as bone marrow 
suppression and stomatitis are also likely to be secondary to the anti-proliferative effects of reducing 
folate metabolism. To support this, MTX induced a cell cycle block in ex vivo lymphocyte cultures 
derived from RA patients[365], and stimulated apoptosis of antigen-responsive T lymphocytes in 
culture. Furthermore, folic acid supplementation  is associated with a reduction in the ability of MTX 
to lower titres of rheumatoid factor[366]. A recent study has shown that many folate cycle genes are 
upregulated in whole blood samples from RA patients, and their expression levels are normalised by 
taking MTX[367].  
There are several reasons to suspect that inhibiting TH4 formation is not responsible for the anti-
inflammatory action of MTX. Firstly, instead of high dose pulsed therapy as a cancer treatment, MTX 
for rheumatic disease is effective at low doses, (1-5g vs 10-25mg), taken on a weekly basis for many 
years. Secondly, the onset of anti-inflammatory action is slow, occurring over 4-6 weeks, whereas the 
half-life of MTX in the serum is 6-8h and is undetectable after 24h. Finally, supplementation with 
folic acid, routinely co-prescribed with MTX to prevent adverse effects, does not appear to alter its 
anti-inflammatory efficacy, although this has not been supported by all studies on the subject[368, 
369]. Therefore, other mechanisms need to be invoked. 
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Adenosine accumulation and extra-cellular release 
The relatively long duration of onset and offset of MTX's anti-inflammatory action was one of the 
factors that suggested folate inhibition was not its sole property. Intracellularly, MTX is converted to 
polyglutamate metabolites which persist for many weeks, and which inhibit a broader array of 
enzymes involved in nucleotide metabolism than does MTX itself, and the timing of its effects might 
be consistent with some of its biological action pertaining to these. The concentration of MTX 
polyglutamates in erythrocytes roughly correlates with therapeutic efficacy. MTX polyglutamates 
inhibit DHFR at least as well as MTX itself, but they inhibit AICAR transformylase more 
strongly[370, 371]. AICAR transformylase catalyses the conversion of the nucleotide AICAR into 
formyl-AICAR, a step in the production of hypoxanthine, and its inhibition leads to intracellular 
accumulation of AICAR. AICAR inhibits AMP deaminase, and can itself can be metabolised to 
AICA-riboside (ZMP), which inhibits adenosine deaminase. This therefore leads to a rise in AMP and 
adenosine levels (Figure 1.5). As adenosine has potent anti-inflammatory actions[372], rises in 
adenosine have been posited as the anti-inflammatory mechanism of action of MTX[373]. 
There is good evidence that long term MTX treatment leads to AICAR accumulation. Patients taking 
low dose MTX to treat psoriasis excrete increased amounts of AICAR in their urine[374], and 
Cronstein et al reported increased AICAR concentrations in HUVEC and fibroblasts treated with 
MTX in vitro[375], and in splenocytes from MTX-treated mice in vivo[376]. Importantly, in both 
papers the MTX concentrations used were low, and administered over relatively long periods of time: 
100nM over 48h in the case of in vitro work and 0.5mg/kg per week in the in vivo studies. There is 
also convincing evidence to suggest that MTX increases adenosine levels, and that this is sufficient to 
mediate anti-inflammatory effects. In the same paper, Cronstein et al showed that adenosine as a 
proportion of total nucleotides was enriched in HUVEC and fibroblasts treated with MTX, and that 
the adenosine release inhibited neutrophil adhesion to EC monolayers[375]. Moreover, in vivo studies 
of MTX 0.5mg/kg per week in mice using a carageenan air pouch model of inflammation showed 
increased adenosine concentrations in inflammatory exudates, accompanied by reduced lymphocyte 
accumulation. This was reversed by the addition of adenosine A2A receptor antagonists[376]. These 
effects were replicated in a model of inflammation in the rat gastro-intestinal tract, where MTX 
administration was associated with rises in adenosine and reduced leucocyte trafficking, and also in a 
model of rat adjuvant arthritis[377, 378]. Finally, drinking coffee appears to reduce the therapeutic 
efficiacy of MTX in RA; which could be due to caffeine acting as an adenosine receptor 
antagonist[379]. 
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Figure 1.5 Mechanism of action of methotrexate. Adapted from Chan and Cronstein[369]. 
Generation of ROS 
In vitro studies of the effects of MTX have shown that it reduces intracellular glutathione and 
increases cytosolic peroxide concentrations in monocytes, and this leads to inhibition of monocyte 
adherence to LPS-activated HUVEC[380]. However, the relevance of this to the patient is not clear, 
since intracellular glutathione levels in the inflamed synovium of the rheumatoid joint are already 
reduced well below that achieved by MTX in vitro, with high levels of ROS mediating injury in joint 
tissue in untreated patients. Moreover MTX has been shown to suppress IL-6- driven ROS production 
in synovial tissue[381]. 
1.7.4 Effects of methotrexate on vascular endothelium 
The effects of MTX on vascular endothelium have not been extensively studied. The observations 
made so far generally fall into three groups: effects on EC proliferation and, by extension, 
angiogenesis; effects on homocysteine and NO production that might be thought pro-atherogenic; and 
effects on adenosine release and cell adhesion molecule expression that might be thought anti-
atherogenic.  
MTX prevents EC proliferation in culture at concentrations achievable, at least in the short term, in 
patient serum[382]. It does not however appear to stimulate EC apoptosis[383], although it does 
induce apoptosis in many cancer cell lines, activated T cells and keratinocytes[380, 384]. This 
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translates into inhibition of angiogenesis, which was observed in a rabbit corneal neovascularisation 
model when animals were treated with MTX 0.3 - 0.7mg/kg weekly for 8 weeks[385]. Inhibition of 
angiogenesis is probably a desirable effect in RA, as one would expect this to help with limiting 
synovial proliferation and may contribute to its disease-modifying properties. There is little known 
about whether MTX alters numbers of circulating endothelial progenitor cells, but a recent study of 
angiogenic T cells in RA suggests that MTX increases their numbers[386]. 
Through inhibition of DHFR, MTX might be expected to exert pro-atherogenic effects on EC. Firstly, 
inhibition of DHFR can lead to rises in homocysteine levels, although prescription of folic acid in 
addition to MTX probably prevents this causing significant problems in clinical practice. However, 
dihydrofolate reductase is also required as a salvage enzyme to maintain levels of tetrahydrobiopterin 
(BH4), an essential co-factor for eNOS. Without BH4, eNOS becomes uncoupled and produces 
superoxide instead of NO. Folic acid supplementation not only improves endothelial function even in 
patients without hyperhomocysteinaemia[387], it has been shown in vitro to upregulate EC DHFR 
expression and NO production, albeit using supra-physiological concentrations. Moreover, this is 
abolished if cells are pretreated with MTX 1µM. A small reduction in NO production was also noted 
when EC were treated with MTX alone[388]. 
Evidence that MTX might exert anti-atherogenic effects on EC comes from Cronstein et al. They 
showed that EC treated with MTX 100nM for 48h released increased adenosine, as a proportion of 
total nucleotides released. This treatment also inhibited neutrophil adherence[375]. Adenosine has 
anti-inflammatory, anti-atherogenic properties. Further anti-inflammatory effects of MTX on EC in 
vitro were demonstrated by Yamasaki et al, who showed that MTX 1µM inhibits TNFα-induced 
ICAM-1 and VCAM-1 expression in HUVEC[382]. MTX has also been shown to reduce the TNFα-
stimulated induction of the pro-inflammatory genes  TNFα, IL-1β, VAP-1, CXCL-2 and TLR-2 , and 
to up-regulate TGFβ in HUVEC, although the study showing this used very high concentrations of 
MTX over a short time period, and thus may not accurately reflect the situation in vivo[364]. 
Further anti-atherogenic effects of MTX have been demonstrated through its effects on reverse 
cholesterol transport in macrophages. Macrophages must be able to metabolise efficiently and process 
engulfed cholesterol: transformation to foam cells occurs when these processes are overwhelmed by 
too much lipid accumulation, as occurs in atherogenesis at the fatty streak stage. Cholesterol efflux in 
cells is regulated by two pathways: ATP-binding cassette transporter A1 (ABCA1) and cholesterol 
27-hydroxylase[389]. In human THP-1 monocyte/ macrophages stimulated with IFNγ or COX-2 
inhibitors, both of which down-regulated ABCA-1 expression, treatment with MTX restored levels, 
and also prevented foam cell formation. These results appeared to involve MTX's effects on 
adenosine levels, as inhibiting adenosine A2A receptors abrogated them[390]. 
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2 HYPOTHESIS 
Mitigation of premature cardiovascular disease driven by chronic inflammation is a key goal in 
improving the outcome of patients with systemic inflammatory disease. Improved disease treatment 
and identification and modification of traditional risk factors will be important approaches, but a clear 
idea of which drugs offer most benefit to the vasculature would help enormously. To determine this, it 
is important to understand firstly how intrinsic mechanisms of endothelial protection operate, as these 
act to reduce endothelial dysfunction, the initial and reversible step in atherogenesis. Secondly, 
investigating the abilities of drugs used commonly in the treatment of chronic inflammatory disease to 
affect endothelial cytoprotective pathways should allow clinicians to offer their patients a more 
refined strategy to reduce their chances of developing atherosclerosis in the future. 
Two key factors in preventing endothelial dysfunction physiologically are chronic exposure to 
pulsatile high flow LSS, and VEGF. Parts of the vasculature where blood flow has such 
characteristics rarely develop atherosclerotic plaques, while VEGF is a powerful driver of NO 
production. Both have been shown to affect similar cytoprotective pathways in EC, such as HO-1 
induction, eNOS activation, and AMPK signalling. This led to the hypothesis that in combination 
VEGF and LSS induce synergistic improvements in endothelial cytoprotection. 
Although MTX, the central DMARD used for long-term control of RA, reduces disease-associated 
CVD, little is known about the mechanisms that explain this effect. The anti-inflammatory effects of 
long-term low dose MTX are probably mediated by long-lasting polyglutamate metabolites of MTX, 
and these inhibit most powerfully AICAR transformylase, an enzyme involved in purine metabolism. 
The upstream effects of this inhibition are increased concentrations of AICAR, ZMP and AMP, and 
these are activators of AMPK. This led to the second hypothesis: that MTX activates AMPK in EC, 
improving resistance to inflammatory injury that ultimately protecting againt atherogenesis. 
To address these hypotheses, four specific questions were formulated: 
Firstly, does exposure of EC, conditioned by LSS, to VEGF result in a synergistic induction of 
cytoprotective enzymes such as HO-1? If so, can the underlying signalling pathways be mapped out? 
Secondly, does long-term low dose MTX activate cytoprotective pathways in EC, particularly AMPK, 
and does this result in functional improvements in EC survival? 
Thirdly, how does activation of AMPK by MTX lead to  changes in expression of cytoprotective 
effector proteins? 
Finally, does MTX activate AMPK in the vasculature in vivo, and does it ameliorate the inflammatory 
vasculopathy that is a feature of the SLE-like illness in (NZWxBXSB)F1 male mice?  
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3 MATERIALS AND METHODS 
3.1 Cell culture techniques and analysis 
3.1.1 Isolation and culture of HUVEC 
The experimental use of HUVEC was approved by the Hammersmith Hospital Research Ethics 
Committee (ref. no.06/QO46/21), and isolation and culture was carried out as described by Jaffe et 
al[391]. Umbilical cords were collected in Hanks' buffered saline solution (HBSS) containing calcium 
and magnesium (Sigma-Aldrich Ltd.), supplemented with 1mM sodium pyruvate (Gibco by Life 
Technologies) and 0.1mg/ml gentamicin (Gibco). A sterile three-way connecter tap (Bunzl 
Healthcare) was inserted into the umbilical vein and flushed with warmed HBSS without Ca/Mg. A 
second three-way tap was inserted in the other end and the vein was filled with 0.5mg/ml collagenase 
in HBSS and incubated for 10 minutes at 37C. The cord was massaged to detach the EC, flushed 
with warm HBSS and the collagenase solution was collected into a 50ml Falcon tube (Helena 
Biosciences). The solution was centrifuged at 1200rpm for 10 minutes, the supernatant was discarded, 
and the pellet resuspended in 5ml M199 EC culture medium (Sigma) supplemented with 100μg/ml 
penicillin and 100μg/ml streptomycin (Gibco), 2mM L-glutamine (Gibco), 20% fetal calf serum 
(FCS; Biosera), 30μg/ml endothelial cell growth factor (ECGF; Sigma) and 10 units/ml heparin. The 
EC were transferred to a 1% gelatine-coated T25 culture flask (Costar) and cultured for 24 hours 
before washing with HBSS to remove debris and blood, and the addition of 5ml of fresh HUVEC 
culture medium. 
3.1.2 Culture of HMEC and HAEC 
Third passage human microvascular endothelial cells (HMEC; gift from Dr E Ades, CDC, Atlanta) 
were retrieved from long term storage at -196C in liquid nitrogen and cultured in MCDB-131 
medium (Gibco) supplemented with 100μg/ml penicillin, 100μg/ml streptomycin, 2mM L-glutamine, 
10 units/ml heparin, 15% FCS and 10μg/ml EGF (Peprotech). 
Fifth passage human aortic endothelial cells (HAEC; Promocell) were retrieved from long term 
storage at -196C in liquid nitrogen (with thanks to Dr D Calay) and cultured in M199 supplemented 
with 100μg/ml penicillin, 100μg/ml streptomycin, 2mM L-glutamine, 10 units/ml heparin, 20% FCS 
and 30μg/ml ECGF. 
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3.1.3 Passage of EC 
EC were passaged once they formed a fully confluent monolayer (Figure 3.1), every 2-4 days. The 
exhausted medium was aspirated, the cells were washed in HBSS and then incubated for 2 minutes 
with 1ml trypsin/ ethylenediaminetetraacetic acid (EDTA; MP Biomedicals) to promote detachment 
from the gelatine basement membrane. They were resuspended in an appropriate volume of complete 
medium to allow passage into a T75 flask (if first passage) or a 1:2 or 3 split if later passages. 
HUVEC were used at passage 2-4; HMEC were used at passage 5 and above and HAEC were used at 
passage 7 and 8. 
 
Figure 3.1 Photomicrograph of confluent passage 3 HUVEC in static culture (x200 magnification) 
3.1.4 Stimulation of EC with pharmacological agents and growth factors 
EC were harvested with trypsin as described in section 2.3 and seeded at 70% confluence into 12 or 6-
well plates (1.75 or 3.5x10
5
 cells per well) coated in 1% gelatine. Following overnight incubation in 
M199 containing 10% FCS and 15μg/ml ECGF to allow the EC to settle, medium was aspirated, the 
cells were washed in HBSS and fresh medium was added. Experimental agents including growth 
factors and pharmacological agents were then added at concentrations described in the results chapters 
and in Table 2.1, along with appropriate negative vehicle controls (either double distilled water 
(ddH2O) or dimethyl sulphoxide (DMSO)). 
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Agent Company Concentration 
AICAR- 5’ phosphate Calbiochem 1mM 
Compound C (AMPK inhibitor) Calbiochem 5μM 
Dimethyl sulfoxide Sigma  
Folic acid  Sigma 50nM - 50 μM 
Hemin Sigma 0.5μM 
Hydrogen peroxide  Sigma  
Methotrexate  TOCRIS 0.1nM – 2μM 
Mito-TEMPO Enzo Life Sciences 5μM 
N-acetyl cysteine Enzo Life Sciences 10mM 
Tumour necrosis factor-α  R&D Systems 0.1-10ng/ml 
Vascular endothelial growth factor (VEGF A165)  Peprotech 25ng/ml 
Table 3.1 Growth factors and pharmacological agents used to treat EC 
3.1.5 RNA interference by lipid-mediated transfection 
Transfection of EC with short interfering RNA (siRNA) was carried out by a liposomal method: 
complexing siRNA with geneFECTOR transfection agent (VennNova Inc), a proprietary lipid 
compound. 3x10
5
 HUVEC were plated onto gelatine-coated 6 well plates in M199/10% FCS/15μg/ml 
ECGF and allowed to settle overnight, aiming for 50% confluence. The following day they were 
washed with ice cold Optimem medium (Gibco) then fed with 800μl pre-warmed Optimen per well. A 
solution of geneFECTOR was prepared containing 6μl geneFECTOR and 100μl Optimem per well, 
and a solution of siRNA directed against the gene of interest and one of a scramble control siRNA 
(Dharmacon) was prepared, diluting 2.5μl of 20μM stock in 100μl Optimem per well. For each 
siRNA reaction 100μl siRNA solution was mixed with 100μl geneFECTOR solution and incubated at 
room temperature for 5 minutes. The entire 200μl siRNA-geneFECTOR solution was then added 
dropwise to each well and incubated at 37
0
C for 6h. The Optimem/ siRNA/ geneFECTOR solution 
was then aspirated and cells allowed to recover in EGM-2 medium (Lonza) overnight. The following 
day, this was aspirated and EC were treated with MTX or DMSO in M199/ 10%FCS/ 15μg/ml ECGF 
for 48h before lysis. 
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Target Gene siRNA name mRNA Target Sequence 5’ – 3’ Company 
AMPKα1 Hs_PRKAA1_5 CCC ACG ATA TTC TGT ACA CAA Qiagen 
AMPKα2 Hs_PRKAA2_6 CCG AAG TCA GAG CAA ACC GTA Qiagen 
CREB-1 CREB-1 pooled 
sequence 
siGENOME 
SMARTpool 
GAG AGA GGT CCG TCT AAT G 
CGT ACA AAC ATA CCA GAT T 
GAG TGG AGA TGC AGC TGT A  
TGA CTT ATC TTC TGA TGC A 
Dharmacon 
Table 3.2 siRNA sequences 
3.1.6 Exposure of EC to LSS 
The effects of exposure to LSS on EC were investigated in the Cytodyne streamer flow system 
(Cytodyne). This consists of a parallel plate flow chamber and a recirculating flow loop as shown in 
Figure 3.2, with an upper and lower reservoir. EC seeded onto a glass slide and are mounted into a 
medium-filled chamber and held in place by vacuum suction. The chamber is then connected to a 
circuit of medium with two reservoirs. Medium is pumped from the bottom reservoir to the top by a 
peristaltic pump (VL500 Basic, Verderflex). It then flows down over the EC mounted within the 
parallel plate chamber, and back into the bottom reservoir. The height of the top reservoir determines 
the degree of shear stress, which was previously measured by Dr A Kinderlerer and determined to be 
12-20 dynes/cm
2
, similar to that in the human aorta. 
HUVEC were seeded onto 75 x 38mm glass slides (Fisher Scientific) coated in 1ml 10μg/ml 
fibronectin diluted in HBSS and incubated in complete medium in 90mm Petri dishes (Nunc) for at 
least 16 hours to allow establishment of confluence. They were then mounted into the Cytodyne 
streamer flow system or left in static conditions in the Petri dish.  
In experiments, two circuits were set up simultaneously and were placed in a chamber heated to 37C, 
connected to a continuous supply of air and 5% CO2 and left to run for 16 to 24h to allow 
equilibration of EC to flow. Drugs and growth factors were then added to one circuit for 4 to 24h 
before cell lysis. This was achieved by rapid disconnection of the glass slide from the parallel plate 
chamber and immediate immersion in ice cold HBSS, before washing and lysis for RNA or protein 
extraction. 
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Figure 3.2 Cytodyne streamer flow system. 
 
Characterisation of response and optimisation of housekeeping genes 
The original experiments to validate the Cytodyne streamer flow system in our department were 
carried out previously by Dr A Kinderlerer and Dr F Ali[189, 248]. Initial characterisation and 
optimisation experiments by me demonstrated that after 24h exposure to LSS, HUVEC changed their 
morphology and realigned in the direction of flow (Figure 3.3). 
 
Figure 3.3 Photomicrographs of HUVEC exposed to static or laminar shear stress conditions. A: static culture; 
B: LSS 20 dynes/cm
2 
for 24h; magnification x100. 
For mRNA analysis by quantitative real-time reverse transcriptase polymerase chain reaction (qRT-
PCR) of HUVEC exposed to LSS or static conditions, three housekeeping genes were used: β-actin, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and hypoxanthine-guanine 
phosphoribosyltransferase (HPRT). It became apparent from studying cycle threshold (cT) values 
after several experiments that β-actin mRNA levels were consistently downregulated when HUVEC 
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were exposed to LSS for 24h or more, while GAPDH and HPRT were unchanged (Figure 3.4). 
mRNA results were compared primarily to GAPDH thereafter. 
 
Figure 3.4 cT values for housekeeping genes under static or LSS conditions. 
 
3.1.7 Cell number assay 
This was carried out using the CellTiter 96 AQueous One Solution cell proliferation assay (Promega). 
HUVEC were plated in a 1% gelatine coated flat bottomed 96 well plate at 5000 cells/well and treated 
in quadruplicate with MTX, DMSO control or serum starvation for 48h (in M199 with 0.1% BSA). 
1.9mg/ml 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) was mixed with 300µM phenazine ethosulfate (PES) and 20µl was added to 100µl 
medium per well. HUVEC were incubated in the MTS/PES medium for 2h and the colour change was 
then quantified by measuring absorbance at 490nm on a plate reader. 
3.1.8 Flow-cytometric analysis by FACS 
HUVEC grown under experimental conditions in 6 well plates were detached with 200μl trypsin/ 
EDTA and split equally into two fluorescence-activated cell sorter (FACS) tubes (Marathon) with 1-
2ml FACS medium (HBSS supplemented with 1% FCS) added. After centrifugation at 1800rpm for 5 
minutes, the cells were incubated with the primary antibody or FACS medium (as negative control) at 
4C for 30 minutes. 2ml FACS medium was then added and the cells centrifuged again before 
incubation with a species-specific FITC-labelled secondary antibody at 4C for a further 30 minutes. 
After further centrifugation in FACS medium, the cell pellet was resuspended in cold phosphate-
buffered saline (PBS) and kept on ice. The antibodies used are shown in Table 3.2. 
Samples were analysed using a Beckman Coulter CyAn flow cytometer. A gate was drawn around the 
EC using the forward scatter/ side scatter histogram and 10 000 cells within this gate were counted 
and fluorescence analysed (as mean fluorescence intensity (MFI)). Relative fluorescence intensity 
(RFI) was caluated by dividing the MFI of cells stained with antibody of interest by that of the 
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unstained negative control. The data was processed using the associated Summit 4.3 software. 
Representative histograms and plots are shown in Figure 3.5. 
Target Antigen Source Species mAb Name Supplier Concentration 
FITC-labelled polyclonal 
anti-mouse IgG 
Rabbit  DAKO 1:50 
CD31 Mouse  P2B1α 
Developmental 
Studies Hybridoma 
Bank, USA 
Supernatant 
Endoglin Mouse RMAC8 
Dr d’Apice, St 
Vincent’s Hospital, 
Australia 
Supernatant 
ICAM-2 Mouse CBR-IC/2 
Dr Springer, Harvard 
University, USA 
Supernatant 
DAF Mouse 1H4 Departmental Supernatant 
ICAM-1  Mouse 6.5B5 Departmental Supernatant 
VCAM-1  Mouse 1.4C3 Departmental Supernatant 
Table 3.3 Antibodies used in FACS analysis. All are monoclonal unless stated otherwise. 
 
Figure 3.5 FACS analysis of HUVEC. SS Lin: side scatter linear scale; FS Lin: forward scatter linear scale: 
FITC Log: fluorescein isothiocyanate staining log scale. 
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3.1.9 Cell cycle analysis by propidium iodide staining 
Cell cycle analysis was carried out by staining fixed EC with propidium iodide (PI), a fluorescent dye 
that binds nucleic acids by intercalation between base pairs. If RNA is removed, the DNA content of 
cells can be quantified and thus the cell cycle stage determined. 
HUVEC pre-treated with MTX, DMSO control or serum starvation in M199/0.1% BSA were 
harvested with 200µl trypsin/EDTA, centrifuged and resuspended in 200µl PBS. They were fixed by 
adding the cell suspension dropwise into vortexing 70% ethanol/PBS, then incubating at 4
0
C for 30 
minutes. After centrifugation at 2000rpm for 15 minutes, the pellet was resuspended in 150µl PBS 
and transferred to FACS tubes containing 500µl PI staining solution (50µg/ml PI) (Sigma), 0.1% 
Triton X-100 (Sigma), 18mg/ml EDTA (Sigma), 20u/ml RNAse (Sigma), PBS). They were then 
incubated in darkness at 37
0
C for 45 minutes before reading by FACS, counting 10000 cells. 
3.1.10 Detection of apoptosis 
Apoptosis was induced in HUVEC by glucose deprivation for 18h. Glucose deprivation was achieved 
by incubating cells in sterile-filtered modified HBSS without glucose (see appendix for recipe), 
supplemented with L-glutamine, penicillin/streptomycin and 2% BSA.  
Apoptosis detection was carried out using Annexin V and PI staining. Cells were washed, trypsinised, 
resuspended in Facs medium, divided into two samples per condition and centrifuged at 1200rpm. 
The resulting pellets were incubated with a perCP-conjugated anti-phosphatidylserine (Annexin V) 
antibody (BD Pharmingen) diluted 1:20 in Annexin V binding buffer (BD Pharmingen) or in buffer 
alone for 30 minutes at 4
0
C. Samples were analysed by FACS, with unstained samples read first and 
then briefly incubated with 0.5mg/ml PI (Sigma)  mixed 50:50 with 2x PBS, before Annexin V 
staining and PI positivity was measured. 
Trypan blue staining was also used as an alternative method of measuring cell death. Briefly, cells 
seeded into a 24 well plate in which apoptosis had been induced were trypsinised and suspended in 
100µl of a 50:50 mix of 0.4% trypan blue staining solution (Sigma) and FACS medium. Numbers of 
living and dead cells (which were stained blue having become permeable to trypan blue) were counted 
in 5 squares of a haemocytometer. 
3.1.11 Detection of intracellular ROS production 
HUVEC were treated with MTX or DMSO for 48h. 5’-chloromethyl-2’,7’-dichlorodihydrofluorescein 
diacetate (CM-H2DCFDA) was thawed, dissolved in DMSO to create a stock concentration of 1µg/ml 
and loaded at 5µM in pre-warmed PBS to each well followed by incubation in darkness at 37
0
C for 45 
minutes to allow its take-up by the cells. The cells were allowed to recover in medium for 15 minutes 
before further incubation with H2O2 for 1h. They were then trypsinised, resuspended in PBS and the 
fluorescent signal was read by counting 10000 cells by FACS. 
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3.2 Molecular biology techniques 
3.2.1 Western blotting 
Cell lysis for protein analysis 
EC exposed to experimental conditions were lysed at 4°C for 20 min in RIPA buffer (Thermo 
Scientific) supplemented with complete protease inhibitor cocktail (Roche) and phosphatase inhibitors 
(Phostop, Roche) and then scraped into 0.5ml tubes. Samples were sonicated for 1 min and 
centrifuged at 14 000 rpm for 20 min at 4°C in a microcentrifuge (Sigma). The supernatant was 
harvested and stored at -80°C. 
Measurement of protein concentration 
Lysate protein concentration (to ensure equal loading of western blot gels) was measured using the 
DC protein assay (Bio-Rad). Lysates were loaded into a 96 well plate in triplicate, along with a BSA 
standard (Bio-Rad). Additional reagents were added as per the manufacturer’s instructions to produce 
a colour intensity proportional to the sample protein concentration. Following incubation for 15 
minutes, samples were read at 595nm on a plate reader (Synergy HT, Bio-Tek). 
Electrophoresis, transfer, antibody probing and developing 
Loading samples were composed of 10 or 20μg sample protein, 7.5μl NuPage sodium dodecyl 
sulphate (SDS) 4X sample buffer (Invitrogen) , 2μl 1M dithiothreitol (DTT) (Fluka) and ddH2O up to 
a total volume of 30μl. They were boiled for 5 minutes, then loaded into 10% or 4-12%, 1 or 1.5mm, 
15 or 10 well NuPage gels (Invitrogen), with at least one lane loaded with 10μl See-Blue molecular 
weight marker (Invitrogen). Gels were run in a Novex minicell tank (Invitrogen) in NuPage MOPS 
SDS running buffer (Invitrogen), at 150V for 90 minutes. 
Transfer to a PVDF membrane was performed using semi-dry blotting apparatus (Bio-Rad), at 0.1A 
per gel for one hour. Membranes were blocked in 5% BSA/ tris-buffered saline-tween (TBS-T) for 
one hour and incubated overnight with the primary antibodies, diluted in TBS-T, on a rocker at 4°C. 
The next day, membranes were washed in TBS-T and incubated at room temperature for one hour 
with a species-matched horseradish peroxidase (HRP)-labelled secondary antibody, diluted in 5% 
BSA/TBS-T. After another wash in TBS-T, membranes were developed using ECL or ECL-plus HRP 
detection systems (GE Healthcare) and exposure to Biomax light film (Kodak) in a Compact X4 
developer (Xograph Imaging Systems). The primary and secondary antibodies used are shown in 
Table 3.4. 
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Target Antigen  Species Supplier Concentration 
AMPKα Rabbit Cell Signaling 1:1000 
Phospho AMPKα Thr172 Rabbit polycloncal Abcam 1:2500 
CREB Rabbit Cell Signaling 1:500 
Phospho CREB 
Ser133
 Rabbit Cell Signaling 1:1000 
HO-1 (OSA111) Mouse monoclonal Abcam 1:2000 
MnSOD Rabbit monoclonal Assay Designs 1:2500 
GAPDH Mouse monoclonal Millipore 1:25000 
α-Tubulin Mouse monoclonal Sigma 1:25000 
Normal IgG1 Mouse DAKO 100mg/L 
HRP-tagged anti-mouse IgG Goat DAKO 1:1500 
HRP-tagged anti-rabbit IgG Swine DAKO 1:3000 
Table 3.4 Antibodies used in immunoblotting. 
Densitometry 
An HP solution centre scanner was used to scan films, and band pixel density was quantified using 
Image J software. Optical density of the band of interest was corrected for any loading inaccuracies by 
dividing by the optical density of the loading control band (α-tubulin or GAPDH). Results were 
expressed relative to the untreated control. 
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3.2.2 Phospho-kinase array 
A human phospho-kinase array kit (Proteome Profiler antibody arrays, R&D systems) was used to 
investigate protein phosphorylation changes in EC exposed to LSS and VEGF. HUVEC pooled from 
3 separate cords were mounted in the Cytodyne streamer system and exposed to LSS for 24h or kept 
in static conditions, before the addition of VEGF 25ng/ml or vehicle control for 15 minutes. This time 
point was chosen on the basis of a preliminary experiment indicating good phosphorylation of 
ERK1/2 by VEGF after 15 minutes. The HUVEC were washed with PBS, then lysed in the kit Lysis 
Buffer according to the manufacturer’s instructions. The lysate was spun at 14000g for 5 minutes, and 
the supernatant collected and stored. A Bradford protein assay was done to ensure loading of equal 
quantites of protein across the four conditions. 
To use the array, each membrane (2 sections, A and B, for each condition) was blocked for 1h at room 
temperature. The cell lysates were diluted in the Array Buffer such that the maximum quantity of 
protein was used while ensuring equal quantities in each condition, and the diluted cell lysate was 
added to each array membrane, and incubated overnight at 4
o
C on a rocking platform. 
The following day, the membranes were washed three times in the kit Wash Buffer, and then 
incubated with the kit Detection Antibody Cocktail at room temperature for 2h. After a further wash, 
they were incubated with streptavidin-HRP for 30 minutes before exposure with ECL-plus chemi-
luminescent reagents and detection with X-ray film. Representative pictures are shown in Figure 3.6. 
A transparent overlay was used to identify the individual phosphorylated proteins, and the signal 
density for each spot was quantified in Image J. 
 
Figure 3.6 Phospho-kinase array image after exposure in ECL-plus for 30s. LSS: laminar shear stress. 
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3.2.3 Quantitative real-time polymerase chain reaction 
RNA isolation 
The RNeasy Mini Kit (Qiagen) was used to isolate RNA. EC were lysed in RLT buffer supplemented 
with 10μl/ml β-mercaptoethanol. To disrupt the cell contents, lysates were either transferred to a 
Qiashredder column and centrifuged at 15000g for 2 min (Sigma 1-13 centrifuge) or passed through a 
21G needle with a 1ml syringe 10-15 times. Each sample was mixed with an equal volume of 70% 
ethanol, then transferred to an RNeasy column and centrifuged at 15000g for 15 seconds, trapping the 
nucleic acids in the column. 350μl RW1 buffer was added and the sample was again centrifuged. 10μl 
deoxyribonuclease (DNAse), mixed with 70μl RDD buffer (Qiagen), was added to each tube and 
incubated for 15 minutes at room temperature. 350μl RW1 buffer was again added to the column, 
followed by centrifugation and two washes in 500μl RPE buffer. Finally, RNA was eluted by adding 
30μl ddH2O. The eluted RNA was quantified on an Ultrospec 3000 spectrophotometer (Amersham 
Pharmacia Biotech Ltd), by comparing the absorbance at 260nm and 280nm of a 1:100 diluted sample 
of RNA (in ddH20) to a sample of ddH2O alone. 
Complementary DNA synthesis 
For synthesis of complementary DNA (cDNA), RNA was diluted to 1μg/10μl ddH2O in 0.2ml PCR 
tubes (Fisher Scientific). 1μl Oligo dT (Invitrogen) and 1μl 10mM dNTP (Roche Diagnostics) were 
added. Samples were heated at 65°C for 15 minutes using a thermocycler (T3 Thermocycler, 
Biometre, GmbH), then placed on ice and 4μl 5x first strand buffer (Invitrogen), 2μl 0.1M DTT 
(Invitrogen) and 1μl ddH2O were added. The thermocycler was set to a hot start programme, and 
when 42°C was reached 1μl Superscript II RNase Reverse Transcriptase (Invitrogen) was added to 
each tube. Samples were then heated for 55 min at 42°C and 15 min at 70°C. 
Quantitative real time PCR 
qRTPCR was performed on a Bio-Rad CFX96 Real Time System C1000 Thermal Cycler with β-
actin, GAPDH and HPRT as housekeeper genes. Each sample was run in triplicate.  
5μl cDNA diluted 1:25 in ddH2O was pipetted into the wells of a 96-well reaction plate (Bio-Rad). 
Validated primers were diluted 1:10 to create a working solution. 1μl of each forward and reverse 
primer working solution was mixed with 12.5μl SYBRgreen jump start taq ready mix (Quanta 
Biosciences), and 6.5μl ddH2O for each reaction. The plate was centrifuged at 335 x g for 1 minute 
and run on the thermal cycler using the protocol shown in Table 3.5. 
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Step Number of cycles Temperature (
0
C) Time (s) 
1 1 95 180 
2 40 95 10 
3 40 56 
45 
Plate read 
4 
Melt Curve 
1 
56-95 
in 0.5
0
C increments 
10 per increment 
Plate read 
Table 3.5 Bio-Rad thermal cycler protocol. 
 
qRTPCR works via the generation of a fluorescent signal which is measured after each cycle to detect 
the replication of the PCR product. The readout is given as the number of cycles required for the 
fluorescent signal to surpass the cycle threshold. The fewer the cycles required, the greater the number 
of mRNAtranscripts present in the sample. Measurement of the signal from constitutively expressed 
genes allows normalisation of results between samples. Data was analysed using the comparative 
cycle threshold method (ΔΔCt). Representative qPCR curves are shown in Figure 3.7. 
 
Figure 3.7 Representative qRTPCR curves. A: β-actin; M: MnSOD. 
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Primer validation 
Each primer pair was tested for the efficiency of its binding and a melt curve was run to check for the 
formation of primer dimer. 10-fold dilutions of cDNA were pipetted in duplicate, along with a no 
template control (ddH2O), and the iCycler protocol was run. The resulting cT values were plotted for 
each pair and a best fit line drawn. Efficiency of 90% or more was considered adequate, with a slope 
gradient close to 1. Primer sequences are shown in Table 3.6. A representative melt curve for MnSOD 
and actin is shown in Figure 3.8. 
 
Figure 3.8 Representative qRTPCR melt curves. A: β-actin; M: MnSOD. 
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mRNA Target Sequences 
A1 
Forward 5’-CAC AGG AGA ATG GAT AAG GCA AA-3’ 
Reverse 5’-AGT CAT CCA GCC AGA TTT AGG TTC-3’ 
AMPKα1 
Forward 5’-TCA GGA AGA TTG TAT GCA GGC CCA-3’ 
Reverse 5’-TTC ATG GGA ATC CAC CTG CAG GAT TA-3’ 
AMPKα2 
Forward 5’-CGA GCT ATG AAG CAG CTG GA-3’ 
Reverse 5’-GAA CGC TGA GGT GTT GAG GA-3’ 
β-Actin 
Forward 5’-GAG CTA CGA GCT GCC TGA CG-3’ 
Reverse 5’-GTA GTT TCG TGG ATG CCA CAG GAC T-3’ 
Bcl-2 
Forward 5’-GCC CTG TGG ATG ACT GAG TA-3’ 
Reverse 5’-GGC CGT ACA GTT CCA CAA AG-3’ 
DAF 
Forward 5’-CCT TAA GGG CAG TCA ATG GT-3’ 
Reverse 5’-CGG CAC TCA TAT TCC ACA AC-3’ 
eNOS 
Forward 5’-CTG GCT GTC TCC ATG GAC CT-3’ 
Reverse 5’-CCA CCA TGG TGA CTT TGG CT-3’ 
GAPDH 
Forward 5’-CAA CAG CCT CAA GAT CAT C-3’ 
Reverse 5’-GAG TCC TTC CAC GAT ACC-3’ 
HO-1 
Forward 5’-CAG TCT TCG CCC CTG TCT AC-3’ 
Reverse 5’-CTG GTG TGT AGG GGA TGA CC-3’ 
HPRT 
Forward 5’-TTG GTC AGG CAG TAT AAT CC-3’ 
Reverse 5’-GGG CAT ATC CTA CAA CAA C-3’ 
KLF-2 
Forward 5’-GCA AGA CCT ACA CCA AGA GTT CG-3’ 
Reverse 5’-CAT GTG CCG TTT CAT GTG C-3’ 
MnSOD 
Forward 5’-AAG GGA GAT GTT ACA GCC CAC-3’ 
Reverse 5’-GTC CAG AAA ATG CTA TGA TTG A-3’ 
NQO-1 
Forward 5’-GGG CAA GTC CAT CCA ACT G-3’ 
Reverse 5’-GCA AGT CAG GGA AGC CTG CA-3’ 
Trx 
Forward 5’-GGT GTG CGC CTT GCA A-3’ 
Reverse 5’-TCA AGG AAT ATC ACG TTC CAA TAC TT-3’ 
Trx reductase 
Forward 5’-CCA CTG GTG AAA GAC CAC GTT-3’ 
Reverse 5’-AGG AGA AAA GAT CAT CAC TGC TGA T-3’ 
UCP-2 
Forward 5’-GGA TAC TGC TAA AGT CCG GT-3’ 
Reverse 5’-CCA TTG TAG AGG CTT CGG G-3’ 
VEGFR-2 
Forward 5’-AAT GAC ACT GGA GCC TAC AAG-3’ 
Reverse 5’-CAC CGA GAC CTG GAA TCA C-3’ 
Table 3.6 qRTPCR primer sequences. 
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3.2.4 Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP), to investigate whether CREB binds the SOD2 promoter in 
EC treated with MTX, was carried out using the ChIP-IT Express kit (Active Motif). 
Cell stimulation and fixation 
 HUVEC from 3 cords were pooled and plated in 15cm cell culture plates in order to give 
approximately 10
6
 cells per condition, then treated with MTX 100nM for 48h or DMSO control. Cells 
were washed with ice-cold PBS then fixed in 1% formaldehyde in HBSS by rocking at room 
temperature for 5 minutes, followed by a glycine stop-fix solution to stop the fixation reaction. The 
cells were then scraped off using a solution of PBS with 500µM phenylmethylsulphonyl fluoride 
(PMSF) as a serine protease inhibitor, transferred to a 15ml conical tube on ice and pelleted by 
centrifugation. The supernatant was discarded, 1µl 100mM PMSF and 1µl protease inhibitor cocktail 
(PIC) were added and the pellets were frozen at -80
o
C. 
Cell lysis and chromatin shearing by sonication 
The cell pellets were resuspended in 1ml ice-cold Lysis Buffer supplemented with PMSF and PIC, 
then incubated on ice for 1h, before homogenisation in a pre-chilled dounce homogeniser with 20 
strokes to improve nuclei release. Adequate cell lysis was checked by examining a 10µl sample in a 
haemocytometer. The nuclei were pelleted by centrifugation, the supernatant discarded and the pellets 
resuspended in shearing buffer. The chromatin was sheared at 4
o
C in a Diagenode Bioruptor for 4 
minutes with 30s pulses of shearing followed by 30s rest in order to generate chromatin fragments 
with an average length of 500bp. The sheared chromatin was centrifuged and the supernatant 
aliquoted and stored at -80
 o
C. 
Ascertaining DNA concentration and shearing efficiency 
The DNA concentration of each sample was checked to ensure an adequate chromatin yield from the 
fixation, lysis and shearing steps. A 50µl sample from each condition was mixed with 150µl ddH2O 
and 10µl 5M NaCl, then heated at 65
o
C in a thermocycler overnight. The following day they were 
treated with RNAse and proteinase K, and a phenol/chloroform extraction performed to purify the 
DNA. 200µl 1:1 phenol/chloroform TE saturated pH8 was added to each sample, vortexed and 
centrifuged at maximum speed for 5 minutes. The top aqueous layer was removed and added to 20µl 
3M sodium acetate pH5.2 and 500µl 100% ethanol, vortexed and placed at -80
 o
C for 1h. The sample 
was centrifuged twice at maximum speed, then the pellet left to air dry before resuspension in ddH2O 
and the DNA concentraton read in a nano-drop. 
Shearing efficiency was checked by comparing the size of DNA fragments after sonication for 3 
minutes and 6 minutes by agarose gel electrophoresis. A 1% agarose gel was made by dissolving 1g 
agarose in 100ml heated tris-acetate-EDTA (TAE) buffer and adding SybrSAFE ethidium bromide 
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substitute. This was poured into an electrophoresis tank tray with comb inserted and allowed to set for 
30mins. 400ml TAE buffer was then added and the comb removed. The samples were prepared by 
adding 2µl Gel Pilot 5x loading dye (Qiagen) to 8µl sample and loaded into the gel. They were run at 
100V alongside a DNA ladder (Direct Load 1kbp Ladder, Sigma) for 1h. Results are shown in Figure 
3.9. 
 
Figure 3.9 ChIP shearing optimisation DNA smear. Both 3 minutes and 6 minutes shearing by sonication 
yielded chromatin fragments around 500bp in size that would be suitable for ChIP. Bp: base pairs. 
 
Immunoprecipitation and elution of chromatin 
10µl chromatin was removed from each sample and stored for use as the input DNA control in the 
qRT-PCR analysis. ChIP reactions were set up with 150µl chromatin added to protein G magnetic 
beads, kit buffer 1, PIC, ddH2O and 2µg anti-CREB antibody (Cell Signaling Technology) or normal 
rabbit IgG control (Cell Signaling Technology).  Maximum chromatin was used in each reaction. The 
reactions were incubated on an end-to-end rotator at 4
o
C overnight, then washed 3 times using a 
magnetic stand in kit buffers to remove all unbound chromatin. The washed beads were resuspended 
in AM2 elution buffer and incubated on the rotator for 15 minutes at room temperature. The cross-
links which joined pulled-down chromatin to antibody or matched IgG were reversed using the kit 
reverse cross-linking buffer, the magnetic beads were pelleted using the magnetic stand and the 
supernatant containing the chromatin of interest taken off. The ChIP and input DNA samples were 
then incubated with proteinase K for 1h before addition of proteinase K stop solution prior to qRT-
PCR analysis. 
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qRT-PCR analysis 
Analysis of the SOD2 promoter sequence (GenBank accession number AF059197) using 
MatInspector software[392] identified 9 putative CREB binding sites: 3 on the 5’-3’ strand and 6 on 
the complementary strand (Figure 3.10). Of these, two were strong binding sites with one full CRE 
and one half site (see Figure 6.8). Primer-BLAST was used to design primers around these two sites 
with amplicons 100-200bp in length, as well as a negative control site in the SOD2 gene (GenBank 
accession number S77127) around 2000bp downstream of the transcription start site as a control for 
promoter binding. These were tested against human genomic DNA (prepared from HUVEC by Dr G 
Birdsey) to ensure a single PCR product when run in the thermocycler at 60
o
C. Primer sequences are 
shown in Table 3.7. 
A qRT-PCR was then run using 5µl undiluted chromatin or input DNA diluted 1/10 from each 
condition, 1µl of primer working solution (forward and reverse primer diluted 1/10), 12.5µl 
SYBRgreen ready mix and ddH2O to make each reaction volume 25µl. Each condition was run in 
triplicate. The thermocycler protocol was the same as that used for the standard qRT-PCR described 
in section 3.2.3. Results were analysed by normalising each sample to input DNA (after correction for 
the 1/10 dilution) and to the IgG control. 
 
Figure 3.10 MatInspector readout of CREB-1 binding sites on the SOD2 promoter. 
Primer Site Sequences 
1 
Forward 5’-TGC AAA TCC TGC CTG CAG TCT C-3’ 
Reverse 5’-GCG CCG TAC CCT TGC TTT GC-3’ 
2 
Forward 5’-GTG CCA GAC CAC CTT GCC TGA-3’ 
Reverse 5’-AAC GCA GAC AAG AGC AGG GGT-3’ 
Downstream 
Forward 5’-GGC ACA CCG TTG TGG TGT CGT-3’ 
Reverse 5’-AAC AAG CCT GTT TCA GTT TCC CAC T-3’ 
Table 3.7 Primer sequences used for ChIP RT-PCR for MnSOD promoter. 
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3.3 In vivo studies 
3.3.1 Breeding of WBF1 cross and animal husbandry 
In vivo experiments were carried out in accordance with Home Office guidelines (Project Licence 
PPL 70/6722) and with attention paid to the principles of reduction, refinement and replacement. 
Experiments were planned and carried out in a single block to minimise breeding of excess animals; 
they were performed once the marjority of the in vitro work was completed in order to best target the 
in vivo experiments; and multiple tissue and serum samples were obtained at sacrifice from each 
animal. These measures kept the number of animals used and number of regulated procedures 
required to a minimum.  
In order to generate male progeny of New Zealand white (NZW) female mice and BXSB male mice, 
breeding trios were set up containing 2 female NZW (Harlan)  and 1 male BXSB (bred in-house with 
thanks to Miss J Rose). Litters were sexed and weaned at 21-26 days, with stock kept as separate 
sexes. Mice were housed in individually ventilated cages, supplied with standard food and water ad 
libitum, at 21°C with a 12 hour light/dark cycle. From 8 weeks onwards male animals were monitored 
twice weekly for signs of illness, and four times weekly from 12 weeks. Female animals were 
monitored twice weekly throughout. Animals showing signs of illness or distress were euthanased. 
Animals were sacrificed at 12, 16 and 24 weeks by CO2 inhalation.  
3.3.2 Treatment of cross with MTX 
From 12 weeks until 16 weeks WBF1 male mice were injected weekly intraperitoneally with 1mg/kg 
MTX (TEVA) or 0.9%  saline. The dose was chosen on the basis of literature reports of the MTX 
dose required to treat collagen-induced arthritis[393, 394] and of the dose needed to elicit changes in 
intracellular AICAR concentration[376] i.e. an anti-inflammatory rather than cytotoxic dosing 
schedule. Animals were numbered sequentially with alternate animals receiving MTX or 0.9% saline, 
to ensure littermates were used as controls and a coding system was used to maintain blinding of the 
investigators. They were weighed at 12 weeks for dose calculation. Total injection volume was 100µl. 
3.3.3 Serum collection and storage 
After sacrifice, blood was collected from experimental animals by cardiac puncture into the right 
atrium or into the inferior vena cava, aiming to extract 500µl. It was placed on ice in a 1.3ml 
microtube (Sarstedt) and allowed to stand at 4°C for 1-4h to allow coagulation, then centrifuged at 
13000 rpm for 10 minutes. The serum was aspirated and re-spun for 5 minutes, then aliquoted and 
stored at -80°C. 
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3.3.4 Post mortem examination and harvesting and preparation of solid organs 
The heart and descending aorta were harvested when the animals were sacrificed and a thorough 
inspection of all other organs was carried out. After confirmation of death, each animal was weighed 
and the abdominal and chest cavities were opened through a longitudinal incision from symphysis 
pubis to manubriosternal joint. Intrathoracic or peritoneal blood, ascites or pleural fluid were looked 
for, and the bowel, liver, spleen, kidneys and heart were examined. The heart was mobilised and 
removed by cutting through the ascending aorta. The descending thoracic aorta was then carefully 
mobilised and removed following an incision as close to the diaphragm as possible. The heart was 
fixed overnight in 10% buffered neutral formalin, then washed in PBS and placed in 70% ethanol. 
The following day they were paraffin embedded (with thanks to Ms L Lawrence). Hearts were 
bisected in a transverse plane at a mid-ventricular point, and both sections embedded side by side. 
5µm sections were cut on a microtome and stained with hematoxylin/eosin (H&E) and periodic acid-
Schiff (PAS) by Ms L Lawrence. 
3.3.5 Preparation of aortae for immunoblotting and frozen sections 
The descending aorta was harvested when the animal was sacrificed and placed in physiological 
saline solution on ice (see Appendix for recipe). It was dissected under microscope to strip off fat and 
connective tissue and then divided horizontally. At this point, aortic aneurysms were recorded if 
present. One half was immediately snap frozen in liquid nitrogen before storage at -80°C. The other 
half was embedded in OCT embedding compound (CellPath) on a cork board. A large drop of OCT 
was put on a small square cork board and the aorta section was laid lengthwise along one arm of small 
straight arm tweezers. It was then thrust into the OCT and immediately immersed in supercooled 2-
methylbutane (Sigma) for 30 seconds. The tweezers were then removed leaving the aorta embedded 
upright, and the tissue stored at -80°C. 
For immunoblotting, snap frozen aortic tissue was ground to a powder using a plastic pestle (Sigma) 
fitted into a 1.5ml eppendorf tube, cooled in liquid nitrogen. It was then dissolved in 100µl RIPA 
buffer supplemented with complete protease and phosphatase inhibitors, and incubated for 30 minutes 
on a rotator at 4°C, before centrifugation at 14000rpm for 15 minutes. The supernatant was collected 
and stored at -80°C for use in immunoblots.  
Transverse sections of descending aorta embedded upright in OCT were cut on a Leica cryostat at 
10µm thickness, and mounted onto Superfrost plus charged slides (Thermo Scientific). These were 
airdried at room temperature before fixing in acetone (for immunofluorescence) for 10 minutes and 
stored dry at -70°C.  
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3.3.6 Scoring of WBF1 arterial vasculopathy 
The vasculopathy of the intramyocardial arteries of WBF1 mice was quantified in two ways, based on 
the scoring system described by Berden et al[395] and designed by me in conjunction with Dr J 
Boyle, consultant cardiovascular histopathologist. Paraffin-embedded PAS-stained  myocardial 
sections were used. Firstly, peri-adventitial leukocytes surrounding each intramyocardial artery and 
aerteriole were counted on a single section per animal. Secondly, PAS staining of arterial walls was 
scored as follows: 0: normal staining; 1: increased basement membrane staining; 2: increased 
basement membrane staining and nodular deposits. This was applied to every intramyocardial artery 
and arteriole in a single section per animal (approximately 10-15 vessels per section were examined in 
this way) and a mean score per animal generated. 
3.3.7 Murine aortic ICAM-1 staining by immunofluorescence 
Frozen transverse sections of murine aorta were dried at room temperature for 30 minutes, washed in 
PBS and blocked in 3% BSA/PBS at room temperature for 30 minutes. The rat anti-mouse ICAM-1 
monoclonal antibody YN-1 (generated in-house), diluted to 10µg/ml in 3% BSA/PBS, was added to 
each slide (or rat IgG2a isotype control (BD Pharmingen)) and incubated for 45 minutes. The slides 
were washed three times in PBS, then incubated with an Alexa Fluor 546-conjugated goat anti-rat IgG 
secondary antibody (Invitrogen Life Technologies), diluted to 8µg/ml in 3% BSA, for 45 minutes at 
room temperature in the dark. A directly conjugated Alexa Fluor 488 rat anti-mouse CD31 
monoclonal antibody (MEC13.3; Biolegend, San Diego, USA) was used as an endothelial marker, and 
DRAQ-5 as a nuclear stain. Slides were incubated with these for 45 and 10 minutes respectively, 
before mounting with Fluoromount-G (Southern Biotech, Birmingham, Alabama), and visualisation 
by confocal microscopy. Quantification of staining was carried out using the LSM 510 META 
software. The endothelial or adventitial area was identified using the co-localised image incorporating 
anti-CD31, and the mean fluorescence intensity of the area recorded. 
3.3.8 Calculation of myocardial infarct area 
Cardiac sections stained with H&E were studied by light microscopy for evidence of infarcts. The 
sections were coded to ensure blinding of the investigator to the animal’s treatment, and were 
examined independently by a second investigator to ensure agreement as to the number of affected 
animals. A single slide per animal was examined. 
Acute infarcts were clearly visible on H&E stained slides. Older, fibrotic infarcts were imaged using 
picrosirius red to stain collagen. Cardiac sections were deparaffinised in Histoclear (National 
Diagnostics), then hydrated through a graded alcohol series to distilled water. Picrosirius red staining 
was carried out using a picrosirius red stain kit (Polysciences Inc), followed by dehydration in graded 
alcohol, brief clearing in Histoclear and mounting using Clarion Mounting Medium (Sigma).  
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Quantification of infarct area was carried out in two ways. Firstly, a single cardiac section from each 
animal was photographed with 8 fields of view per section, using the x10 objective, and the collagen 
area determined by thresholding using Image J software. In each photograph, a selection was made of 
infarct area and a histogram generated of intensity/ number of red pixels using the green image. This 
was compared to a selection representing background levels, to derive a cutoff above which any pixel 
was deemed to represent pathological collagen staining. 
Secondly, photomicrographs were taken of each infarcted area to cover the whole infarct at x40 
magnification, and the total area measured in Image J. Collagen morphometry with thresholding to 
determine the background cutoff was used to calculate the area of fibrotic infarcts as previously 
described, and acute infarcts were measured using a straightforward area measurement. 
3.3.9 Murine serum cardiac troponin I ELISA 
A high-sensitivity murine serum cardiac troponin I (cTnI) ELISA kit was purchased from Life 
Diagnostics UK Ltd. Murine serum samples (diluted 1:2 using the kit cTnI diluent) and serial 
dilutions of a murine cTnI standard supplied with the kit were pipetted in duplicate into microtitre 
wells coated in solid-phase anti-cTnI, along with a second HRP-conjugated anti-cTnI antibody in 
solution. The plate was incubated for 1hr on a rocking platform at room temperature, then washed 
using an automated plate washer (Thermo Scientific) to remove unbound HRP-conjugated antibodies 
and serum.  A tetrameythlbenzamine solution (an HRP substrate) was added and the plate was 
incubated for a further 20 minutes, resulting in the development of a blue colour proportional to the 
amount of bound cTnI. The colour development was stopped by the addition of a 1N HCl stop 
solution, resulting in a colour change to yellow. Absorbance at 450nm was then read on a plate reader, 
with concentration of cTnI proportional to absorbance. The standard curve was plotted using 
Microsoft Office Excel 2007, and the sample concentrations determined. 
As the blood samples were obtained by puncture into the right atrium, an initial run of the ELISA was 
performed using serum samples obtained from two six month old female C57/Bl6 animals being used 
in another experiment. Paired blood samples were obtained from the inferior vena cava (IVC) and 
right atrium. 
 
3.4 Statistical analyses 
Data are expressed as the mean of at least 3 experiments, with error bars representing the standard 
error of the mean. All experimental results were analysed using Graphpad Prism 4 software. 
Normalised data was analysed using Pearson's test for normality, followed by a single sample t-test, 
or Wilcoxon Rank Sum if the data was not normally distributed. Other parametric data was analysed 
by one-way or repeated-measures analysis of variance (ANOVA) or t-tests. Non-parametric data was 
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analysed using Mann-Whitney U test or Fisher's exact test. Results were considered significant if the 
p-value was less than 0.05. 
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4 HUVEC CHARACTERISATION AND RESPONSES TO VEGF 
AND HIGH FLOW LSS 
4.1 Introduction 
The aim of the work presented in this thesis was to establish how best to reduce atherosclerosis in the 
setting of chronic inflammatory disease, and to do so by investigating how to improve endothelial 
defence against inflammatory injury. The majority of the experiments were carried out in vitro using 
HUVEC isolated in the laboratory, and so initial experiments characterised these cells to ensure that 
those used were indeed endothelial. As high flow LSS and VEGF are powerful exogenous inducers of 
cytoprotective responses in adult vascular endothelium, these were investigated in vitro to look for 
evidence of synergy in the induction of cytoprotective genes. 
4.1.1 Human umbilical vein endothelial cells 
The majority of the experiments performed in this project were carried out on multiple isolates of 
HUVEC, used at an early passage (2-4).  Using primary cells from multiple individuals has the 
advantage of representing population variability in genetic background, unlike a cell line, but there are 
a couple of drawbacks. First, it is possible to isolate smooth muscle cells and fibroblasts from the 
umbilical vein in addition to EC. Secondly, EC grown in culture over multiple passages can lose their 
endothelial-specific phenotype and de-differentiate.  Therefore, in order to establish that the cells 
isolated were indeed endothelial in origin and maintained an endothelial phenotype for the duration of 
the experiments, staining with both constitutively expressed and inducible EC surface markers was 
carried out. 
Vascular endothelium is a highly heterogenous tissue, and EC have different properties depending on 
both the tissue they are resident in, and the type of vessel they line. This has implications for 
experimental practice, as HUVEC will not develop atherosclerosis. EC differentiation is stimulated 
and maintained by contact with neighbouring cells (both endothelial and pericytes); including via 
direct cell-cell adhesion through tight junctions, release of soluble mediators, and via the synthesis 
and organisation of the matrix proteins that form the endothelial basement membrane[396]. Many of 
these signals are rapidly lost when EC are grown in culture, which entails huge disruption in basement 
membrane, confluence, and loss of the tissue milieu of other cell types. 
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4.1.2 Endothelial cell characterisation 
Confirming that the isolated cells are endothelial can be achieved in a number of ways. They can be 
stained for constitutive and inducible cell surface proteins that are specific to EC. They can be 
examined under microscopy for structures unique to EC such as Weibel-Palade bodies. Finally, they 
can be exposed to shear stress to mimic blood flow and their responses observed.  
Constitutively expressed EC surface proteins include platelet-endothelial cell adhesion molecule 
(PECAM-1; CD31), ICAM-2 and endoglin. A list, along with the other cell types that express them, is 
shown in Table 4.1. CD31, a member of the immunoglobulin superfamily, is expressed on EC mostly 
at intercellular junctions, where it is the principal component[397]. In addition it forms part of an EC 
mechanotransduction complex and is essential for altering intracellular signalling based on the shear 
stress applied to EC surface[147]. ICAM-2, a transmembrane glycoprotein and another member of the 
immunoglobulin superfamily, binds LFA-1 on leucocytes. It is constitutively expressed at a much 
higher level than ICAM-1 on resting EC, and is found principally at intercellular junctions, where it  
is important for mediating leucocyte trafficking[398]. Endoglin, also a transmembrane glycoprotein, 
forms part of the TGFβ receptor complex. In resting EC it is constitutively expressed at low levels, 
but is much more highly expressed on proliferating cells and thus on those grown in culture[399]. 
Adult vascular endothelium can be activated by a variety of cytokines and growth factors resulting in 
extensive changes in gene expression, which can be reversible[400]. Responses to growth factors in 
particular can be very different depending on whether the cells are confluent and securely attached to 
their neighbours via tight junctions. Cell-cell contact inhibits both spontaneous and growth factor-
induced cell growth and division, and other key endothelial properties are also changed: e.g. 
arachidonic acid metabolism, and release of lytic enzymes and growth factors[396]. Inducible EC 
surface proteins include DAF, which is induced by VEGF via ligation of VEGFR2 and a pathway that 
includes PKCε and phospholipase Cγ[176], and the cell adhesion molecules ICAM-1, VCAM-1 and 
E-selectin which are induced by pro-inflammatory cytokines such as TNFα and IL-1 via activation of 
NFκB[401]. Table 4.2 illustrates the array of inducible cell surface proteins expressed by vascular 
endothelium. 
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Antigen Cell Type 
PECAM-1 (CD31) EC, platelets, lymphocytes, monocytes, neutrophils 
Angiotensin-converting enzyme EC, epithelial cells, monocyte-macrophages, T 
lymphocytes 
Type I scavenger receptor (acetylated-
LDL uptake) 
EC, macrophages, SMCs, pericytes, fibroblasts 
Ulex europaeus I agglutinin binding / 
O(H) blood-type antigen 
EC, erythrocytes 
Bandeirea simplicifolia  lectin binding EC 
Griffonia simplicifolia agglutinin 
binding 
EC 
V-E cadherin (CD144) EC, trophoblasts, PLN sinus macrophages 
CD34 EC, hemopoietic precursors 
ICAM-2 (CD102) EC, lymphocytes, monocytes, platelets 
CD51/61 (vitronectin receptor) EC, platelets, osteoclasts, mast cells, lymphocytes 
Endoglin (CD105) EC, monocyte-macrophages, B lymphocytes, 
syncytiotrophoblasts 
CD36 Microvascular EC, monocyte-macrophages, erythroid cells, 
platelets 
VAP-2 EC, lymphocytes, tonsillar epithelium 
S-ENDO 1/MUC18 EC, SMCs, dendritic cells 
Thrombomodulin ECs, SMCs 
Table 4.1 Constitutively expressed EC surface markers (adapted from Garlanda and Dejana[396]). 
 
Antigen Cell Type Stimulus 
CD54/ ICAM-1 ECs, leukocytes, epithelium, fibroblasts Upregulated in ECs by inflammatory 
cytokines 
CD106/ VCAM-1 ECs, macrophages, synoviocytes, 
dendritic cells, mesothelium 
Upregulated in ECs by inflammatory 
cytokines 
CD62E/ E-selectin ECs, (postcapillary venules restricted in 
vivo) 
Induced by inflammation, CK and 
neoangiogenesis 
CD62P/ P-selectin ECs, platelets Membrane exposed after CK 
activation 
VEGFR-2 ECs Angiogenesis, KS, vascular tumors, 
laminar flow 
VEGFR-1 ECs Angiogenesis, KS 
Tie-1 ECs Angiogenesis 
Tie-2/Tek ECs Angiogenesis 
DAF (CD55) EC Statins, VEGF 
VAP-1 EC  
Table 4.2 Inducible EC surface markers (adapted from Garlanda and Dejana [396]). 
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4.1.3 High flow LSS and VEGF 
Blood vessel walls exposed to long term high flow laminar shear stress (LSS) are resistant to the 
development of atheroma, which occurs mainly at branch points and other sites of low or turbulent 
flow[143]. LSS conditions the vascular endothelium to adopt an anti-inflammatory, anti-apoptotic, 
quiescent phenotype, through effects on gene expression. Similarly, the endothelial growth factor 
VEGF also alters gene expression to promote survival and enhance endothelial defence against 
injury[174, 177]. The ways in which LSS and VEGF encourage endothelial cytoprotection were 
discussed in Section 1.4. 
Synergy, the co-operative action of two or more stimuli to result in a response that is different or 
greater than the sum of the actions together, is an important biological phenomenon. There are many 
examples of synergy between stimuli acting on EC to produce an enhanced response: treating EC with 
atorvastatin and rapamycin together results in a synergistic induction of DAF[206]; and treating EC 
exposed to LSS with atorvastatin results in a synergistic induction of HO-1[248]. This last paper 
indicates that LSS alters the way in which EC respond to other exogenous mediators, which may 
explain its effects on atheroma development. 
This chapter addresses the hypothesis that exposing EC to LSS and VEGF together results in 
synergistic induction of cytoprotective genes. Understanding how such a mechanism might work 
would be important for addressing how best to tackle atheroprotection pharmacologically.  
There is some evidence to suggest that LSS and VEGF may interact to enhance endothelial 
cytoprotection. Firstly, LSS induces expression of VEGFR2, and indeed is capable of signalling 
through it[147, 402]. VEGFR2 is the principal endothelial VEGF receptor. In addition to mediating 
VEGF signalling, however, it also forms part of the endothelial mechanosensing and 
mechanotransduction system for transmitting the effects of shear stress intracellularly. It forms a 
complex with VE-cadherin and PECAM-1, and is activated very rapidly by the onset of laminar 
flow[147].  
Secondly, VEGF and LSS both activate eNOS and enhance NO production, an action that requires 
phosphorylation and activation of VEGFR2[148, 403]. They also both enhance expression of 
prostacyclin[171, 404].  
Thirdly, both LSS and VEGF can induce expression of HO-1, a highly inducible enzyme that has 
well-established cytoprotective properties, discussed in Section 1.4. It is readily induced by LSS[140, 
248], and by VEGF[405-407]. It should be noted however that those papers showing induction of HO-
1 by VEGF do so in the context of angiogenesis, where cell-cell contact is very different to that in 
confluent monolayers. This change in EC environment may have significant effects on the 
characteristics of the response to VEGF. 
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Finally , there is the question of whether LSS induces VEGF expression itself by EC. The evidence 
for this is conflicting. Passerini et al reported a 3 fold increase in VEGF mRNA expression in 
HUVEC exposed to LSS at 15 dynes/cm
2
 for 24h[408]. However, other studies have reported a down-
regulation in VEGF expression, albeit after shorter periods of exposure to flow[409]. Conklin et al 
reported enhanced expression of VEGF in porcine carotid arteries exposed to low shear stress for 24h, 
interpreting this as a reason for increased endothelial permeability to lipid at regions in the arterial 
tree of low or turbulent flow[410]. 
4.1.4 Chapter Aims 
The aims of the experiments presented in this chapter were, firstly, to establish that the cells isolated 
and used for the project were indeed endothelial in origin; and, secondly, to investigate synergy in the 
actions of VEGF and LSS on HUVEC, using the induction of HO-1 as a model. The effects of LSS 
and VEGF on the induction of a wider selection of genes linked with cytoprotection was then 
explored. These were either genes known to be induced by VEGF (such as DAF, BCL-2 or A1), or 
those thought to be regulated by both (VEGFR2, eNOS). Lastly, a phosphokinase array was used to 
explore the signalling pathway changes that occurred following VEGF stimulation under static or LSS 
conditions. 
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4.2 Results 
4.2.1 Staining of constitutively expressed EC surface markers 
Passage 3 HUVEC were stained with antibodies to the constitutively expressed proteins PECAM-1 
(CD31), ICAM-2 and endoglin and the percentage of positively stained cells was analysed by FACS. 
97.7% of cells stained with anti-CD31 (Figure 4.1A), 96.7% with anti-ICAM2 (Figure 4.1B) and 
72.6% with anti-endoglin (Figure 4.1C), indicating that a high percentage of the cells in culture are 
indeed endothelial in origin. 
 
 
Figure 4.1 HUVEC stain with antibodies specific to EC surface proteins. HUVEC were stained with antibodies 
to CD-31, endoglin and ICAM-2 and positive cells were counted by flow cytometry. A: black: unstained cells; 
red: anti CD-31 antibody. B: black: unstained cells; purple: anti-endoglin antibody. C: black: unstained cells; 
blue: anti-ICAM-2 antibody. 
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4.2.2 Inducible EC surface markers: DAF induction by VEGF 
 
HUVEC were treated with VEGF 25ng/ml for 48h. Induction of DAF was measured by FACS, and a 
two-fold induction was observed (Figure 4.2), consistent with the published literature[176]. 
 
 
 
Figure 4.2 Induction of DAF expression in HUVEC by VEGF. HUVEC were treated with VEGF 25ng/ml x 
48h, then stained with anti-DAF and analysed by flow cytometry. A: representative histogram. Black: unstained 
HUVEC; green: untreated HUVEC stained with anti-DAF antibody (1H4); red: HUVEC treated with VEGF 
25ng/ml stained with anti-DAF antibody. B: histogram showing RFI of 3 experiments. Results are expressed as 
mean +/- SE and represent at least 3 experiments. * = p<0.05. 
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4.2.3 Inducible EC surface markers: ICAM-1 and VCAM-1 induction by TNFα 
HUVEC were treated with TNFα 1 and 10ng/ml for 16h, then stained with anti-ICAM-1 and anti-
VCAM-1 and their expression levels were measured by FACS. A 12-fold induction of ICAM-1 and 
15-fold induction of VCAM-1 was observed (Figures 4.3 and 4.4 respectively), consistent with the 
published literature. 
 
Figure 4.3 Induction of ICAM-1 by TNFα. HUVEC were treated with TNFα 1ng/ml or 10ng/ml for 16h, then 
stained with anti-ICAM1 antibody and analysed by flow cytometry. A: representative histogram; red: unstained 
cells; green: untreated cells stained with anti-ICAM-1 antibody; blue: cells treated with TNFα 10ng/ml stained 
with anti-ICAM-1 antibody (6.5B5). B: histogram showing normalised RFI of 3 experiments. Data are 
presented as mean +/- standard error. * = p<0.05; ** = p<0.01 
 
Figure 4.4 Induction of VCAM-1 by TNFα. HUVEC were treated with TNFα 1ng/ml or 10ng/ml for 16h, then 
stained with anti-ICAM1 antibody and analysed by flow cytometry. A: representative histogram; red: unstained 
cells; green: untreated cells stained with anti-VCAM-1 antibody (1.4C3); blue: cells treated with TNFα 10ng/ml 
stained with anti-VCAM-1 antibody. B: histogram showing normalised RFI of 3 experiments. Data are 
presented as mean +/- standard error.  * = p<0.05. 
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4.2.4 Effect of VEGF on HO-1 expression in static-cultured HUVEC 
Although induction of HO-1 by VEGF has been previously shown[405-407], I was unable 
consistently to demonstrate this (Figure 4.5). A trend towards induction of HO-1 mRNA at 8h was 
observed, and protein at 24h; however this failed to reach statistical significance. Changing cell 
confluence (50% vs 75%); medium conditions (varying concentrations of FCS) and cell type (HMEC 
were also tried) did not result in a consistent improvement in the induction seen. HO-1 protein 
expression was also analysed according to whether the untreated cells expressed high or low 
quantities of HO-1, but there was no relationship between this and response to VEGF. Cells with 
either high or low baseline HO-1 levels were capable of responding to VEGF in some cases, and not 
in others. 
 
Figure 4.5 HO-1 mRNA and protein expression in HUVEC stimulated with VEGF. HUVEC were treated with 
VEGF 25ng/ml over a 24h time course then lysed and analysed by qRTPCR or by western blot. A: Time course 
of induction of HO-1 mRNA by VEGF 25ng/ml. B and C: HO-1 protein expression in HUVEC after stimulation 
with VEGF 25ng/ml for 24h. Data shown are the results of >9 experiments and are expressed as mean +/- 
standard error. 
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4.2.5 LSS induces HO-1 expression in HUVEC 
The Cytodyne Streamer parallel plate apparatus was used to expose HUVEC grown on a fibronectin-
coated slide to LSS 12-20 dynes/ cm
2
 for 24h. Induction of HO-1 mRNA (Figure 4.6A) and protein 
(densitometry in Figure 4.6B; representative immunoblot shown in Figure 4.9) was confirmed, 
consistent with the published literature. 
 
Figure 4.6 Induction of HO-1 mRNA and protein by LSS. HUVEC were exposed to LSS 20 dynes/cm
2
 for 24h 
in the cytodyne streamer parallel plate system, or static conditions in a Petri dish. A: induction of HO-1 mRNA. 
B: normalised densitometry results of induction of HO-1 protein. A representative blot is shown in Figure 4.9. 
Data shown are the results of 4 experiments and expressed as mean +/- standard error. * = p<0.05; ** = p<0.01. 
4.2.6 Effect of VEGF and LSS on induction of HO-1 
I hypothesised that exposure to LSS may sensitise vascular endothelium to VEGF, leading to 
enhanced induction of cytoprotective genes. In order to explore this, two cytodyne flow circuits were 
set up simultaneously, and after allowing 16h equilibration to flow, VEGF 25ng/ml was added to one 
circuit, as well as to HUVEC kept in static conditions. Two time points were investigated to try to 
capture all effects of VEGF on gene transcription in HUVEC equilibrated to LSS: an early one (4h for 
mRNA and 8h for protein) and a late one (24h). These were chosen on the basis of experiments 
exploring VEGF-induced anti-apoptotic gene expression in confluent HUVEC and those previously 
investigating HO-1 induction by VEGF[175, 405]. HO-1 mRNA levels were measured after exposure 
to VEGF for 4h, and a significant increase in HO-1 mRNA was observed when VEGF was added to 
cells exposed to LSS, indicating a synergistic induction (Figure 4.7). However, this was not 
consistently observed at 24h where only 2/5 replicates followed this pattern (Figure 4.8). Furthermore, 
a synergistic induction of HO-1 protein by LSS and VEGF was not demonstrated (Figures 4.9 and 
4.10). 
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Figure 4.8 Induction of HO-1 mRNA by LSS and VEGF for 24h. HUVEC were exposed to static conditions or 
LSS 20 dynes/cm
2
 for 16h, before the addition of VEGF 25ng/ml for 24h. A: comparison of results under static 
conditions, VEGF added under static conditions (S+V), LSS, and VEGF added to HUVEC exposed to LSS 
(LSS+V). B: fold change in HO-1 mRNA induction when VEGF is added under LSS conditions, demonstrating 
the variability in response between experiments. Data are expressed as mean +/- standard error and represent the 
results of 5 experiments. 
 
Figure 4.7 Induction of HO-1 mRNA by LSS and VEGF for 4h. HUVEC were exposed to static conditions or 
LSS 20 dynes/cm
2
 for 16h, before the addition of VEGF 25ng/ml for 4h. A: comparison of results under static 
conditions, VEGF added under static conditions (S+V); LSS, and VEGF added to LSS (LSS+V). B: fold change 
in HO-1 mRNA induction when VEGF is added under LSS conditions. Data are expressed as mean +/- standard 
error and represent the results of 3 experiments. * = p<0.05. 
 103 
 
 
 
Figure 4.9 Induction of HO-1 protein by LSS and VEGF for 8h. HUVEC were exposed to static or LSS 
conditions for 16h, before the addition of VEGF 25ng/ml for 8h. A: representative western blot. S: static 
conditions, S+V: VEGF 25ng/ml for 8h under static conditions, LSS: laminar shear stress, LSS+V: LSS and 
VEGF 25ng/ml for 8h (LSS+V). B: normalised densitometry quantifying change in HO-1 protein. Data are 
expressed as mean +/- standard error and represent the results of 4 experiments. 
 
 
 
Figure 4.10 Induction of HO-1 protein by LSS and VEGF for 24h. HUVEC were exposed to static or LSS 
conditions for 16h, before the addition of VEGF 25ng/ml for 8h. A: representative western blot. S: static 
conditions, S+V: VEGF 25ng/ml for 8h under static conditions, LSS: laminar shear stress, LSS+V: LSS and 
VEGF 25ng/ml for 8h (LSS+V). B: normalised densitometry quantifying change in HO-1 protein for cells 
exposed to LSS only. Data are normalised to LSS, are expressed as mean +/- standard error and represent the 
results of 4 experiments. 
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4.2.7 Effect of VEGF and LSS on induction of other cytoprotective genes 
VEGF and LSS  induce many other anti-oxidant, anti-inflammatory and anti-apoptotic genes in 
addition to HO-1, but the effect of exposing HUVEC to both together in vitro has not been explored. I 
investigated the induction of eNOS, VEGFR2, DAF, A1, Bcl-2 and MnSOD mRNA in cells exposed 
to laminar shear stress or static conditions, then stimulated with VEGF for 4 or 24h. 
Although serine 1177 phosphorylation of eNOS by VEGF is well documented[411], induction of 
eNOS mRNA expression by VEGF under static conditions did not occur at 4 or 24h (Figure 4.11). 
LSS did induce eNOS mRNA, consistent with the published literature[153]. The addition of VEGF to 
LSS conditions resulted in a down-regulation of mRNA at 4h, which had normalised at 24h. 
 
 
Figure 4.11 Induction of eNOS mRNA by LSS and VEGF. HUVEC were exposed to static or LSS conditions 
for 16h, before the addition of VEGF 25ng/ml for 4h (A) or 24h (B). S+V: VEGF added in static condtions; 
LSS: laminar shear stress; LSS+V: VEGF added to LSS conditions. Data are expressed as mean +/- standard 
error and represent 4 experiments. * = p<0.05. 
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Again, consistent with the published literature, I observed a trend towards induction of VEGFR2 
mRNA with LSS, although this did not reach statistical significance, and a small induction with 
VEGF stimulation for 24h under static conditions. No statistically significant change in VEGFR2 
mRNA levels was observed with VEGF stimulation under LSS conditions (Figure 4.12). 
 
 
Figure 4.12 Induction of VEGFR2 mRNA by LSS and VEGF. HUVEC were exposed to static or LSS 
conditions for 16h, before the addition of VEGF 25ng/ml for 4h (A) or 24h (B). S+V: VEGF added in static 
condtions; LSS: laminar shear stress; LSS+V: VEGF added to LSS conditions. Data are expressed as mean +/- 
standard error and represent 4 experiments. * = p<0.05. 
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DAF is a complement inhibitory protein which is induced in EC by VEGF. In my system, the 
expected induction of DAF mRNA with VEGF treatment under both static and flow conditions was 
observed, but the presence of LSS did not alter this (Figure 4.13). 
 
Figure 4.13 Induction of DAF mRNA by LSS and VEGF. HUVEC were exposed to static or LSS conditions for 
16h, before the addition of VEGF 25ng/ml for 4h (A) or 24h (B). S+V: VEGF added in static condtions; LSS: 
laminar shear stress; LSS+V: VEGF added to LSS conditions. Data are expressed as mean +/- standard error and 
represent 4 experiments. * = p<0.05; ** = P<0.01. 
 
A1 and Bcl-2 are two related anti-apoptotic proteins that have previously been shown to be induced in 
EC by VEGF[174].  No statisically significant increase in either was seen in static-cultured cells 
treated with VEGF, but this may have been to do with timing, as the optimal time point for induction 
of both is thought to be around 8h. These samples were studied at 4h and 24h. A1 mRNA was 
surprisingly significantly down-regulated by LSS for 24h, but this was a transient phenomenon and 
had recovered by 40h (Figure 4.14). However, induction of A1 mRNA by VEGF was likely to be 
preserved under LSS conditions at the short time point, although the large error bars prevented this 
reaching significance. No consistent effect of VEGF or LSS on Bcl-2 mRNA expression was 
observed (Figure 4.15). 
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Figure 4.14 Induction of A1 mRNA by LSS and VEGF. HUVEC were exposed to static or LSS conditions for 
16h, before the addition of VEGF 25ng/ml for 4h (A) or 24h (B). S+V: VEGF added in static condtions; LSS: 
laminar shear stress; LSS+V: VEGF added to LSS conditions. Data are expressed as mean +/- standard error and 
represent 4 experiments. *** = P<0.001. 
 
Figure 4.15 Induction of Bcl-2 mRNA by LSS and VEGF. HUVEC were exposed to static or LSS conditions for 
16h, before the addition of VEGF 25ng/ml for 4h (A) or 24h (B). S+V: VEGF added in static condtions; LSS: 
laminar shear stress; LSS+V: VEGF added to LSS conditions. Data are expressed as mean +/- standard error and 
represent 2 experiments. 
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Finally, the effect of VEGF and LSS on MnSOD mRNA was studied. LSS did not induce MnSOD, 
but VEGF may do so under static conditions, although loss of samples meant that this did not reach 
significance. However, there was no potentiating effect on MnSOD mRNA expression of LSS and 
VEGF together. 
 
 
Figure 4.16: Induction of MnSOD mRNA by LSS and VEGF. HUVEC were exposed to static or LSS 
conditions for 16h, before the addition of VEGF 25ng/ml for 4h (A) or 24h (B). S+V: VEGF added in static 
condtions; LSS: laminar shear stress; LSS+V: VEGF added to LSS conditions. Data are expressed as mean +/- 
standard error and represent 4 experiments (A) or 2 experiments (B). 
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4.2.8 Effect of VEGF under LSS conditions on protein phosphorylation 
Given that no clear pattern of synergistic induction with VEGF and LSS was observed with any of the 
cytoprotective genes analysed earlier, a different approach was adopted to look for evidence in the 
Cytodyne system of synergy between VEGF and LSS. A phosphokinase array was used to screen for 
phosphorylation changes in HUVEC treated with VEGF under both static and LSS conditions. 
Preliminary experiments established that VEGF induced strong ERK1/2 phosphorylation after 15 
minutes. HUVEC were therefore exposed to static conditions or LSS for 24h, before the addition of 
VEGF 25ng/ml for 15 minutes, then immediate lysis on ice. Quantification of the results is shown in 
Figures 4.17, where results are expressed relative to the untreated static condition. In Figure 4.18, the 
effect of VEGF alone is shown by expressing the effects of VEGF on static-cultured cells relative to 
the untreated static control, and VEGF under LSS conditions expressed relative to LSS alone. 
In the majority of cases, the addition of VEGF under LSS conditions resulted in reduced 
phosphorylation compared to VEGF addition to static cells (e.g. eNOS). Those phosphokinases 
exhibiting increased phosphorylation with VEGF and LSS together are summarised in Tables 4.1 and 
4.2. Interestingly, several of these are thought to have roles in preventing cell proliferation (AMPK; 
p27), while VEGF is usually thought of as an endothelial mitogen[324, 412]. Although these changes 
were not subsequently validated and therefore no conclusions can be drawn, it does suggest that the 
influence of VEGF on confluent EC exposed to LSS is likely to be very different to that exerted when 
VEGF is used to stimulate static-cultured cells. 
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Figure 4.17 Phosphokinase array densitometry results presented with static-cultured cells as baseline. 
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Figure 4.18 Phosphokinase array densitometry results presented relative to static or LSS-cultured HUVEC. 
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Phosphokinases exhibiting greater 
phosphorylation with VEGF under 
LSS than under static conditions 
Functions in EC 
JNK pan 
Cell proliferation and migration; response to 
inflammatory mediators 
GSK-3α/β 
Phosphorylation usually leads to deactivation of target 
proteins. Cell proliferation; migration. EC permeability 
in response to VEGF 
Akt
Ser473 
Cell proliferation and survival. Mediates effects on 
metabolism of insulin signalling. May have role in 
angiogenesis 
β-catenin EC permeability in response to VEGF 
Hck 
SrcB subfamily tyrosine kinase. Little known about 
actions in endothelium 
Table 4.3 Phosphokinases exhibiting increased synergy with VEGF and LSS together and their functions in EC. 
 
Other phosphokinases activated by VEGF 
under both static and LSS conditions 
Functions in EC 
p38α 
Response to cytokines and stress. Increased EC 
permeability in response to VEGF 
ERK1/2 Cell proliferation 
AMPKα1 
Energy homeostasis; reduced cell proliferation; 
increases eNOS phosphorylation 
Hsp27 
Refolding proteins in times of stress. 
Downstream substrate of p38. Cell proliferation. 
p27
T198
 
Cell cycle regulator. Blocks cell cycle 
progression. Role in cell motility 
Table 4.4 Phosphokinases activated by VEGF in both static and LSS conditions and their functions. 
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4.3 Discussion 
The results presented in the first part of this chapter show that the early passage HUVEC isolated for 
use in this project express CD31, ICAM-2 and endoglin constitutively. Stimulation with VEGF results 
in cell surface DAF expression, and stimulation with TNFα induces ICAM-1 and VCAM-1 
expression. This indicates that the HUVEC isolated do retain the characteristics of vascular 
endothelium. 
In the second part of the chapter, cytoprotective responses in HUVEC exposed to VEGF in the 
presence of LSS were investigated, exploring the hypothesis that LSS would condition EC such that a 
synergistic induction of HO-1 would be stimulated. I was not able to confirm this: induction of HO-1 
by VEGF in static conditions was not observed, although induction by LSS was, and although a 
synergistic induction of HO-1 mRNA by VEGF and LSS was observed at an early time point, this 
was not sustained at later points and nor was it replicated with HO-1 protein expression. I also 
investigated changes in expression of other genes known to be affected by VEGF or LSS, but did not 
consistently observe a synergistic response from these either. Finally, I performed a phosphokinase 
array on HUVEC conditioned to LSS, then stimulated with VEGF. Although the majority of kinases 
included were phosphorylated either by LSS or by VEGF in static conditions, in most cases the 
addition of VEGF under static conditions reduced the extent of phosphorylation. 
4.3.1 Induction of HO-1 by VEGF 
Although three groups have previously demonstrated VEGF induction of HO-1 in EC[405-407], this 
was not demonstrated in my work. This may partly be because of differences in the cell conditions 
studied. While I studied the responses to VEGF of confluent HUVEC, analogous to the endothelium 
lining mature blood vessels, all three previously published studies were done in the context of 
angiogenesis. It is known that EC respond differently to VEGF depending on the degree of confluence 
and cell-cell contact maintained[164]. Part of the explanation therefore may be that the induction of 
HO-1 by VEGF is lessened in confluent cells.  
HMOX-1 promoter polymorphisms may also be important.The HMOX-1 promoter contains a 
sequence of GT repeats where the number is distributed in a bimodal fashion such that a shorter 
number of repeats is associated with a more readily inducible gene[413]. Given that I studied multiple 
isolates of HUVEC, it is possible therefore that they were derived from people with less inducible 
HO-1 genes. Lastly, EC isolated from some umbilical cords had high basal HO-1 expression and these 
tended not to show a good additional induction. 
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4.3.2 Effect of VEGF on HUVEC pre-conditioned with LSS 
Cytoprotective gene expression 
In contrast to the lack of HO-1 induction observed with VEGF, exposure to LSS for 24h resulted in a 
robust induction, as has been previously reported[140, 248]. However, in HUVEC pre-conditioned 
with LSS for 24h, I did not observe a consistent additional induction when VEGF was added, beyond 
a transient effect on HO-1 mRNA after 4h stimulation, that was not replicated with HO-1 protein or 
with mRNA at longer time points. Moreover, when the expression pattern of other genes thought to be 
affected by LSS and VEGF was analysed, no synergy was seen with these either. For VEGFR2 and 
eNOS, there was either no effect on mRNA expression or a down-regulation following VEGF 
stimulation after LSS pre-conditioning. The induction of DAF by VEGF was not altered by exposure 
to LSS, and MnSOD did not respond to LSS at all. The only gene whose expression did appear to be 
influenced by VEGF and LSS together was the anti-apoptotic protein A1. A striking down-regulation 
was observed after expsure to LSS for 28h, which was then overcome by the addition of VEGF. 
However, this is likely to be transient phenomenon related to HUVEC equilibration to flow, as levels 
had recovered after 40h . 
In addition to the lack of synergetic response to VEGF and LSS together, the changes in gene 
expression in those genes that responded to both (eNOS, HO-1, VEGFR2, A1) were highly variable, 
meaning that the results obtained are difficult to interpret with any confidence. Natural population 
variability in responses may be part of the explanation. However, I encountered significant technical 
difficulties with the Cytodyne streamer system used to expose HUVEC to shear stress. The apparatus 
was hard to assemble without any loss of cells, leading to variation in levels of confluence of cells as 
well as frequent cell loss due to an imperfect vacuum seal.  
In addition, I think pre-conditioning to LSS of 16h was in hindsight too short a period and did not 
allow the cells to accommodate completely to flow, leading to odd transient changes in gene 
expression that do not reflect what would be found in arterial EC in vivo. This reflects wider 
difficulties modelling EC behaviour when exposed to flow in vitro. For example, when endothelial 
HO-1 expression is examined in vivo by en face confocal microscopy, expression levels in 
atheroprotected areas are very low, the opposite of that seen in in vitro[248]. A different flow system 
made by Ibidi has now been set up in Prof Mason's laboratory. This is much more user-friendly, and I 
would use this if I were to explore this area further in future.  
Phosphokinase array 
The final experiments presented in this chapter were the results of a phosphokinase array carried out 
to investigate changes in signalling in EC stimulated with VEGF under static conditions or 
conditioned by LSS. Although the results should be subject to the same caution in interpretation as 
those of changes in gene expression discussed in the previous section, care was taken to minimise the 
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potential sources of inaccuracies. Pooled HUVEC were used to reduce bias arising from using small 
numbers of isolates. HUVEC were exposed to LSS for 24h before the addition of VEGF, rather than 
16h. Longer would have been even better, but I ran the risk of unacceptably high levels of cell loss 
with prolonged use of the flow apparatus. Lastly, the experiment was run three times and only 
samples from slides that remained confluent throughout were used in the array to prevent variations in 
response to VEGF being due to alterations in confluence.  
The predominant pattern observed with the majority of the phosphokinases included in the array was 
of increased phosphorylation following exposure to VEGF or LSS compared to static untreated 
conditions, but a reduction in phosphorylation when VEGF was added to HUVEC conditioned to 
LSS. This could represent a homeostatic response, in that kinases which were perhaps optimally 
phosphorylated with LSS alone are then not activated further by VEGF. It may also reflect the fact 
that, although both LSS and VEGF are capable of inducing expression of cytoprotective genes, in 
other areas of EC biology they have opposing actions. For example, VEGF is associated with 
increased EC permeability and stimulates EC growth, migration and proliferation, while LSS reduces 
proliferation[156, 164]. 
The kinases whose phosphorylation status was enhanced by VEGF stimulation under LSS were JNK, 
GSK-3α/β, β-catenin, Akt and Hck. Those that were phosphorylated equally by VEGF whether 
HUVEC were exposed to LSS or not were AMPKα1, p27, ERK1/2, Hsp27 and p38α. Activation of 
these kinases share several broad common functions, including cell proliferation, motility and 
enhancement of EC permeability. Meanwhile, p27 and AMPKα1 inhibit cell proliferation[313, 412]. 
Overall there seems little evidence to support the idea of synergy between VEGF and LSS in 
endothelial cytoprotection, or that LSS primes EC to respond more exuberantly to VEGF as it does 
with other protective mediators such as statins, although technical limitations mean that important 
effects may have been missed. Indeed VEGF seems to act to switch off LSS-induced signalling 
pathways in the main and this may indicate a stabilising homeostatic influence of VEGF on the adult 
vasculature. However,  AMPKα1, activation of which is associated with cytoprotective effects in EC, 
was phosphorylated by both LSS and VEGF, although there was no additional phosphorylation seen 
with both together. AMPK is increasingly recognised as an important kinase in the vascular 
endothelium, above and beyond its well known metabolic roles. The following three chapters report 
findings on the pharmacological activation of AMPK and on changes in downstream cytoprotective 
gene expression. 
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5 MTX ACTIVATES AMPK AND INDUCES CYTOPROTECTIVE 
GENE EXPRESSION IN EC 
5.1 Introduction 
The second aim of the work presented in this thesis was to investigate the mechanisms underlying the 
protection against cardiovascular mortality seen with MTX use in RA. MTX use is associated with a 
reduction in CVD of  21% in the meta-analysis conducted by Micha et al, and up to 70% in individual 
studies[79, 361]. Although it is possible that this arises entirely through MTX's anti-inflammatory 
properties, another possibility is that MTX has effects directly on the vascular endothelium. 
Specifically, MTX may be operating through induction of cytoprotective pathways in EC.  
It is known that the long-lasting polyglutamate metabolites of MTX alter purine and adenosine 
metabolism leading to increases in adenosine, which has anti-inflammatory and cytoprotective 
effects[369]. In addition however, inhibition of purine metabolism enzymes by MTX leads to 
accumulation of AMP, AICAR and ZMP, all activators of AMPK signalling. I therefore formulated 
the hypothesis that MTX treatment activates AMPK and induces expression of cytoprotective genes, 
thus enhancing endothelial resistance to injury.  
5.1.1 Previous studies of MTX and AMPK 
There is preliminary evidence to support the hypothesis that MTX activates AMPK. Beckers et al 
showed that MTX 5µM potentiated AMPKα phosphorylation by AICAR in cancer cell lines[314]. 
Secondly, a more recent study of a new anti-folate cancer chemotherapy agent, pemetrexed, shows 
that it inhibits AICAR transformylase, leading to ZMP accumulation and AMPK activation[414]. 
Older papers also support a role for MTX in altering cellular metabolism in ways that are consistent 
with activation of AMPK. High dose MTX (220µM) activates glycogenolysis in isolated perfused rat 
liver[415]. MTX also inhibited the pentose cycle enzymes glucose-6-phosphate dehydrogenase and 6-
phosphogluconate dehydrogenase when used at high doses in HeLa cells[416].  
If MTX does activate AMPK, this is likely then to lead to changes in expression of those genes that 
are targets of AMPK signalling. In EC, these include antioxidant cytoprotective genes such as 
MnSOD and HO-1, anti-apoptotic members of the Bcl-2 family, complement inhibitory proteins such 
as DAF and proteins involved in mitochondrial metabolism such as uncoupling proteins[206, 217, 
276, 277, 417]. Previous studies looking at the effect of MTX on the SOD enzymes have variously 
shown no effect on activity or on induction in HeLa cells or in lung adenocarcinoma and 
mesothelioma cell lines[416, 418]. There are no studies published investigating whether low dose 
MTX affects expression of HO-1, Bcl-2 family members, DAF or uncoupling proteins. 
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5.1.2 Anti-proliferative, pro-apoptotic effects of MTX and serum concentrations 
Previous studies of the effects of MTX on vascular endothelium were discussed in the general 
introduction. Given that MTX's predominant mechanism of action when used in cancer chemotherapy 
is anti-proliferative, it will be important to investigate whether it affects EC proliferation, or indeed 
induces apoptosis, at the concentrations achievable in patient sera when taken as a treatment for 
autoimmune inflammatory disease.  
There are not many studies of plasma concentration of MTX. Combe et al measured the 
concentrations achieved in 20 RA patients taking a stable dose of MTX 10mg weekly (a low dose - 
many patients take up to 25mg). They found peak total MTX concentrations of 400nM, falling after 
24h to a plateau around 10nM[419]. Similarly, Chladek et al, studying patients taking oral MTX 7.5 - 
15mg to treat plaque psoriasis, found peak serum concetrations around 125nM, falling to a plateau 
between 10-20nM after 36h[420].  
Previous studies suggest that MTX does exert an anti-proliferative effect on EC at doses analogous to 
that achieved in patient serum. Hirata et al found that MTX 5nM reduced DNA synthesis in HUVEC , 
and 0.7mg/kg weekly for 8 weeks prevented neo-vascularisation in a rabbit cornea embedded with an 
ECGF pellet[385]. Similarly, Yamasaki et al noted inhibition of HUVEC proliferation with MTX 
100nM and 1000nM, without evidence of cytotoxicity[382]. However, other studies have not found a 
reduction in DNA synthesis with similar MTX concentrations used on the endothelial cell line 
EA.hy926 cells and on bovine EC[383]. 
No previous studies have found that MTX induces apoptosis in benign, quiescent EC grown in culture 
at the sort of doses found in patient sera. However , it has been found to induce apoptosis in 
keratinocytes at similar concentrations in vitro[384], and in activated T lymphocyte and monocyte cell 
lines[380, 421]. This last is thought to rely on generation of ROS, and blocking ROS production using 
NAC reduces MTX-induced apoptosis in Jurkat T cells and U937 monocytes[380]. 
5.1.3 Other features pertinent to studying MTX treatment of EC 
MTX affects the redox balance within cells, with many studies attributing MTX toxicity, and possibly 
part of its therapeutic effect, to increased oxidative stress[380, 416, 422]. It therefore follows that 
cytoprotective responses induced by MTX might occur in response to oxidative stress as the cell 
attempts to restore homeostasis. In this case, one might expect a broad range of antioxidant genes to 
be activated by MTX treatment, including those containing anti-oxidant response elements in their 
promoters that are Nrf-2 transcription targets. Previous studies looking at the effect of MTX on redox-
sensitive genes in HeLa cells have shown that high dose MTX inhibits glutathione reductase and γ-
glutamylcysteine synthase, and depletes the pool of intracellular glutathione, but does not alter 
activity of SOD or catalase[416]. 
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MTX in clinical practice is nearly always given with high dose folic acid as this is an effective way of 
ameliorating common gastro-intestinal side effects such as stomatitis, mouth ulcers and nausea. It 
would therefore be important to investigate whether the effects of MTX on EC are maintained in the 
presence of folic acid supplementation. Plasma concentrations in people treated with folic acid can 
reach up to 30 - 40nM, in patients supplemented with 2mg folic acid daily[423].  
Similarly, MTX is used to treat people suffering chronic systemic inflammation, and thus it is 
important to model endothelial dysfunction if at all possible, by measuring whether EC maintain 
responsiveness in MTX after pre-treatment with pro-inflammatory cytokines sufficient to induce EC 
activation. 
Finally, it will be important to establish whether MTX has any beneficial functional effect on EC, 
following on from the induction of changes in gene expression. AMPK activation in EC has 
previously been associated with protection against apoptosis induced by oxidative challenge and also 
by oxygen and glucose deprivation[262, 277]. If MTX does activate AMPK, it may therefore be 
capable of enhancing EC survival when exposed to glucose deprivation. 
5.1.4 Chapter Aims 
The experiments described in this chapter were performed to investigate the mechanism underlying 
the cardioprotective effect of MTX observed clinically; specifically, whether it is capable of 
activating AMPK and causing downstream changes in cytoprotective gene expression. The following 
experimental aims were addressed: 
 Is MTX primarily a toxic drug that reduces EC proliferation or even induces apoptosis? 
 Does MTX treatment of EC activate AMPK? 
 Does MTX treatment of EC result in changes in cytoprotective gene expression? 
 Does concurrent treatment of EC with folic acid change EC responses to MTX? 
 Does pre-treatment of EC with pro-inflammatory cytokines alter EC response to MTX? 
 Can MTX inhibit EC activation by pro-inflammatory cytokines? 
 Can MTX protect EC against apoptosis? 
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5.2 Results 
5.2.1 Effect of MTX on EC number 
As MTX is known to inhibit folate metabolism, a major part of its cancer chemotherapeutic efficacy 
and, it was once thought, of its disease-modifying properties, is its ability to inhibit cell growth and, in 
malignant cells, to induce apoptosis. It was therefore hypothesised that MTX is likely to inhibit 
HUVEC growth in culture. An MTS assay (Promega) was used to measure EC number after treatment 
with MTX or vehicle control (a volume of DMSO equal to that of the highest concentration of MTX) 
at varying concentrations for 48h (Figure 5.1). A trend towards reduction in cell number with 
increasing concentrations of MTX was observed, as expected. However, the MTS assay measures 
viable EC numbers, and does not distinguish between increased cell death or reduced cell 
proliferation. Therefore, cell cycle analysis by propidium iodide staining was also performed in order 
to clarify whether MTX merely prevented EC proliferation or whether it induced apoptosis. 
 
Figure 5.1 MTX reduces viable EC number. HUVEC were treated with MTX at the concentrations shown for 
48h, or with DMSO vehicle control. Viable EC number was determined by loading with MTS dye and 
measuring absorbance at 490nm. Data shown are the results of 4 experiments. Ns: not statistically significant. 
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5.2.2 MTX reduces EC replication but does not induce apoptosis 
Propidium iodide staining allows identification of the numbers of cells at each point in the cell cycle, 
as the degree of staining correlates with the amount of DNA contained within the cell. HUVEC were 
treated with MTX or an equal volume of DMSO for 48h at increasing concentrations, or subjected to 
serum starvation for 48h before cell cycle analysis. Increasing concentrations of MTX did not change 
the sub-G0% (Figure 5.2), indicative of numbers of apoptotic cells, but did cause an increase in the 
numbers in S-phase. This suggests that MTX treatment reduces EC proliferation by preventing entry 
into G2/M phase, but does not cause EC apoptosis. Although this has not been studied in HUVEC 
previously, this is consistent with the available literature investigating MTX effects on the cell cycle 
in other cell types.  
Taken together with the results of the MTS assay, these results suggest that MTX reduces EC 
proliferation but does not precipitate apoptosis in healthy EC monolayers. 
 
Figure 5.2 MTX reduces HUVEC replication but does not induce apoptosis. HUVEC were treated with MTX 1-
100nM or vehicle control or serum starrvation for 48h, then fixed and stained with propidium iodide before 
reading by Facs. A: typical cell cycle profile of untreated cells; B: typical cell cycle profile of cells treated with 
MTX 100nM for 48h; C: percentage of apoptotic (sub G0) cells; D: percentage of EC in S-phase. C and D 
represent the results of 6 experiments, expressed as mean +/- standard error. UT: vehicle control; SS: serum 
starvation for 48h; ns: not statistically significant; ** = p<0.01; *** = p<0.001. 
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5.2.3 MTX treatment phosphorylates AMPKα in HUVEC 
Given that the currently accepted mechanism of action of MTX involves intracellular accumulation of 
AICAR and AMP, and that these are known activators of AMPK, it was hypothesised that MTX may 
activate AMPK. HUVEC were treated with MTX 100nM, vehicle control or AICAR 1mM as a 
positive control for 24-72h. The concentration chosen was based on that able to increase intracellular 
AICAR[375] and to be measured in patient sera following therapeutic dosing[419].  Because of 
technical difficulties with stripping and reprobing a single membrane, each condition was loaded onto 
two gels, and phosphorylated AMPK and total AMPK were blotted for separately, and corrected for 
loading by probing each membrane separately for GAPDH.  
A two-fold increase in AMPKαThr172 phosphorylation was observed at 48h, but not at 24h (Figure 
5.3A and B), consistent with this being a delayed response dependent on the production of MTX 
polyglutamate metabolites, and the accumulation of AICAR and AMP following enzyme inhibiton. A 
less consistent increase in phosphorylation was observed at 72h (Figure 5.3C). It should also be noted 
that there was a degree of variation in basal level of AMPK phosphorylation. 
 
 
Figure 5.3 MTX phosphorylates AMPKα in HUVEC. HUVEC were treated with MTX 100nM or AICAR 1mM 
as positive control for 24h (A), 48h (B) or 72h (C). Representative blots and densitometry are shown, with 
AMPKαThr172 expressed relative to total AMPKα and GAPDH. Data plotted are mean +/- SEM and represent the 
results of 3-6 experiments. UT = vehicle control; *=p<0.05. 
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5.2.4 MTX induces MnSOD expression in HUVEC and HAEC  
Following the discovery that MTX can activate AMPK in EC, I explored whether MTX treatment 
results in induction of cytoprotective genes known to be targets of AMPK signalling. MnSOD is an 
antioxidant enzyme, essential for life, that catalyses the conversion of superoxide radicals into H2O2, 
and is located in mitochondria[221]. Induction of MnSOD is an important vascular cytoprotective 
response, capable of protecting against mitochondrial damage and atherogenesis[226]. 
Induction of MnSOD mRNA and protein was seen after 48h MTX treatment in HUVEC, and 
maintained at 72h (Figure 5.4A and C). This response was concentration-dependent, first seen with 
MTX 0.1nM and maximal at 10 and 100nM (Figure 5.4D). Moreover, a two-fold induction in 
MnSOD protein was reproduced in HAEC treated with MTX 100nM for 48h (Figure 5.4B). Again, 
consistent with this being linked to AMPK activation and dependent on changes in purine nucleotide 
levels, the induction was only observed after 48h treatment and not at earlier time points. Increased 
MnSOD expression was also shown following AICAR treatment of HUVEC (Figure 6.4) , and has 
previously been linked with AMPK activity[262, 276, 310].  
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Figure 5.4 MTX induces MnSOD mRNA and protein. HUVEC were treated with MTX at concentrations 
varying from 0.1nM to 100nM for 24-72h. A: representative western blot and corresponding densitometry 
showing MnSOD protein expression in HUVEC in response to increasing MTX concentrations for 48h. B: 
representative western blot and corresponding densitometry demonstrating MnSOD induction by MTX 100nM 
for 48h in HAEC. C: time course of MnSOD mRNA induction in HUVEC following stimulation with MTX 
100nM. D: dose response of MnSOD mRNA induction after stimulation with MTX for 48h. Data shown are 
mean +/- SE and are the results of >3 experiments. UT = vehicle control; *=p<0.05; **=p<0.01. 
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5.2.5 MTX induces HO-1 expression in HUVEC 
Another known AMPK target in EC is the anti-oxidant, anti-inflammatory and anti-apoptotic enzyme 
HO-1. HO-1 is an extremely inducible enzyme which catalyses the breakdown of heme into bilirubin, 
creating carbon monoxide, iron and biliverdin as its end-products. Its induction in EC is associated 
with vascular health in a number of different ways, including resistance to transplant vasculopathy. 
Treatment of EC with MTX resulted in a dose dependent induction of HO-1 mRNA and protein, most 
pronounced at 10 and 100nM, and after 48h treatment (Figure 5.5). 
 
Figure 5.5 MTX treatment induces HO-1 mRNA and protein expression. HUVEC were treated with MTX 0.1 – 
10nM for 0 to 72h. A: representative western blot showing HO-1 protein expression in response to rising 
concentrations of MTX for 48h. B: corresponding densitometry. C: Time course of HO-1 mRNA induction 
following stimulation with MTX 100nM for 24-72h. D: HO-1 mRNA induction in response to increasing 
concentrations of MTX over 48h. Data shown represent the results of >3 experiments. UT = vehicle control; 
*=p<0.05; **=p<0.01. 
 125 
 
5.2.6 MTX induces expression of other AMPK target genes 
AMPK signalling results in the induction of many target genes with cytoprotective functions: 
antioxidants, anti-apoptotic proteins, proteins involved in the regulation of mitochondrial ROS 
production and promoting oxidative phosphorylation, and anti-inflammatory genes. mRNA from 
HUVEC treated with MTX 100nM for 48h was therefore analysed to look for changes in other 
cytoprotective genes known to be a target of AMPK. 
The Bcl-2 family of proteins have both pro- and anti-apoptotic members. A 12-fold induction of A1 
mRNA, an anti-apoptotic member of the family, was observed (Figure 5.6A). Induction of this gene 
has not previously been linked to MTX use or to AMPK signalling. A trend towards induction of Bcl-
2 itself was observed (Figure 5.6B) but this was not statistically significant. 
Induction of UCP2 mRNA was also seen in HUVEC treated with MTX after 48h (Figure 5.6C). UCP-
2 is involved in the regulation of mitochondrial ROS production, by dissipating the proton gradient 
that drives ATP generation. It has also recently been implicated in the maintenance of endothelial 
homeostasis[241].  
Lastly, in HUVEC treated with MTX for 72h, induction of DAF was observed (Figure 5.6D). This 
complement-inhibitory protein prevents the formation and accelerates the decay of C3 and C5 
convertases, minimizing deposition of C3 and generation of C3a, C5a and C5b-9[237]. Thus, MTX-
mediated AMPK activation in EC is linked to the regulation of a variety of AMPK-dependent 
protective genes, all of which are anti-atherogenic.  
 
 126 
 
 
Figure 5.6 MTX treatment causes induction of other AMPK target genes. HUVEC were treated with MTX 
100nM for 48h (A-C) or 72h (D). Relative mRNA levels were determined by qRT-PCR, using β-actin as 
housekeeping gene. A: induction of A1; B: induction of Bcl-2; C: induction of UCP-2 and D: induction of DAF. 
Data shown are the results of 4 experiments. UT = vehicle control; *=p<0.05; **=p<0.01. 
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5.2.7 MTX does not cause a general induction of antioxidant enzymes 
Given that it has been demonstrated that MTX induces expression of two anti-oxidant enzymes in 
HUVEC (MnSOD and HO-1), induction of other anti-oxidant enzymes was investigated. mRNA from 
HUVEC treated with MTX 100nM for 48h was analysed by qRTPCR to look at relative expression 
levels of NQO-1, Trx, and Trx reductase. No induction was seen (Figure 5.7). These were the same 
samples in which induction of MnSOD, HO-1 and other AMPK target genes was observed, indicating 
that the cells had responded to MTX and validating this result. Thus, MTX does not appear to elicit a 
general rise in anti-oxidant enzymes, but rather promotes the specific induction of certain genes.  
 
Figure 5.7 MTX does not induce expression of other antioxidant genes. HUVEC were treated with MTX 100nM 
for 48h, and mRNA levels of the antioxidant genes NQO-1 (A), thioredoxin (B) and thioredoxin reductase (C) 
were measured. Data shown represent the results of 4 experiments. UT = vehicle control. 
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5.2.8 Co-treatment with MTX and folic acid does not alter MnSOD induction 
In an attempt to determine whether the MTX-induced changes in gene expression in quiescent EC are 
relevant to the clinical scenario, responses in EC co-treated with folic acid (FA) were investigated. FA 
is routinely prescribed alongside MTX to mitigate side effects and it was therefore important to 
establish whether the observed changes in gene expression were maintained in its presence. In the first 
experiments, EC were treated with MTX 100nM for 48h, and FA 50nM for the second 24h. The dose 
was chosen to reflect the plasma concentrations achieved in people given FA supplementation[423-
425]. No influence of FA on induction of MnSOD mRNA was observed (Figure 5.8A). Secondly, 
HUVEC were treated with MTX 100nM for 48h, or a 10-fold dilution series of FA from 50nM to 
50µM for 24h. FA even at 50µM did not alter HO-1 or MnSOD mRNA levels, and there was no 
evidence of a dose response in cells treated with MTX and FA together. It should be noted that this 
latter experiment was performed only once (Figure 5.8B and C). However, as it showed no difference 
in HO-1 induction with folic acid added, this was not therefore repeated on the samples used to 
generate Figure 5.8. 
 
Figure 5.8 Co-treatment of EC with folic acid does not alter the induction of MnSOD mRNA by MTX. A: 
HUVEC were treated with MTX 10nM for 48h and FA 50nM for 24h. MnSOD mRNA induction was measured 
by qRT-PCR. Data shown are the results of 4 experiments. B and C: HUVEC were treated with MTX 100nM 
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for 48h and FA in varying concentrations from 0.05μM to 50µM for 24h, before analysis of MnSOD and HO-1 
mRNA levels by qRT-PCR. Data shown are the results of 1 experiment. UT: vehicle control; FA: folic acid; ns: 
not statistically significant; *=p<0.05. 
5.2.9 EC pre-treated with TNFα maintain responsiveness to MTX 
Patients with RA and those with primary coronary artery disease exhibit endothelial dysfunction as an 
early feature. This is characterised by reduced NO bioavailability, often linked to excess ROS 
production, increased endothelial apoptosis and lipid permeability, and impaired endothelial responses 
to exogenous stimuli. The pro-inflammatory cytokine TNFα is an important mediator of endothelial 
dysfunction and was chosen to model this in vitro. EC were exposed to TNFα (1ng/ml) for 24h prior 
to the addition of MTX for 48h. MTX-induced upregulation of MnSOD and HO-1 mRNA was 
preserved, and as expected a small induction of MnSOD with TNFα alone was also seen (Figure 5.9A 
and B). Overall, the effect of TNFα and MTX together on MnSOD induction appeared to be additive. 
To characterise further the induction of MnSOD mRNA by MTX and TNFα, a time course was 
performed (Figure 5.9C). This was not done to look at HO-1 mRNA induction as this is not known to 
be a target of TNFα, unlike MnSOD, and no induction was observed with TNFα alone in the 
preceding experiments. The time course showed that TNFα causes a rapid induction of MnSOD that 
peaks at 4-8h and has largely subsided by 24h. By contrast, MTX causes a delayed induction, 
maximal at 48h. This may have implications for the mechansims by which TNFα and MTX induce 
MnSOD: while TNFα causes a direct activation of NFκB which alters gene expression in a matter of 
hours, MTX is likely to be effecting changes indirectly through alterations in various purine pathway 
metabolites. Alterations in gene expression are delayed while levels of these metabolites build up. 
These findings confirm the ability of MTX to condition EC in the face of a chronic pro-inflammatory 
stimulus such as that seen in patients with RA.  
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Figure 5.9 Induction of MnSOD and HO-1 by MTX still occurs when HUVEC are pre-treated with TNFα. A 
and B: HUVEC were treated with TNFα 0.1ng/ml or 1 ng/ml for 24h, before the addition of MTX 10nM for 
48h. MnSOD and HO-1 mRNA levels were measured by qRT-PCR. Data represent the results of 5 experiments. 
UT: vehicle control; T0.1: TNF 0.1ng/ml; T0.1M: TNF 0.2ng/ml + MTX 10nM; T1: TNF 1ng/ml; T1M: TNF 
1ng/ml + MTX 10nM. *=p<0.05; **=p<0.01. C: Time course of MnSOD mRNA induction by TNF 1ng/ml and 
MTX 10nM. Data represents the results of 1 experiment. Black squares: TNF treatment; black triangles: MTX 
treatment. 
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5.2.10 MTX does not alter ICAM-1 and VCAM-1 induction by TNFα in vitro 
In order to explore further how EC pre-treated with TNFα respond to MTX, ICAM-1 and VCAM-1 
cell-surface expression was investigated by flow cytometry. These are canonical TNFα target genes, 
reponsible for EC-leucocyte adhesion. HUVEC were treated with MTX 10nM for 36h, before the 
addition of TNFα 1 or 10ng/ml for 16h. As expected, a brisk induction of both VCAM-1 and ICAM-1 
with TNFα was observed. However, this was not reduced by the simultaneous addition of MTX, and 
indeed MTX alone caused a small induction of both VCAM-1 and ICAM-1 on the cell surface (Figure 
5.10). 
These findings were unexpected, given that MTX is an anti-inflammatory drug and previous studies in 
HUVEC and in samples from patients have suggested that it reduces ICAM-1 and VCAM-1 
expression[382]. They were further investigated by looking at a time course of changes in ICAM-1 
mRNA and both ICAM-1 and VCAM-1 cell-surface expression in response to TNFα and MTX 
(Figure 5.11). These indicated that the magnitude of induction seen with MTX was many times 
smaller than that seen with TNFα. These results may reflect a non-specific effect of MTX on cells in 
culture as they do not correspond to the situation seen in patients treated with MTX. They highlight 
however the limits to which conclusions about drug actions can be drawn from in vitro experiments 
only. 
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Figure 5.10 MTX pre-treatment does not reduce induction of ICAM-1 or VCAM-1 by TNFα. HUVEC pre-
treated with MTX 10nM for 36h were stimulated with TNFα 1 and 10ng/ml for 16h. ICAM-1 and VCAM-1 
expression were analysed by Facs. A and C: representative uncompensated Facs images of ICAM-1 and 
VCAM-1 expression respectively. Yellow: untreated; red: MTX 10nM; blue: TNFα 10ng/ml; green: MTX and 
TNFα. B and D: normalised RFI for ICAM-1 and VCAM-1 respectively. UT: vehicle control; T1: TNFα 
1ng/ml; T10 TNFα 10ng/ml; MT1: MTX 10nM and TNFα 1ng/ml; MT10: MTX 10nM and TNFα 10ng/ml. 
Data are the results of 3 experiments. * = p<0.05; ** = p<0.01. 
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Figure 5.11 Time course of ICAM-1 and VCAM-1 induction by TNFα and MTX. HUVEC were stimulated with 
TNFα 1ng/ml or MTX 10nM for varying times. Untreated cells were also analysed and the results subtracted 
from those of the stimulated cells. A: time course of ICAM-1 mRNA induction; B: time course of ICAM-1 cell 
surface expression; C: time course of VCAM-1 cell surface expression.  Squares: TNFα; triangles: MTX. Data 
shown are the results of one experiment. 
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5.2.11 MTX protects against apoptosis induced by glucose deprivation 
AMPK is principally known for its role in conserving cellular energy[181]. Thus, in order to 
determine whether its activation by MTX was functionally important in EC, a glucose deprivation 
assay was used. Similar assays have been used in previous studies of AMPK-mediated protection 
against apoptosis, sometimes in combination with oxygen deprivation. EC were treated with MTX 
100nM for 48h, and then maintained for 18h in HBSS or glucose-deficient HBSS. Cell viability was 
initially determined by Trypan blue exclusion, and 18h glucose deprivation resulted in a marked 
increase in numbers of dead EC (Figure 5.12) while MTX alone made no difference to the numbers of 
dead cells, as expected from the results of early experiments with MTS and cell cycle analysis 
(Figures 5.1 and 5.2). 
In order to study death by apoptosis specifically, early apoptosis was detected by staining with 
Annexin V which binds phosphatidylserine, the membrane phospholipid exposed when the inner 
surface of the cell membrane is flipped outwards early in the process. Established cell death was 
detected by permeability to propidium iodide, using flow-cytometric quantification. Glucose 
deprivation led to a marked increase in binding of Annexin V to the EC surface and resulted in a 
doubling of PI-positive cells. These responses were significantly reduced by MTX (Figure 5.13). 
Moreover, MTX alone did not increase EC apoptosis under normal glucose conditions. These data 
suggest that the effect of MTX treatment on vascular EC is protective, as opposed to representing a 
stress response to a noxious stimulus. 
 
 135 
 
 
Figure 5.12 Glucose deprivation induces apoptosis. HUVEC were treated with MTX 100nM for 54h, then 
incubated either in HBSS containing 2% BSA and L-glutamine, or modified HBSS without glucose for 18h. A: 
photomicrograph of HUVEC in HBSS; B: photomicrograph of HUVEC pre-treated with MTX in HBSS; C: 
photomicrogaph of HUVEC after undergoing glucose deprivation for 18h; D: photomicrograph of HUVEC pre-
treated with MTX then deprived of glucose for 18h. All taken at x40 magnification. E: analysis of trypan blue 
staining of HUVEC. HBSS: HUVEC incubated in HBSS; HBSS M: pre-treated with MTX then incubated in 
HBSS; GD: HUVEC incubated in HBSS without glucose; GD M: HUVEC pre-treated with MTX then 
incubated in HBSS without glucose. *** = p<0.001. 
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Figure 5.13 MTX protects EC from apoptosis induced by glucose deprivation. HUVEC were pre-treated with 
MTX 100nM for 54h, before glucose deprivation for 18h. Early apoptosis was detected by Annexin V staining 
(A and C), and cell death by propidium iodide positivity (B and D). A: representative Facs image depicting 
Annexin V staining. Green: untreated cells in HBSS; red: glucose deprivation; blue: glucose deprivation after 
MTX pre-treatment. B: representative Facs image depicting propidium iodide positivity. Black: untreated cells 
in HBSS; red: glucose deprivation; blue: glucose deprivation in cells pre-treated with MTX. C: normalised 
relative fluorescence intensity of Annexin V staining, representing 3 experiments. D: percentage propidium 
iodide positivity, representing 6 experiments. APC: allophycocyanin; PE-Cy5: Phycoerythrin-cyanine 5; HBSS: 
HUVEC incubated in HBSS with 2% BSA and L-glutamine; HBSS M: HUVEC pre-treated with MTX then 
incubated in HBSS as before; GD: HUVEC incubated in HBSS without glucose, with 2% BSA and L-
glutamine; GD M: HUVEC pretreated with MTX incubated in HBSS without glucose as before. * = p<0.05; ** 
= p<0.01; *** = p<0.001. 
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5.3 Discussion 
The results presented in this chapter demonstrate that low-dose MTX exerts changes in signalling and 
protective gene expression in HUVEC in culture. Specifically, low-dose MTX activates AMPK and 
induces MnSOD, HO-1 and other known AMPK target genes including UCP2, DAF and A1. 
Moreover these changes do not involve a general rise in anti-oxidant enzymes, perhaps suggesting 
that they represent a specific signalling response and not a general defence against oxidative stress. 
The effects are preserved when EC are pre-treated with FA, and also when EC are exposed to TNFα 
to mimic a dysfunctional endothelium. Moreover, although MTX reduces EC proliferation, it does not 
induce apoptosis, and indeed was able to provide some protection against apoptosis induced by 
glucose deprivation. However, it did not alter induction of cell adhesion molecules by TNFα. 
5.3.1 Functional effects of MTX on EC viability and apoptosis 
One major concern with the results presented in this chapter is whether the observed changes in 
protective gene expression are occurring because MTX is a noxious stimulus, causing oxidative stress 
or even inducing apoptosis in EC, as it does in activated leucocytes. Some support to this notion was 
provided by the observation that MTX reduces cell proliferation by inducing a cell cycle block at the 
S-phase - G2/M phase transition. A cell cycle block at this stage with MTX has previously been 
reported in colon cancer cell lines, activated T lymphocytes and in astrocytes in culture, and in these 
papers was associated with increased apoptosis[426-428]. That this is not the case was shown by 
experiments indicating that MTX does not increase the sub G0% in cell cycle analysis, and does not 
induce apoptosis measured either by trypan blue staining, Annexin V binding or propidium iodide 
permeability. In fact, MTX protected EC against apoptosis when induced by glucose deprivation. 
It should be noted that in the experiments presented here, the effect of MTX on EC proliferation, as 
measured by MTS assay, was not statistically significant (Figure 5.1). Given the clear dose response, I 
interpret this as being due to small n numbers and not because of a lack of biological effect. An effect 
of low dose MTX on EC proliferation is, however, much less likely to be relevant in vivo given that 
EC turnover in mature vascular beds is much lower than that seen in cells in culture[87]. 
MTX treatment of EC exerted a demonstrable functional effect and was able to attenuate apoptosis 
induced by complete glucose deprivation. The mechanism underlying this response is likely 
multifactorial. AMPK activation moves cells away from glycolysis as an ATP source, with glucose 
used more efficiently by oxidative phosphorylation in the mitochondria, thus prolonging cell survival 
in low glucose conditions. Additionally, the induction of A1 and HO-1 by MTX may exert anti-
apoptotic effects. The induction of MnSOD, HO-1 and UCP-2 will also impart important anti-oxidant 
effects which are likely to improve cell survival. 
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5.3.2 AMPK activation by MTX  
A notable feature of the experiments presented here is the relatively long delay between exposing 
HUVEC to MTX, and the onset of changes in AMPK phosphorylation state and changes in gene 
expression. HUVEC were treated with MTX for 48h before AMPKα phosphorylation and MnSOD 
and HO-1 induction occurred, and 72h for DAF induction. This delay is consistent with activation of 
AMPK by MTX occuring due to changes in intracellular AICAR, ZMP and AMP levels as a result of 
enzyme inhibition, as I speculate that these would take some time to accumulate following MTX 
conversion to polyglutamate metabolites and subsequent inhibition of AICAR transformylase and 
adenosine deaminase. Although no experiments have been reported here that investigate this, 
Cronstein et al have previously shown that treating HUVEC with MTX 100nM for 48h results in 
measurable increases in intracellular AICAR concentration[375], and Beckers et al show that treating 
cancer cell lines with MTX and AICAR together increases ZMP concentrations and enhances the 
AMPKα phosphorylation seen with AICAR treatment alone[314]. These studies support the 
hypothesis that MTX activates AMPK by increasing concentrations of AICAR, leading in turn to 
increased concentrations of the allosteric activators of AMPK, AMP and ZMP. 
The choice of MTX and FA concentration was very carefully made, based on the plasma 
concentrations achievable in patients treated with MTX for chronic inflammatory conditions[419, 
420, 423]. This improves the chance that the changes in AMPK signalling and gene expression seen 
are applicable to the clinical situation, but nevertheless this is a long way from full confidence that 
these results are pertinent to the actions of MTX when taken by patients.  
AMPK signalling is a significant mediator of vascular protection, and activation in EC by MTX, at 
concentrations achievable in clinical practice, is highly suggestive that this is a clinically relevant new 
mechanism of action for MTX. It could potentially explain why MTX improves CV mortality in RA. 
In EC, AMPK activation has been linked to eNOS activation and enhanced NO production, protection 
against apoptosis, beneficial effects on mitochondrial metabolism and on antioxidant gene expression; 
a small proportion of which have been investigated here[262, 276, 277, 292]. Further research would 
be needed to establish whether MTX is capable of replicating all effects previously ascribed to AMPK 
activation in EC. 
If MTX activates AMPK in EC, it is possible that it also does so in other cells. AMPK signalling and 
the metabolic changes it promotes have been linked to anti-inflammatory processes in cells of the 
immune system[266]. It is possible therefore, that AMPK activation underlies the anti-inflammatory 
effects of MTX treatment, alongside the changes in adenosine metabolism previously discussed. 
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5.3.3 Induction of MnSOD by MTX  
This chapter demonstrated that MTX treatment induced MnSOD expression in both HUVEC and 
HAEC, with significant increases in mRNA transcripts shown even at MTX concentrations of 0.1nM. 
MnSOD, the SOD isoform found within mitochondria, has previously been linked with vascular 
protection and with AMPK activation and thus its induction may be an important mechanism by 
which MTX preserves endothelial function[226, 310]. In addition, it is possible that MnSOD 
activation plays a part in the anti-inflammatory actions of MTX. Cuzzocrea et al showed that treating 
rats with collagen-induced arthritis with MTX and a SOD mimetic together allowed a 10-fold 
diminution in the dose of MTX needed to have a disease-altering effect[394]. In vitro, MTX has been 
shown to reduce superoxide production by neutrophils, which could involve increases in MnSOD 
expression or activity[429]. 
A further limitation is the degree to which experimental results obtained in HUVEC can be 
extrapolated to other vascular EC types. Although using multiple isolates of early passage HUVEC 
has the advantage of maintaining some population variability, clearly the umbilical vein is not a vessel 
ever likely to develop an atherosclerotic plaque. To overcome this, induction of MnSOD protein at 
least was reproduced in HAEC, and in Chapter 7 the results of MTX treatment on murine vascular 
MnSOD and AMPK expression are presented. 
5.3.4 Induction of other cytoprotective genes by MTX 
I also demonstrated in this chapter that MTX treatment increases expression of other known AMPK 
targets: HO-1, DAF, A1 and UCP-2. There are no pubmed-cited articles exploring a relationship 
between MTX and HO-1, DAF, A1 or UCP-2. However, all may be relevant to what we know of how 
MTX operates. Induction of HO-1 is often linked with anti-inflammatory effects in addition to being 
anti-oxidant, and so HO-1 expression could be an important facet of MTX mechanism of action[430]. 
Induction of the anti-apoptotic Bcl-2 family protein A1 by MTX seems counterintuitive given its 
actions in cancer chemotherapy, where MTX causes apoptosis of tumour cells. That EC behave 
differently demonstrates the differences between the responses of non-malignant primary cells and 
cancer cell lines, and potentially between the responses to different doses of MTX, with high doses 
being toxic but low doses protective. 
Induction of UCP-2, alongside  MnSOD by MTX, coupled to the previous knowledge that MTX alters 
ROS production in leucocytes, raises the possibility that it is altering mitochondrial metabolism and 
signalling. 
 Although MTX treatment led to induction of two anti-oxidant enzymes, MnSOD and HO-1, this was 
not part of a general induction of anti-oxidant mechanisms, as no induction at all was seen with Trx, 
Trx reductase or NQO-1. Speculatively, this suggests that MTX treatment does not affect activity of 
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the Nrf-2/ARE system, which is an important regulator of transcription of these enzymes. Although 
HO-1 expression can be regulated via Nrf-2, MnSOD is not[140]. 
5.3.5 MTX does not alter TNFα-stimulated cell adhesion molecule expression in vitro 
One surprising finding was the failure of MTX to inhibit the induction byTNFα of the cell adhesion 
molecules ICAM-1 and VCAM-1. Morever, expression of these was slightly increased by MTX itself. 
This is not consistent with previously published studies of the effects of MTX on cell adhesion 
molecule expression: soluble ICAM-1 and VCAM-1 are reduced in patients with early RA treated for 
6 months with MTX[431]; other researchers have found a reduction in ICAM-1 and VCAM-1 in 
HUVEC treated with MTX for similar time periods and concentrations (although quantified by 
western blot and immunofluorescence rather than flow cytometry)[382]; and AMPK activation has 
previously been demonstrated to reduce endothelial NFκB-mediated transcription, the major driver of 
ICAM-1 and VCAM-1 expression[335]. This may represent an artefact relating to the in vitro 
conditions, or may relate to the ability of MTX to alter ROS levels, as these can play a role in the 
TNFα-mediated induction of cell adhesion molecules. The effect of MTX on vascular ICAM-1 
expression was further explored in vivo and the results are shown in Chapter 7, underlining the 
importance of not relying solely on in vitro findings when drawing conclusions about how biological 
mechanisms really operate. 
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6 MECHANISM OF INDUCTION OF MNSOD AND HO-1 BY 
MTX 
6.1 Introduction 
This chapter presents data exploring how MTX treatment of EC leads to induction of the 
cytoprotective genes MnSOD and HO-1. It has already been demonstrated that prolonged low-dose 
MTX leads to AMPK phosphorylation and induction of cytoprotective genes including MnSOD and 
HO-1; therefore, whether AMPK activation is required for this induction by MTX was studied. CREB 
is a phosphorylation-dependent transcription factor known to be a direct target of AMPK and also 
known to bind the promoters and activate transcription of MnSOD and HO-1. Therefore, its role in 
their induction was also explored. Finally, the role of ROS was investigated. 
6.1.1 Prior studies of AMPK induction of MnSOD and HO-1 
AMPK activation has been shown previously to lead to HO-1 induction in some but not all settings in 
EC. While Liu et al found that AMPK activation with AICAR did induce HO-1 in HUVEC, HAEC 
and rat carotid arteries, leading to protection against apoptosis, Colombo and Moncada, who used 
hypoxia as an AMPK activator, did not observe HO-1 induction[217, 276]. MnSOD induction 
following AMPK activation with AICAR or metformin has also been demonstrated in EC[262, 310]. 
6.1.2 CREB 
CREB was the first phosphorylation-dependent transcription factor identified[432]. It is a member of 
a family that also includes CREM and ATF-1, the defining feature of which is that all members are 
capable of stimulating gene expression from promoters containing cAMP-responsive element (CRE) 
sites[433]. It is involved in the regulation of cell survival, proliferation, pro- and anti-inflammatory 
gene expression and the mediation of fasting and feeding signals on the expression of metabolic genes 
in insulin-sensitive tissues (ie liver, pancreas, adipose tissue and skeletal muscle)[199, 433]. A wide 
variety of signals can induce phosphorylation, but gene transcription is initiated in response in only a 
subset of genes to which it is capable of binding. How CREB discriminates between activating signals 
and directs transcription in a specific subset is not yet understood.  
The best characterised extra-cellular signals that activate CREB are the small peptide hormones such 
as glucagon that bind G-protein-coupled receptors, leading to increased activity of adenylyl cyclase 
and rising concentrations of the archetypal second messenger cAMP[434]. However, it can also 
respond to signals from growth factors and from adverse stimuli such as osmotic stress and UV 
light[433].The principal upstream activator of CREB is cAMP. Rising concentrations of cAMP 
activate PKA which is capable of direct phosphorylation of CREB at Ser133. AMPK, PKC and 
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CaMKII can also phosphorylate CREB on the same serine residue[434]. Dephosphorylation and thus 
de-activation is controlled by two serine/ threonine phosphatases: PP1 and PP2A[435]. 
The CREB molecule structure consists of an amino terminal transactivation domain and a carboxy 
terminal basic leucine zipper domain. The transactivation domain itself consists of two parts: a kinase-
inducible domain (KID) and a constitutive activation domain. The KID contains the Ser133 residue 
that is the phosphorylation target and thus mediates the ability of CREB to activate in response to 
cAMP and calcium through phosphorylation[434]. 
CREB binds to DNA at CRE sites - a palindromic sequence TGACGTCA - or half-sites - TGACG or 
CGTCA[434]. These sequences occur approximately 750 000 times in the human genome, but most 
are unoccupied due to a cysteine methylation within the site that disrupts CREB binding[436]. Around 
4000 genes are thought to have functional CRE sites: unmethylated sequences lying wthin 250 bp of 
the transcription start[436]. CREB is constitutively bound to a large proportion of these and can also 
be phosphorylated in a large number in response to cAMP, but only genes with TATA boxes are 
capable of responding to a cAMP signal with induction of transcription[437]. CREB is more active 
the closer it is to a TATA box. However, TATA boxes are not present in about two thirds of CREB-
occupied promoters, raising a question about how gene expression is regulated by CREB in these 
cases[433]. Of note, the SOD2 promoter does not contain a TATA box. 
Phosphorylation on Ser133 in CREB, although not enough alone to activate gene transcription, 
facilitates recruitment of co-activators, of which there are at least two sorts. Firstly, CREB-binding 
protein (CBP) and p300 are coactivators which bind to the KID[434, 438]. They can modify histone 
acetylation on promoters[439], and recruit RNA polymerase II[440], and their recruitment is more 
predictive of increased gene expression than the promoter being occupied by phCREB in response to 
cAMP[436]. 
The second group of CREB co-activators are CREB-regulated transcription coactivators (CRTCs). 
These bind to the leucine-zipper DNA-binding domain. They normally reside in the cytoplasm, and 
are activated themselves through de-phosphorylation. Following dephosphorylation they can 
translocate to the nucleus and interact with CREB[433, 441].  In addition to affecting gene expression, 
CRTC binding may mediate some effects of CREB on alternative splicing, and these effects have 
been demonstrated in TATA-less genes, which may provide a partial explanation for how CREB 
affects gene expression in this group[433].  It is through regulation of the binding of the coactivators 
that signal discrimination through CREB is achieved, explaining why some signals increase CREB 
phosphorylation without necessarily affecting gene expression. 
As above, there are around 4000 CREB target genes in the human genome. Impey et al explored the 
CREB regulon in rat phaeochromocytoma cells[442]. Consistent with the diverse functions ascribed 
to CREB activation, the targets include antioxidants such as MnSOD and UCP-2, anti-inflammatory 
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or pro-inflammatory genes such as DAF, IL-10 or IL-6, and some with roles in cell survival, such as 
Bcl-2 and A1[199, 434]. 
6.1.3 Prior studies of CREB and AMPK, and CREB and HO-1/ MnSOD interaction 
AMPK interacts with CREB in two ways. Firstly, it can directly phosphorylate CREB on Ser133, an 
action which promotes CREB activation[200]. However as explained above phosphorylation may be 
insufficient for initiation of gene transcription, which also requires binding of transcriptional co-
activators. Nevertheless, the interaction has been shown to result in functionally important changes in 
gene transcription in EC, mediating an increase in DAF expression in response to HUVEC treatment 
with atorvastatin and rapamycin[206]. 
Secondly, AMPK can interact with CRTCs by phosphorylating them, which would be predicted to 
cause deactivation and thus reduce CREB-mediated transcription. In C. elegans, the AMPK 
homologue has been shown to phosphorylate the CRTC homologue, thus preventing its translocation 
to the nucleus and association with CREB. This action promoted longevity[443]. An interaction 
between AMPK and CRTC has also been shown to inhibit hepatic gluconeogenesis in human 
cells[444]. Thus AMPK can in different cells and in different circumstances both activate and inhibit 
CREB-related transcription. 
CREB has previously been linked with HO-1 induction in HUVEC. Kronke et al showed that HO-1 
induction by oxidised phospholipids depends on CREB binding to the CRE site in the HO-1 
promoter[203]. Kim et al and Chung et al have demonstrated that MnSOD induction in response to 
12-O-tetradecanoylphorbol-13-acetate (TPA) in a lung cancer cell line requires CREB activation and 
binding to the MnSOD promoter[445, 446].  
6.1.4 Transcriptional regulation of human SOD2  
MnSOD is encoded by the SOD2 gene, which is located on chromosome 6q25 in the human genome 
(GenBANK accession S77127). The gene is composed of 5 exons and 4 introns, and in addition to the 
5' flanking promoter, an enhancer region in the 2nd intron around 2 kbp downstream of the 
transcription start site has been described (Figure 6.1)[221]. The SOD2 promoter contains 78% GC 
nucleotides and does not contain a TATA or CAAT box for initiation of gene transcription.  
Constitutive transcription appears to be regulated by the transcription factors specificity protein-1 
(SP-1) and activating protein-2 (AP-2), with SP-1 initiating and AP-2 inhibiting transcription[447, 
448]. SP-1-dependent promoters are characteristically rich in GC residues, as is the SOD2 promoter. 
There are multiple sites for binding SP-1 within the promoter, which is shown in Figure 6.1. 
SP-1 is also necessary for inducible expression of MnSOD, but additional transcription factors are 
also important for induction of MnSOD in response to various stimuli. CREB can bind to a CRE site 
located around 1200 bp upstream of the transcription start site, and this has been shown in response to 
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stimulation with TPA[445]. NFκB can bind both to the distal promoter and also to the intronic 
enhancer region, and mediates MnSOD induction in response to TNFα and IL-1[224]. FOXO3a, 
PPARγ and C/EBP have all also been shown to be involved in MnSOD induction in response to 
various stimuli across different cell types[221]. 
 
Figure 6.1 Transcription factor binding sites in the SOD2 promoter and intronic enhancer region. Adapted from 
Miao and St Clair[221]. 
6.1.5 The role of ROS in MnSOD and HO-1 induction 
Normal homeostatic principles of negative feedback would suggest that, given both MnSOD and HO-
1 are antioxidant enzymes, elevated levels of ROS might be an important stimulus to their induction, 
and this has previously been demonstrated in other settings[198, 449]. A further avenue explored in 
this chapter therefore was the role of ROS in the induction of MnSOD and HO-1 by MTX. 
Previous research has shown that MTX increases production of intracellular ROS, at least in 
macrophage and T cell lines, and does so at concentrations compatible with long term low dose 
treatment in patients[380]. Several studies have shown that high dose (up to 20 mg/kg) MTX causes 
oxidative damage in vivo[422, 450]. These studies have not consistently been linked however with 
changes in antioxidant enxyme activity or expression level. 
Recent research on ROS biology has shown that the location and extent of ROS production within a 
cell are important in terms of its significance and effects on cell function, with low levels of 
surperoxide and H2O2 production likely being important as a signalling mechanism[136]. MnSOD is 
located within the mitochondrial matrix where it catalyses the conversion of superoxide to H2O2. It is 
possible therefore that it is specifically mitochondrial ROS production that is most important for its 
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induction. HO-1 by contrast is predominantly located on microsome membranes within the 
endoplasmic reticulum, and so might respond more to changes in cytosolic ROS levels. 
6.1.6 Chapter Aims 
This experiments reported in this chapter sought first to establish the role of AMPK activation in the 
induction of MnSOD and HO-1 by MTX, using predominantly a loss-of-function approach. Secondly, 
the role of CREB in mediating transcription in response to AMPK activation was investigated in 3 
ways: phosphorylation in response to MTX; effect of CREB depletion by RNA interference on 
MnSOD and HO-1 induction; and ChIP to explore CREB binding to the SOD2 promoter. Finally, the 
role of ROS signalling was explored by establishing firstly whether MTX increases intracellular ROS 
levels, and secondly whether abolishing ROS production affects HO-1 and MnSOD expression in 
response to MTX. 
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6.2 Results 
6.2.1 Inhibition of AMPK reduces MTX-induced HO-1 and MnSOD mRNA 
expression but not protein 
In order to explore whether AMPK phosphorylation is necessary for the induction of MnSOD and 
HO-1 by MTX, Compound C, a pharmacological inhibitor of AMPK activation, was used. HUVEC 
were treated with 5µM Compound C 30 minutes before the addition of MTX 100nM for 48h. The 
addition of Compound C significantly abrogated the MnSOD and HO-1 mRNA response to MTX 
(Figure 6.2A and B). However, no effect was seen on MnSOD and HO-1 protein levels, and moreover 
Compound C alone caused an induction of MnSOD and HO-1 protein (Figure 6.2C-F). This has since 
been reported in the literature in relation to HO-1 expression[451]. Given that the study of HO-1 
induction by Compound C reported that this occurred independently of its effects on AMPK activity, 
it seemed likely that the explanation for the results of these experiments was that Compound C caused 
an acute induction of MnSOD and HO-1 mRNA, which then resolved. However, its inhibition of 
AMPK signalling remained, thus preventing the later induction of MnSOD and HO-1 mRNA by 
MTX. However, the induction of MnSOD and HO-1 protein by Compound C, being longer-lasting, 
obscured the response to MTX. Therefore, AMPK depletion by RNA interference was carried out to 
investigate its role in MTX induction of cytoprotective genes more specifically. 
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Figure 6.2 Pharmacological AMPK inhibition reduces induction by MTX of MnSOD and HO-1 mRNA, but not 
protein. HUVEC were treated with MTX 100nM and the AMPK inhibitor Compound C 5μM for 48h. A and B: 
change in MnSOD and HO-1 mRNA. C and D: representative western blots. E and F: densitometry of western 
blots. Data shown represent the results of at least 3 experiments. UT: vehicle control CC: compound C; MTX 
CC and MC: MTX and Compound C together. * = p<0.05. 
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6.2.2 Depletion of AMPKα1 or AMPKα2 inhibits induction of HO-1 and MnSOD by 
MTX 
Given that pharmacological inhibition of AMPK signalling was not successful in demonstrating 
whether AMPK activation is required for MnSOD induction by MTX, an alternative loss of function 
approach was adopted. AMPK signalling was inhibited using RNA interference. HUVEC were 
transfected with siRNA directed against the AMPK α1 or α2 subunit, which contain the 
phosphorylation site for activation, and then treated with MTX for 48h. The efficiency of knockdown 
was difficult to assess by western blot as the anti-AMPKα antibody used did not distinguish between 
the α1 and α2 isoforms. A reasonable degree of knock-down was however achieved when measured 
by qRTPCR (Figure 6.3C and D).  
Induction of MnSOD mRNA and protein by MTX was significantly attenuated by AMPKα2 siRNA 
and by α1 and α2 siRNA together (Figure 6.3A and 6.4A and B). Similar analysis of HO-1 expression 
showed that depletion of either the α1 or α2 subunit of AMPK inhibited mRNA and protein induction 
(Figure 6.3B and 6.4A and C), but depletion of both together resulted paradoxically in an increase in 
HO-1 mRNA expression levels, although not protein.  
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Figure 6.3 RNA interference with siRNA directed against the α1 and α2 subunits of AMPK prevents the 
induction of MnSOD and HO-1 mRNA by MTX. HUVEC were transfected with 40nM siRNA directed against 
the α1 and α2 subunits of AMPK or scramble control sequences, then treated with MTX 100nM for 48h. A: 
MnSOD mRNA levels relative to those of cells treated with control siRNA; B: HO-1 mRNA levels; C: 
AMPKα1 mRNA levels; D: AMPKα2 mRNA levels. C: control siRNA; CM: control siRNA and MTX 100nM; 
α1: AMPKα1 siRNA; α1M: AMPKα1 siRNA and MTX 100nM; α2: AMPKα2 siRNA; α2M: AMPKα2 siRNA 
and MTX 100nM; α12: AMPKα1 and AMPK α2 siRNA; α12M: AMPKα1 and AMPK α2 siRNA and MTX 
100nM. Data shown are the results of 3 experiments. * = p<0.05; ** = p<0.01; *** = p<0.001. 
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Figure 6.4 Inhibition of AMPK signalling with siRNA targetting the α1 and α2 subunits reduces induction of 
MnSOD and HO-1 protein by MTX. HUVEC were transfected with control, AMPKα1, AMPKα2 or AMPKα1 
and α2 siRNA together then treated with MTX 100nM for 48h. A: representative Western blot; B: densitometry 
of MnSOD expression; C: densitometry of HO-1 expression; D: densitometry of AMPKα expression to show 
knockdown efficiency. C: control siRNA; CM: control siRNA and MTX 100nM; α1: α1 siRNA; α1M: α1 
siRNA and MTX 100nM; α2: α2 siRNA; α2M: α2 siRNA and MTX 100nM; α12: α1 and α2 siRNA ; α12M: α1 
and α2 siRNA and MTX 100nM. Data shown are the results of 6 experiments.  * = p<0.05; ** = p<0.01; *** = 
p<0.001. 
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6.2.3 AMPK activation with AICAR induces MnSOD expression 
To confirm the role of AMPK in expression of cytoprotective genes, HUVEC were treated with the 
AMPK activator AICAR. AICAR is converted to the purine nucleotide ZMP intracellularly, which is 
capable of binding to the regulatory γ subunit and allosterically activating AMPK in the same fashion 
as AMP. An induction of MnSOD protein was observed with 1mM AICAR after 16-24h (Figure 6.5), 
as has previously been published[262], lending further support to the hypothesis that MTX activation 
of MnSOD is dependent on AMPK activation. 
 
 
 
Figure 6.5 AMPK activation using AICAR leads to induction of MnSOD protein. HUVEC were treated with 
AICAR 1mM over the course of 48h. A: western blot image of MnSOD induction. B: Densitometry results. 
Data shown is the result of a single experiment. OD: optical density. 
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6.2.4 MTX treatment causes phosphorylation of CREB in EC 
 
The transcription factor CREB is known to be a direct target of AMPK activation[200], and has also 
been shown to bind to the SOD2 promoter and activate transcription[276, 445]. Moreover, its activity 
is positively associated with vascular health[201]. It was therefore considered a good candidate to 
study as a potential intermediary in the induction of MnSOD by AMPK activation with MTX 
stimulation. CREB is activated by phosphorylation at Ser133. By western blot, a significant induction 
of phosphorylated CREB
Ser133
 was seen when HUVEC were treated for 48h with MTX 10nM and 
100nM (Figure 6.6). 
 
 
 
Figure 6.6 MTX causes CREB phosphorylation. HUVEC were treated with MTX or DMSO vehicle control at 
increasing concentrations for 48h. A: representative western blot; B: corresponding densitometry. Data shown 
are the results of >3 experiments. UT = vehicle control; *=p<0.05. 
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6.2.5 Disruption of AMPK with siRNA inhibits CREB phosphorylation by MTX 
 
In order to establish whether CREB was activated by AMPK in HUVEC treated with MTX,  CREB 
phosphorylation was examined in HUVEC treated with AMPKα1 and α2 siRNA.  CREBSer133 
phosphorylation was abrogated by AMPKα1 or α2 siRNA, suggesting a linear signalling pathway 
(Figure 6.7).  This is consistent with the published literature suggesting that CREB is a direct target of 
AMPK activation[200]. 
 
 
 
 
Figure 6.7 Disruption of AMPK signalling with siRNA targetting the α1 and α2 subunits inhibits CREB 
phosphorylation by MTX. HUVEC were transfected with control, AMPKα1, AMPKα2 or AMPKα1 and α2 
siRNA together then treated with MTX 100nM for 48h. A: representative western blot; B: densitometry of 
CREB expression. Knockdown efficiency is shown in Figure 5.2. C: control siRNA; CM: control siRNA and 
MTX 100nM; α1: α1 siRNA; α1M: α1 siRNA and MTX 100nM; α2: α2 siRNA; α2M: α2 siRNA and MTX 
100nM; α12: α1 and α2 siRNA ; α12M: α1 and α2 siRNA and MTX 100nM. Data shown are the results of 6 
experiments.  * = p<0.05; ** = p<0.01. 
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6.2.6 CREB depletion reduces MnSOD and HO-1 induction by MTX 
Next, in order to explore whether CREB is required for the induction of MnSOD and HO-1 by MTX, 
CREB was inhibited using RNA interference. A pool of 5 siRNA sequences directed against CREB 
was transfected into HUVEC for 16h before treatment with MTX 100nM for 48h. This resulted in a 
reduction of CREB protein by over 80% (Figure 6.8C). MnSOD and HO-1 mRNA levels were 
significantly reduced in HUVEC treated with CREB siRNA and MTX, compared with those treated 
with MTX after transfection with scramble control siRNA (Figure 6.8A and B). This suggests that 
CREB protein is required for the induction by MTX of MnSOD and HO-1, and that this forms an 
important intermediary in AMPK- mediated cytoprotection. 
 
Figure 6.8 Inhibition of CREB prevents induction of MnSOD and HO-1 mRNA by MTX. CREB was inhibited 
with pooled CREB siRNA, before stimulation with MTX 100nM for 48h. A and B: results of qRT-PCR for 
MnSOD and HO-1 mRNA. C: Western blot demonstrating efficiency of CREB knockdown. C: control siRNA; 
M: MTX 100nM; CREB: CREB siRNA; tCREB: anti-CREB antibody. A and B represent the results of 6 
experiments; C shows the results of 1 experiment. *=p<0.05; ***=p<0.001. 
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6.2.7 MTX treatment causes CREB binding to the SOD2 promoter 
The final step was to look for enhanced binding of CREB to the SOD2 promoter in HUVEC treated 
with MTX. This was done using chromatin immunoprecipitation. Analysis of the SOD2 promoter 
(GenBank accession number AF059197) using MatInspector software[392] identified 2 strong 
potential CREB binding sites (Figure 6.9). Direct demonstration of CREB binding to the SOD2 
promoter has previously been shown for the more proximal half site[445]. A significant increase in 
the binding of CREB to the MnSOD promoter following MTX treatment was found using primers 
designed to capture this site (Figure 6.10), although a trend towards enhanced binding was also seen 
with primers designed around the more distal site. This is understandable, as these sites are within 300 
kbp of each other and therefore may have been pulled down with each other given that average 
chromatin shearing was 500bp segments. No significant enhanced binding was detected with primers 
designed at a downstream site 2kbp further away (data not shown). 
 
 
Figure 6.9 SOD2 promoter sequence. Putative CREB binding sites are marked in red, and the transcription start 
site in blue. 
 156 
 
 
Figure 6.10 MTX causes an increase in CREB-1 binding to the SOD2 promoter. Pooled HUVEC were 
stimulated with MTX 100nM for 48h before chromatin immunoprecipitation for CREB-1. Data shown are the 
fold change in transcript level detected by qPCR, normalised to input DNA and IgG control for each condition. 
Data represent the results of 5 experiments. UT = vehicle control;* = p<0.05. 
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6.2.8 Role of ROS in MnSOD and HO-1 induction by MTX 
There is evidence suggesting that MTX treatment promotes ROS production and that high dose MTX 
causes oxidant damage to tissues. Indeed, production of ROS has been proposed as a major 
mechanism of action to explain MTX's anti-inflammatory efficacy[380]. Conversely, other work 
suggests that MTX reduces ROS with one study demonstrating a reduction in IL-6-induced ROS in 
synovial tissue treated with MTX[381]. I therefore sought to explore whether MTX alters ROS 
production in HUVEC, whether its effects are predominantly on mitochondrial ROS generation or 
other sources, and whether ROS production is an important intermediate step in AMPK activation or 
induction of anti-oxidant genes by MTX. 
First, I looked for evidence of ROS production in HUVEC  treated with MTX 100nM for 48h. 
HUVEC were loaded with the ROS reporter dye CM-H2DCFDA and fluorescence measured by flow 
cytometry. A 50% increase in ROS generation was observed in HUVEC treated with MTX, although 
this was highly variable. This compares with a doubling in ROS levels in cells treated with 10µM 
H2O2 for 1h (Figure 6.11A and B). 
The next step was to study whether ROS production was important for the induction of the anti-
oxidant genes HO-1 and MnSOD. HUVEC were pre-treated with the ROS scavenger NAC for 1h 
prior to MTX 100nM for 48h. NAC is a derivative of cysteine with an acetyl group added to the 
nitrogen atom. It is a precursor to glutathione, thus treating cells with NAC increases the pool of 
glutathione available. The use of NAC inhibited HO-1mRNA induction but not MnSOD (Figure 
6.11C and E). 
Finally, I explored the specific role of mitochondrial ROS, by pre-treating HUVEC with the specific 
mitochondrial ROS scavenger mitoTEMPO for 30 minutes before the addition of MTX. This did not 
alter MnSOD or HO-1 mRNA induction (Figure 6.11D and F). However, this may be a technical 
failure rather than a true result: the experiment lacked a suitable gene response to demonstrate an 
effect of mitochondrial ROS scavenging. 
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Figure 6.11 MTX increases ROS production, but abolishing ROS affects induction of HO-1 mRNA only and not 
MnSOD. A and B: HUVEC stimulated with MTX or H2O2 were loaded with CM-H2DCFDA and fluorescence 
measured by FACS. Yellow: unstained HUVEC; pale blue: unstained HUVEC treated with MTX; dark blue: 
untreated HUVEC loaded with CM-H2DCFDA; red: HUVEC treated with H2O2 10µM and DCF-DA; green: 
HUVEC treated with MTX 100nM and CM-H2DCFDA. C and D: HO-1 mRNA was measured after pre-
treatment with NAC 10mM or Mitotempo 10µM and MTX 100nM. E and F: MnSOD mRNA was measured 
after pre-treatment with NAC 10mM or Mitotempo 10µM and MTX 100nM. UT = vehicle control; M: MTX 
100nM; mito: mitoTEMPO 10µM; * = p<0.05; *** = p>0.001. 
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6.3 Discussion 
In this chapter I have presented data exploring the mechanisms by which MTX induces cytoprotective 
gene expression in EC. The induction of MnSOD and HO-1 is dependent on AMPK activation; shown 
by inhibition of AMPK both pharmacologically and using RNA interference. The involvement of the 
transcription factor CREB has also been established: MTX treatment results in CREB 
phosphorylation, which is abolished when AMPK is inhibited, thus demonstrating that CREB 
activation lies downstream of AMPK. Inhibition of CREB using siRNA prevented the MTX-mediated 
induction of MnSOD and HO-1, and ChIP was used to show direct binding of CREB to the MnSOD 
promoter. Finally, the role of ROS was studied. MTX treatment of HUVEC resulted in a modest 
increase in intracellular ROS, detected using the reporter dye CM-H2DCFDA. Inhibition of 
generalised intracellular ROS production using NAC prevented the induction of HO-1 but not 
MnSOD mRNA. However, neither was altered by the addition of the specific mitochondrial ROS 
scavenger mitoTEMPO. 
6.3.1 AMPK is required for MTX-mediated induction of MnSOD and HO-1 
The initial experiments presented in this chapter demonstrated that AMPK is required in order for 
MTX treatment of HUVEC to induce MnSOD and HO-1 expression. Two loss-of-function techniques 
were used: firstly AMPK was inhibited pharmcologically using Compound C, and secondly RNA 
interference was performed to deplete selectively AMPKα1, AMPKα2, or both together. 
Pharmacological inhibition with Compound C did reduce the MTX-mediated induction of MnSOD 
and HO-1 mRNA, but not of protein. Indeed, treatment with Compound C alone increased expression 
of HO-1 and MnSOD protein. This has subsequently been reported for HO-1, as an effect independent 
of its AMPK-inhibiting properties[451].  It is therefore possible that Compound C stimulated an 
induction of HO-1 and MnSOD. mRNA transcription perhaps peaked and fell while inhibition of 
AMPK remained, thus allowing the delayed, MTX-mediated induction of MnSOD and HO-1 mRNA 
to be seen. However, protein expression induced by Compound C remained present at 48h, thus 
obscuring any effects of MTX mediated via AMPK. 
Inhibition of AMPK signalling using RNA interference carried several advantages over 
pharmacological inhibtion. Firstly, the effects of depleting either the α1 or α2 isoform, or both 
together, could be explored. Secondly, the targetting of one specific mRNA transcript means that this 
technique is much more specific.  
siRNA depletion of AMPKα1, AMPKα2 or both together prevented the MTX-mediated induction of 
MnSOD and HO-1 mRNA and protein, with a couple of caveats. Firstly, the effects on MnSOD 
reached statistical significance when the AMPKα2 isoform or both together were depleted, although 
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there was only a trend towards reduction in MnSOD induction with siRNA directed against AMPKα1. 
This may be due to technical limitations; it is possible that the other isoform compensates for the loss 
of one when either is depleted. Alternatively, it may reflect the mechanism by which MTX is likely to 
activate AMPK. Salt et al have shown that AMPKα2 is more sensitive to AMP than AMPKα1[264], 
thus speculatively it may be that AMPKα2 is more responsive to MTX's effects on AMP and ZMP 
levels. 
Previous studies have shown that the AMPKα1 isoform is more abundant in EC and thus have 
focused on its functional effects[262, 276]. More recently, however, evidence has emerged suggesting 
that important vasculoprotective effects are also mediated through AMPKα2[331]. Our study 
suggested that the effects of MTX on MnSOD induction were predominantly mediated through 
AMPKα2, although depletion of either α subunit attenuated the responses. 
Secondly, although HO-1 induction by MTX was significantly inhibited when either AMPKα1 or 
AMPKα2 was depleted, when both were depleted there was a paradoxical rise in HO-1 mRNA and 
protein, and also in CREB phosphorylation. I think this is likely to represent a stress response 
following a profound loss of AMPKα: while the other isoform may be able to compensate partially for 
the loss of either α1 or α2, loss of both may alter other intracellular signalling more profoundly and 
may have consequences for cellular metabolism that loss of a single isoform does not. It suggests that 
AMPK is not necessary and sufficient for HO-1 induction or for CREB phosphorylation, even if it is 
capable of it, but MnSOD induction is not possible without AMPK functioning. This is not surprising 
given the large number of other mechanisms of HO-1 induction and of CREB phosphorylation 
previously identified. However, it is difficult to draw firm conclusions given that the siRNA 
experiments were performed with a single sequence and so could represent an off-target effect. 
Several other technical limitations to these experiments should be noted. Firstly RNA interference 
was performed using only a single siRNA sequence for each isoform. It is therefore theoretically 
possible that the effects observed relate to an off-target effect of that sequence. However, the finding 
that depletion of either isoform gave broadly the same result, and that pharmacological inhibition of 
AMPK produced similar findings in mRNA results, suggests that these results are valid. Secondly, the 
quantification of the AMPKα isoform knockdown by western blot is not very impressive. This is 
probably because the antibody used was not specific for α1 or α2 isoform. Finally, the degree of 
MnSOD and HO-1 induction seen with MTX treatment in cells transfected with scrambled control 
siRNA was much reduced compared to that seen in untransfected cells. This may reflect the process 
of transfection itself, which is presumably stressful to cells, and so led to an induction in MnSOD and 
HO-1 (data not shown), and thus there was limited scope to show an additional induction beyond this. 
In view of the limitations described above, a further approach was taken to establish the role of 
AMPK in induction of MnSOD. HUVEC were treated with the AMPK activator AICAR and this led 
 161 
 
to a two fold induction in MnSOD protein expression, thus providing additional supportive evidence 
that AMPK activation leads to MnSOD expression. This data confirms previously reported 
findings[262, 310]. Therefore, it seems reasonable to conclude that MTX activation of AMPK leads to 
the induction of the cytoprotective genes MnSOD and HO-1. 
6.3.2 CREB is activated by MTX via AMPK and promotes MnSOD expression 
The second set of experiments reported in this chapter explored the role of the transcription factor 
CREB in the MTX-AMPK-mediated induction of MnSOD and HO-1. A variety of techniques was 
employed to do this. Firstly, it was established that CREB
Ser133
 phosphorylation is increased in 
HUVEC treated with MTX. Secondly, it was shown that AMPKα1 or α2 depletion prevented this, 
suggesting that CREB lies downstream of AMPK. Thirdly, depletion of CREB by RNA interference 
completely abrogated the induction of MnSOD and HO-1 mRNA by MTX. Lastly, ChIP 
demonstrated enrichment of CREB on the SOD2 promoter in HUVEC treated with MTX. 
CREB
Ser133
 phosphorylation was first studied in HUVEC treated with increasing concentrations of 
MTX. Although a statistically significant increase in phosphorylation was seen at 10nM and 100nM 
MTX, there was no dose-response relationship, and in fact even very low concentrations of MTX 
(0.1nM) may have had some effect. This makes the observation more likely to be relevant to patients, 
if even very low concentrations of MTX exert biological effects observable in vitro. 
It was also demonstrated that CREB
Ser133
 phosphorylation is abrogated by depletion of AMPKα1 or α2 
siRNA. This was expected, given previous reports that CREB is a direct phosphorylation target of 
AMPK[200]. Similar to the effects on HO-1, however, depletion of both AMPKα isoforms together 
resulted in a paradoxical increase in phosphorylation. This may also represent a stress response; 
certainly a number of other kinases are also capable of CREB phosphorylation, particularly 
PKA[434]. 
Finally, the role of CREB in the MTX-mediated induction of MnSOD and HO-1 was explored. 
Depletion of CREB by RNA interference abolished the induction of MnSOD and HO-1 mRNA, and 
ChIP demonstrated increased binding of CREB to the SOD2 promoter in MTX-treated cells. Due to 
time limitations, ChIP was not performed to look for binding of CREB to the HO-1 promoter. A 
previous study of MnSOD induction in cancer cells by TPA demonstrated that CREB binding to the 
MnSOD promoter enhanced MnSOD transcription[445]. A reporter assay employing a series of 
reductions in promoter size established that the responsible site was the CRE half site identified in my 
experiments by MATinspector, and it was with primers designed to pick up this site that I detected an 
increase in CREB binding to the MnSOD promoter in the ChIP assay. 
However, neither CREB occupancy of the MnSOD promoter nor increased CREB phosphorylation 
with MTX treatment means that activation of transcription by CREB in response to MTX has been 
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established conclusively. Firstly CREB phosphorylation has previously been shown not to be 
sufficient to drive transcription; recruitment of co-activators is also required[433]. Secondly, a large 
number of genes have CREB occupying their promoters without it necessarily promoting gene 
expression[434]. Ideally, a luciferase reporter assay should also have been performed to investigate 
directly whether MTX treatment leads to enhancement of MnSOD transcription via CREB, and also 
perhaps co-immunoprecipitation to look for enhanced binding of CREB to its coactivators in the 
presence of MTX. Nevertheless, the complete abolition of MnSOD or HO-1 induction with CREB 
depletion does suggest its presence is necessary for this to occur. 
Although I only studied the role of CREB in the induction of MnSOD and HO-1 expression, it is also 
likely to be important for the expression of a number of the other genes induced by MTX in Chapter 
5. UCP-2 and Bcl-2 also contain CRE sites in their promoters, while Hamdulay et al showed using a 
luciferase reporter assay that CREB promotes DAF transcription in response to atorvastatin and 
rapamycin[206, 434]. A1 induction via CREB has been studied in the context of microbe-induced 
macrophage apoptosis. Park et al did not observe an interaction, although Hsu et al did following 
activation of the same precursor signalling pathways[452, 453]. 
I have demonstrated that AMPK inhibition prevents CREB phosphorylation, and thus conclude that 
this indicates a pathway whereby MTX activates AMPK, which in turn activates CREB and alters 
gene expression. However, CREB activation may also occur via adenosine. Adenosine exerts anti-
inflammatory effects by binding to A2A receptors, G-protein-coupled receptors which signal via 
cAMP[372]. Given that CREB activation in most circumstances occurs through changes in cAMP 
levels resulting in PKA activation, this is definitely possible. However, the genes activated by CREB 
in response to changes in cAMP all contain TATA boxes in their promoters, and CRE sites within 
250bp of that TATA box[436, 437]. This is not the case with SOD2, where the promoter CRE sites 
are 1200 - 1500bp distal to the transcription start site, and there is no TATA box[221]. Therefore, 
SOD2 would seem not to have the characteristics of a gene capable of responding via CREB to 
changes in cAMP, suggesting that changes in adenosine might not be so important for its induction by 
MTX. 
 Given that CREB-mediated activation of gene transcription is thought only to occur via cAMP in 
genes with TATA boxes, and then only when bound to CRE sites within 250bp of a TATA box, a 
question remains as to how CREB activates transcription in genes where it binds to more distal 
promoter regions, and in genes with no TATA box such as SOD2. It is known that it is still capable of 
activating transcription in these circumstances, as was revealed by MnSOD induction in response to 
TPA[445]. The SOD2 gene forms loops, bringing together the promoter and the intronic enhancer to 
allow NFκB binding to the intronic enhancer to activate transcription[454]. Speculatively, a similar 
loop could also form between proximal and distal regions of the promoter itself to allow distal CREB 
binding to activate transcription. 
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6.3.3 The contribution of ROS to MnSOD and HO-1 induction 
The final section of experiments presented in this chapter concerned the role of ROS in the induction 
by MTX of MnSOD and HO-1. Firstly, it was established that treating HUVEC with low 
concentrations of MTX caused a small rise in intracellular ROS levels, detected by the non-specific 
ROS reporter dye CM-H2DCFDA. Secondly, treating HUVEC with NAC to abolish ROS production 
completely prevented HO-1 induction by MTX, but did not alter MnSOD induction. Finally, treating 
HUVEC with mitoTEMPO, a mitochondrial-specific ROS scavenger, did not alter either MnSOD or 
HO-1 induction. 
It was already known that treating macrophages and T-cells with doses of MTX similar to those used 
in these experiments results in increased ROS production and promotes apoptosis of activated 
cells[380]. I showed that, although a modest increase in ROS does occur in HUVEC treated with 
MTX, as demonstrated in Chapter 5, MTX treatment of relatively quiescent cells in culture does not 
increase apoptosis. MTX may do this through an effect on glutathione metabolism: high doses of 
MTX, at least, inhibit glutathione reductase and may thus reduce the intracellular pool of reduced 
glutathione[416]. It remains unclear whether the increase in ROS is an unwanted effect of MTX or 
whether it is a useful signalling phenomenon that is essential to the changes in gene expression and 
cell metabolism promoted by it. 
Treating HUVEC with a high concentration of NAC should have prevented MTX exerting any effect 
on the pool of reduced glutathione available for redox reactions, and so the abolition of HO-1 
induction by the addition of NAC was unsurprising, given that HO-1 is a gene highly responsive to 
changes in ROS. It contains ARE sites in its promoter and its transcription is closely regulated by the 
ROS-responsive transcription factor Nrf-2[140, 430].  
What was surprising to me was that MnSOD induction was not altered; indeed NAC alone led to a 
small induction. This may reflect the subcellular localisation of MnSOD in the mitochondrial matrix: 
it is therefore not involved in the regulation of redox processes in the cytosol and thus its expression 
may not change in response to changes in the cytosolic concentration of reduced glutathione. Instead 
MnSOD is likely to be important for regulating ROS levels within the mitochondria, and given that 
EC do not generally rely on mitochondria for energy production, changes in endothelial mitochondrial 
ROS are likely to have a signalling function rather than just be a by-product of necessary 
respiration[120, 455]. To explore this HUVEC were treated with the mitochondrial-specific ROS 
scavenger mitoTEMPO, but this also did not change the induction of MnSOD by MTX. Although this 
may exclude a role for ROS in MnSOD induction, a technical failure due to too low a concentration of 
mitoTEMPO cannot be excluded in the absence of a positive control. Of note, my colleague Fahad 
Alrashed has since shown that mitoTEMPO 20µM inhibits celecoxib-mediated HO-1 induction 
(personal communication).  
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7 MTX TREATMENT OF WBF1 MURINE VASCULOPATHY 
7.1 Introduction 
The work presented in this thesis thus far has demonstrated that laminar shear stress and VEGF, 
known endogenous endothelial protective factors, can activate AMPK signalling in HUVEC, as can 
MTX, a common and effective treatment for RA. In addition, MTX treatment of HUVEC leads to 
induction of cytoprotective genes such as MnSOD, and this is dependent on both AMPK and on 
CREB activation. This may be an important contributor to the ability of MTX to reduce CV mortality.  
In order to explore this hypothesis further, a murine model of inflammatory vascular disease was bred, 
characterised and then treated with low-dose MTX analogous to that used to treat chronic 
inflammatory disease. (NZWxBXSB)F1 (WBF1) male mice develop a lupus-like illness[456], 
characterised by glomerulonephritis, anti-DNA and anti-phospholipid antibodies[457] and 
thrombocytopenia[458]. A high proportion also develop a vasculopathy affecting the gastro-intestinal 
tract[459] and muscular intramyocardial arteries[395], which can progress to arterial occlusion 
resulting in myocardial and bowel infarction. These features suggest that these mice represent a good 
model of a chronic immune-mediated inflammatory vascular disease in which to test whether MTX 
can improve outcome. 
7.1.1 Lupus-prone mice 
Several murine strains exist that spontaneously develop an illness analogous to SLE, characterised by 
a fatal immune complex-mediated glomerulonephritis and auto-antibody production. The three best 
known are the MRL/lpr, the (NZBxNZW)F1 and the BXSB strains. They each arose in different 
manners, and have phenotypic and genetic features in common and ones particular to each 
strain[460]. They have been closely studied for the last 40 years for the insights they yield into the 
genetic background and pathogenesis of SLE. 
The disease in (NZBxNZW)F1 mice is more severe in female animals and its principal features are 
glomerulonephritis and anti-DNA antibodies[460].  
The MRL/lpr strain was developed from a mixture of other strains where a recessive mutation in the 
Fas gene, responsible for activation of the extrinsic apoptosis pathway, arose spontaneously. In 
addition to glomerulonephritis and anti-DNA antibodies, these animals develop a florid necrotising 
vasculitis, massive lymphadenopathy and arthritis[460]. 
The BXSB strain is a recombinant inbred line derived from an original cross between a C57BL/6 
female and SB/Le male[461]. These animals also suffer glomerulonephritis and develop anti-DNA 
antibodies, but also vasculitis, at a reduced frequency compared to MRL/lpr mice, splenomegaly, 
hypergammaglobulinaemia and hypocomplementaemia[462]. Male animals develop earlier and more 
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severe disease than females, with a mean survival of 5 months, compared to 15 months in females. 
This is due to an acceleration factor on the Y chromosome called the Y-linked autoimmine 
acceleration (Yaa) locus[463].  This region exacerbates the severity of autoimmune disease when 
crossed into other models, but is not enough to cause disease by itself as it is not associated with the 
onset of disease if crossed onto a non-autoimmune background[464]. 
7.1.2 WBF1 genetic background 
The WBF1 model of lupus was generated by crossing the NZW female with BXSB male and was first 
described in 1981[456]. Like its parent strains these animals develop a lupus-like illness, with 
accelerated disease in male animals, although they have also been used variously as a model of acute 
MI, immune thrombocytopenic purpura (ITP), and anti-phospholipid antibody syndrome (APS)[458, 
465, 466].  
The reason disease is accelerated in this model, and in male BXSB animals, is because of the presence 
of the Yaa locus on the Y chromosome. Two papers published in 2006 established that this region is a 
translocation from the X chromosome containing at least 13 genes, of which the one most likely to be 
the accelerating factor is toll-like receptor 7 (TLR7), although TLR8 is also present[467, 468]. Male 
animals with a Yaa locus thus have a double copy of TLR7 and TLR8 and transcription of these genes 
is increased roughly two-fold.  
TLR7 recognises single stranded RNA and is expressed by B cells, dendritic cells and macrophages. 
A major functional result of its ligation and activation is production of type 1 interferons[469]. Its 
importance in driving disease in WBF1 animals is shown by a study in which female WBF1 mice 
were treated with IFNα, which markedly accelerated the onset of proteinuria and death[470]. As it is 
known that increased circulating IFNα is an important driver of SLE activity in patients and may be 
important in the development of CVD in SLE[54], this aspect of the model makes it particularly good 
for studying ways to reduce CVD in chronic inflammation in patients.  
Other features of the genetic background of WBF1 animals are less well characterised, although it 
clearly shares features of its parents' backgrounds. In both NZW and BXSB animals, the major 
histocompatibility complex (MHC) is a major source of genetic contribution to disease, and there are 
further contributions from multiple areas on chromosome 1 including the telomeric region, and also 
chromosomes 3, 4 and 10[460, 471]. 
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7.1.3 WBF1 clinical features and course of disease 
WBF1 male mice develop an inexorably progressive lupus-like disease very similar to that seen in 
BXSB males, with immune-complex mediated glomerulonephritis, hypocomplementaemia and 
autoantibodies. The first features of disease generally develop around 12 weeks and then progress 
rapidly, with 50% mortality at 4.5 months and 90% at 8 months. Females in contrast have 50% 
mortality at 11 months[456]. 
The most striking feature of this model when originally described was the high incidence of a 
degenerative coronary vascular disease associated with myocardial infarction, with approximately 
80% (31/37) of animals affected at the time of death in the original description[456]. Other studies 
have variously reported rates of vasculopathy of 85% with accompanying MI rates of 35% at 16 
weeks[395], 22% MI at 16 weeks[472] and 91% vs 56% MI in animals who were alive or dead at 51 
weeks[473]. 
The coronary vasculopathy exhibited by male WBF1 mice is not unique to the strain. Female 
littermates also develop it, as do BXSB males, (NZB x NXW)F1 and MRL/l animals, albeit at a lower 
frequency (approximately 20 - 30%)[456, 474].  It is a disease that affects the small muscular 
intramyocardial arteries, leading to multiple small areas of infarcted tissue, predominantly in the 
ventricles. It is characterised by a sparse adventitial inflammatory cell infiltrate, rather than a 
vasculitis. Immunofluorescence and electron microscopy studies indicate the presence of immune 
complexes and thrombosis, and others have demonstrated the deposition of PAS-positive 
immunoglobulin and complement within the arterial wall[395, 456, 474].  
The vasculopathy has also been demonstrated in the blood vessels supplying the GI tract in WBF1 
mice. Mizutani et al showed that 61% of WBF1 males develop lesions in the arterioles of the 
duodenum, jejunum and ileum, consisting of subintimal fibrinoid degeneration[459]. 
100% of WBF1 animals develop a progressive glomerulonephritis, resulting in proteinuria and renal 
failure as shown by rising serum creatinine. This feature is identical to that seen in parent BXSBs. 
Histologically, deposits of IgG and gp70 are seen in affected glomeruli[456]. 
Autoantibody production in the WBF1 mouse is generally of chronic low levels rather than the very 
high titres seen in other strains such as the MRL/lpr. Anti-single stranded DNA antibodies and anti-
thymocyte antibodies were noted in the original description, and anti-gp70 antibodies have been 
linked most closely with the onset of coronary vascular disease and glomerulonephritis[395, 456]. 
They also produce anti-cardiolipin antibodies[457], which may be important in the pathogenesis of 
the vascular disease[459, 475]. 
Haematological abnormalities in WBF1 animals include splenomegaly and hepatic sinusoidal 
lympocytosis, which affected 70% of male animals in the original description of the model[456]. 
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Later in the course of disease, thrombocytopenia becomes apparent, associated with anti-platelet 
antibodies and increased numbers of megakaryocytes in the bone marrow. This has led to its use in 
some studies as a model for ITP[458]. 
7.1.4 Effect of treatment of WBF1 disease course 
WBF1 mice have been studied in several contexts: as a model of vascular disease in SLE, as a model 
of ITP or APS, or as a model of microvascular ischaemic heart disease. Studies of various treatment 
modalities have shed light not only on what might help in the equivalent human illnesses but also on 
the disease course of WBF1 animals. 
Immunosuppression, unsurprisingly, has been studied in WBF1 animals. Bone marrow 
transplantation, anti-CD4 monoclonal antibodies, cyclophosphamide or treatment with CTLA4-Ig 
(which blocks T-cell co-stimulation via CD28) all prevented the onset of disease if given at around 8- 
10 weeks of age, before the appearance of auto-antibodies[459, 476-480]. CTLA4-Ig had no effect on 
disease progression if started later at around 12 weeks although bone marrow transplantation did, 
suggesting that this illness cannot be reversed once it has begun, without total removal of the immune 
system. Treatments aimed specifically at preventing B-cell activation such as anti-BAFF (belimumab) 
and TACI-Ig (atacicept) also reduce rates of MI and nephritis and improve survival[481].  
One previous study has treated WBF1 mice with MTX. Mihara et al gave MTX 1mg/kg orally three 
times weekly to 7 male WBF1 animals, from 8 to 34 weeks. They did not observe any difference in 
rates of proteinuria, anti-DNA antibody titres or survival between treated and control animals[482]. 
However, aside from the very small numbers used, they may have masked an effect by using a high 
dose of MTX that may have accumulated as the animals' renal function declined, causing toxicity. 
Their study end-point was also very long: previous reports suggest a 90% mortality at 8 months so a 
modest effect of MTX may have been lost by this point. 
WBF1 mice have also been treated with cardiac drugs. ACE inhibition, nifedipine and bretylium 
improved mortality and lowered blood pressure while nifedipine and bretylium also reduced the rate 
of MI [465, 480, 483]. Given that thrombosis is a key histological feature that leads to tissue 
infarction, anti-coagulation has also been tried from the age of 2 months. Aspirin resulted in a small 
reduction in coronary vasculopathy and MI and delayed the onset of glomerulonephritis, but heparin 
and ticlopidine had no effect[480]. 
Finally, calorie restriction has been tested as a treatment, and found to be very effective. Mizutani et 
al compared a normal diet with a 32% reduction in available calories (from an average of 10 to 7 
calories/ mouse/ day) without affecting vitamin and mineral intake, started at 6, 14, 17 or 22 weeks. 
Calorie restriction starting at 6 weeks resulted in 90% survival at 40 weeks, compared to 15% in 
animals not subjected to calorie restriction, and 60%, 35% and 20% survival in those who started 
calorie restriction at 14, 17 or 22 weeks respectively. All forms of calorie restriction improved the 
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coronary vasculopathy, glomerulonephritis and reduced titres of anti-DNA and anti-cardiolipin 
antibodies[484]. Although the mechanism underlying this was not explored, AMPK activation may 
have been important, given that it is activated by calorie restriction and has anti-inflammatory 
effects[266]. 
7.1.5 Hypothesis and aims  
The aim of the work presented in the chapter was to establish and characterise WBF1 animals in our 
laboratory,  and then treat them with low-dose MTX, with the aim of exploring the following 
questions: 
Does MTX activate AMPK and up-regulate vascular cytoprotective gene expression in vivo? 
Does MTX alter the course of disease in WBF1 animals? 
Does MTX have functionally important anti-inflammatory effects on the vasculature of WBF1 
animals? 
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7.2 Results 
7.2.1 Characterisation of WBF1 murine vasculopathy model 
The WBF1 male model of SLE and inflammatory vasculopathy was intially studied by examining 
cohorts of male and female animals aged 12, 16 and 24 (females only) weeks. After euthanasia, 
animals were studied post-mortem for signs of organ infarction and other evidence of vascular 
disease, and the results are shown in Table 7.1.  
Female animals showed no evidence of vascular disease at any age. In male animals there was a 
single death at 16 weeks, and a slightly lower rate of MI than would be expected from the 
literature[395, 456, 472, 473]. A single bowel infarct was observed in a male animal at 16 weeks. 
Representative images of the myocardial infarcts seen are shown in Figure 7.1. Infarcts predominantly 
involved the right ventricle, and large ones were visible macroscopically (Figure 7.1 A and B). Both 
old infarcts resulting in fibrosis and acute infarcts with myocardial necrosis were observed (Figure 7.1 
C and D). 
Myocardial infarcts in this model are thought to be due to a vasculopathy of small muscular arteries, 
characterised by a little or no adventitial inflammatory cell infiltrate and deposition of 
immunoglobulin and complement causing PAS-positive staining of the vessel wall[395, 474]. Similar 
vascular injury has been reported involving the gastro-intestinal tract and may be responsible for the 
bowel infarcts observed[459]. Representative images of the vasculopathy of the intramyocardial 
arteries are shown in Figure 7.2.  
Aortic aneurysms were found in 2 male animals at 16 weeks. These have not been reported in this 
model before. Both saccular and fusiform aneurysms were observed (Figure 7.3 A and B). It was very 
diffcult to obtain histology, as the diseased aortae did not easily hold together for embedding in OCT, 
but frozen sections through a fusiform aneurysm were obtained and an unstained transverse section is 
shown in Figure 7.3 C.  In this case a dissection had developed - the fraying of the aortic wall at the 
intima-media junction is visible, and the false lumen is filled with blood. 
Finally, hepatosplenomegaly was observed in both 12 and 16 week males, but more frequently in the 
older cohort. This was not seen in any 12 or 16 week old females, but in 2/6 24 week females. 
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 Male Female 
12 weeks 16 weeks 12 weeks 16 weeks 24 weeks 
Numbers 11 13 6 6 7 
Deaths 1 1 0 0 0 
Myocardial infarct 2 3 0 0 0 
Aneurysm 0 2 0 0 0 
Bowel infarct 0 1 0 0 0 
Table 7.1 Characteristics of (NZWxBXSB)F1 murine vasculopathy model. 
 
Figure 7.1 WBF1 myocardial infarcts. A: the macroscopic appearance of a WBF1 heart with a large right 
ventricular infarct. B: x10 magnification image of a short axis section taken at the mid-ventricular point showing 
a large haemorrhagic right ventricular infarct. C: x40 magnification image of an old, fibrotic right ventricular 
infarct. D: x40 magnification image of an acute, haemorrhagic right ventricular infarct. 
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Figure 7.2 WBF1 vasculopathy of the intramyocardial arteries. A: photomicrograph of an intramyocardial artery 
demonstrating the mild adventitial leucocytic infiltrate (arrows). H&E stain, x200 magnification. B and D: same 
vessel as shown in A at x100 and x40 magnification respectively. C: PAS staining of same vessel, x200 
magnification. These photomicrographs were taken by Dr JJ Boyle. 
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Figure 7.3 WBF1 aortic aneurysms. A: a saccular aneurysm of the descending aorta. B: a fusiform aneurysm or 
dissection of the descending aorta. C: low power, unstained frozen section of a dissected aorta. 
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7.2.2 MTX increases vascular MnSOD expression in vivo 
WBF1 male mice were treated with MTX 1mg/kg or 0.9% saline by weekly intraperitoneal injection 
for 4 weeks from 12 to 16 weeks of age. The dose of MTX chosen has been shown to increase 
adenosine levels [376] and to protect against collagen-induced arthritis [393], and is representative of 
the long-term low-dose MTX therapy used to treat inflammatory diseases clinically. Treatment started 
at 12 weeks because the disease is known to be under way at that point[478], and the aim was to treat 
in a manner close to that used in clinical practice: after the onset of disease, to look for amelioration in 
disease features rather than prevention of its onset. 
In order to determine if the changes in cytoprotective enzymes demonstrated in vitro also occurred 
when MTX is used in vivo, snap-frozen descending aortae harvested from the MTX- and saline-
treated mice described above were analysed. Immunoblotting of aortic lysates revealed increased 
MnSOD protein expression in those animals treated with MTX (Figure 7.4). Female littermate 
controls were also analysed as a disease-free control group, and there was no significant difference in 
MnSOD protein expression between male and female animals. 
 
 
Figure 7.4 MTX increases vascular MnSOD expression in WBF1 mice. WBF1 male mice were treated with 
MTX 1mg/kg weekly by intraperitoneal injection for 4 weeks or 0.9% saline as control. Female littermates were 
used as a healthy control population. Snap frozen aortic tissue from each animal was pulverised and run in 
western blots. A: representative immunoblot showing MnSOD expression from 2 female, 4 MTX-treated and 3 
saline-treated males; B: densitometry of MnSOD protein expression relative to GAPDH. N=18 in the MTX and 
control groups; and 6 females. F: female; M: MTX-treated male animal; C: male saline control animal. 
*=p<0.05. 
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7.2.3 MTX increases AMPK phosphorylation in vivo 
Aortic lysates harvested from MTX- and saline-treated WBF1 mice were also analysed to look for 
changes in phosphorylated AMPK. MTX treated animals had significantly more phosphorylated 
AMPK in vascular tissue (Figure 7.5). This supports the in vitro findings shown in Chapter 5, and 
suggests that enhanced AMPK phosphorylation may be a real phenomenon in patients treated with 
MTX. 
 
 
Figure 7.5 MTX increases vascular AMPK phosphorylation in WBF1 mice. WBF1 male mice were treated with 
MTX 1mg/kg or 0.9% saline weekly by intraperitoneal injection for 4 weeks. Snap frozen aortic tissue was 
ground and used in western blots. A: representative blot showing AMPK phosphorylation in 4 control and 3 
MTX treated animals. B: densitometry of phAMPK expression, relative to total AMPK and GAPDH as loading 
control. Data shown are the results of 12 MTX treated and 10 control animals and * = p<0.05. C: control 
animal; M: MTX treated animal. 
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7.2.4 MTX reduces organ damage in WBF1 mice 
Besides verifying the in vitro findings of AMPK activation and induction of cytoprotective genes with 
MTX treatment of EC, a further aim of treating WBF1 mice with MTX was to establish whether it 
had a disease-modifying effect on the vascular disease suffered by these animals. Observation of the 
animals at 16 weeks, just prior to euthanasia, revealed that those treated with MTX appeared to be in 
better general health compared to the control. Saline-treated animals looked unwell, with ruffled fur, 
and were huddled together. The MTX-treated animals had smooth sleek coats and were active and 
inquisitive (Figure 7.6). 
To establish the impact of therapeutic intervention on the systemic disease, a multisystem organ 
damage score was composed, based on pathology observed post-mortem (Table 7.2). This was 
devised according to the post mortem disease features first observed in the 16 week old male animals 
used to characterise the model, that were not present in their healthy female littermates. The presence 
or absence of hepatosplenomegaly, bowel infarcts or ascites or pleural fluid was recorded at post 
mortem. The presence of aortic aneurysms was recorded following microscopic dissection of the 
descending aortae. Finally the presence and size of myocardial infarction was examined 
histologically, with confirmation from a second blinded investigator, as described in section 3.3.8. 
The damage score revealed a significant disease-modifying effect of MTX, with no treated animals 
scoring 4 or 5, and a majority showing no visible signs of ill-health at all (Figure 7.7).  
 
 
Figure 7.6 WBF1 male mice at 16 weeks. A: animals given 0.9% saline; B: animals treated with MTX.  
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Feature Score 
Death  2 
Myocardial infarct: full thickness  2 
Myocardial infarct: small fibrotic  1 
Bowel Infarct  1 
Aortic aneurysm 1 
Ascites or pleural fluid  1 
Hepatosplenomegaly  1 
Table 7.2 Composition of WBF1 post mortem damage score 
  
 
Figure 7.7 MTX improves damage score in WBF1 mice. A damage score was constructed (Table 7.2), based on 
post mortem finding in the original characterisation cohort,  and applied to post mortem findings in all mice 
treated with MTX or 0.9% saline. Data shown represent the results from 18 control and 19 MTX-treated 
animals. * = p<0.05. 
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7.2.5 MTX improves the vasculopathy of intramyocardial arteries 
Having established that MTX ameliorated the WBF1 disease in general, its effect on the coronary 
vasculopathy was investigated. PAS-stained myocardial sections were examined by myself and a 
second investigator (with thanks to Dr JJ Boyle) and a modified scoring system based on Berden et al 
was formulated[395]. This involved quantifying the vasculopathy in two ways: firstly, by counting 
infiltrating leukocytes in the adventitia; and secondly by scoring the deposition of PAS-positive 
material in the arterial walls. The scoring was as follows: 0: normal staining; 1: increased basement 
membrane staining; 2: increased basement membrane staining and nodular deposits. A single section 
per animal was examined, each of which contained approximately 10-15 intramyocardial small 
arteries. 
Following four weeks' treatment with MTX, a significant reduction in the vasculopathy affecting the 
intramyocardial arteries was observed, with MTX treatment causing a reduction in both the numbers 
of adventitial leukocytes and the degree of PAS staining of the vessel walls (Figure 7.8). This 
provides direct evidence that low-dose MTX can improve an inflammatory vascular disease. 
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Figure 7.8 MTX improves WBF1 coronary vasculopathy. Myocardial sections stained with PAS from WBF1 
mice treated with MTX 1mg/kg (n=19) or normal saline (n=17) weekly from 12 - 16 weeks were examined and 
the vasculopathy quantified. Firstly, the number of leukocytes infiltrating the adventitia was counted. Secondly, 
the deposition of PAS-positive material in the arterial walls was scored. A: an artery with a large number of 
infiltrating leukocytes; B: an example of heavy deposition of PAS-positive material; C and D: examples of 
normal arteries with no leukocyte infiltration and no excess PAS staining; E: quantification of adventitial 
leukocyte infiltration; F: quantification of PAS staining of arterial wall. AU: arbitrary units. * = p<0.05; *** = 
p<0.001. 
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7.2.6 Effect of MTX treatment on myocardial infarction in WBF1 mice 
Having established that low-dose MTX attenuates the histopathological appearance of the arterial 
vasculopathy in WBF1 mice, I next studied whether the reduction in vascular disease was associated 
with a reduction in myocardial infarction. Coded myocardial sections were examined by two 
investigators including me (with thanks to Dr JJ Boyle) to establish which animals had suffered 
myocardial infarctions. At 16 weeks, 7/17 (41%) untreated mice had suffered an MI and 4/19 (21%) 
MTX-treated animals. Although this represents a near 50% reduction in MI rate, the proportion of 
affected animals is too small for the difference to be statistically significant. However, the rate is 
consistent with previous reports of MI incidence in this model at this time point[395, 472]. The 
optimal time point to study for an effect on MI is probably 24-30 weeks when the incidence is 53-
62%, but the data would be likely to be confounded by the onset of renal impairment and thus 
increased MTX toxicity. 
Myocardial damage was quantified in two ways. Firstly serum cardiac troponin I (cTnI), a highly 
senstitive and specific marker for myocardial damage, was measured in post-mortem blood samples 
by ELISA. Although large troponin rises were seen only in untreated animals, no statistically 
significant effect of MTX treatment was observed (Figure 7.9). This was because the majority of 
animals in each group did not have detectable cTnI levels, including animals in which MI was seen 
histologically. This reflects the time course of cTnI release following MI: as it is a relatively acute 
marker and cleared within two weeks in the majority of cases, animals with older MIs were unlikely 
still to have detectable serum cTnI. 
Secondly, infarct area was quantified on sections stained with picrosirius red. This is a specific stain 
for collagen and therefore can be used to show fibrotic damage caused by prior infarction. Areas of 
infarct were photographed consecutively and the images quantified on the green channel in Image J 
by thresholding using the histogram function. The area of the image that stained red and thus 
constituted infarct was obtained, and this was expressed as a proportion of the area of the whole 
myocardial section (obtained from separate ultra-low power photographs).  However, given that a 
small number of animals had suffered acute MI that had not yet been converted to collagen scar 
tissue, using this method alone would have under-reported the extent of MI. Therefore acute MI, as 
identified by two investigators, was also photographed and quantified by straightforward area 
measurement in Image J. However, although fewer animals treated with MTX suffered an MI, and 
those that did had small infarcts, no statistically significant difference in myocardial area could be 
demonstrated between the groups (Figure 7.10).  
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Figure 7.9 Serum cTnI concentration in WBF1 mice treated with MTX or saline control. Murine serum cTnI 
was quantified by ELISA. N=17 controls and 19 methotrexate treated animals. Data are expressed as mean and 
were analysed by Mann-Whitney U-test. No significant difference between the groups was observed. 
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Figure 7.10 Quantification of MI area using picrosirius red staining. All photomicrographs are of myocardium 
stained with picrosirius red and taken at x40 magnification. A: an extensive fibrotic infarct involving the entire 
right ventricle; collagen stained red. B: infarcts of various ages are seen in a single animal: an acute infarct 
staining dark brown in the free wall of the right ventricle, and an old fibrotic infarct staining red in the septal 
wall of the right ventricle. C: a large acute infarct involving the free wall of right ventricle. D: a small fibrotic 
infarct in an animal treated with MTX. E: quantification of infarct size; ns: not statistically significant. 
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7.2.7 MTX reduces aortic endothelial and adventitial ICAM-1 expression 
The final question addressed was whether MTX exerts an anti-inflammatory effect on the vasculature 
of WBF1 mice. To do this, aortic ICAM-1 expression was studied. Transverse sections of descending 
aortae from MTX and saline-treated WBF1 mice and from a cohort of female littermates as healthy 
controls were stained with an anti-mouse ICAM-1 mAb, anti-CD31 and DRAQ5 and examined by 
immunofluorescence confocal microscopy (a single section per animal).  Male animals had 
significantly greater aortic endothelial and adventitial ICAM-1 expression than females (Figure 7.11), 
reflecting the presence of inflammatory vascular disease in the male study population. MTX treatment 
significantly reduced endothelial and adventitial ICAM-1 staining (Figure 7.11). The reduction in 
adventitial staining is likely to be of particular relevance in the amelioration of organ damage in this 
model, given the reduction in the adventitial leukocyte inflammatory infiltrate also observed in the 
intra-myocardial arteries (Figure 7.8).  
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Figure 7.11 MTX reduces aortic endothelial and adventitial ICAM-1expression in WBF1 male mice. WBF1 
male mice were treated with MTX 1mg/kg weekly for four weeks. Frozen transverse sections of descending 
aorta were stained with anti-ICAM-1 and mean fluorescence intensity was measured. A: control WBF1 male; B: 
MTX-treated WBF1 male; C: female littermate control; D: quantification of endothelial fluorescence; E: 
quantification of adventitial fluorescence. Confocal microscopy images: green: anti-CD31; red: anti-ICAM-1; 
purple: DRAQ5 nuclear stain. Data are expressed as mean +/- SEM. * = p<0.05; ** = p<0.01; *** = p<0.001. 
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7.3 Discussion 
This chapter presented experiments exploring the effects of using MTX to treat male WBF1 mice, 
which develop a lupus-like illness and an inflammatory vasculopathy of small and medium-sized 
arteries that leads to thrombosis and tissue infarction. The model was first established in the 
laboratory, and then a cohort of animals were treated with MTX 1mg/kg weekly by intra-peritoneal 
injection for 4 weeks from 12 - 16 weeks of age, and compared both to littermate controls treated with 
0.9% saline and to healthy female siblings. MTX treatment resulted in increased expression of 
phosphorylated AMPK and MnSOD in aortic lysates, and in addition reduced aortic adventitial and 
endothelial ICAM-1 expression providing direct evidence of an anti-inflammatory effect. This was 
reflected by reduced organ damage and improved coronary vasculopathy, but there were not sufficient 
animals affected to show an effect on myocardial infarction.  
7.3.1 Choice of murine model 
Any animal model of atherosclerosis will only ever be an approximation; the natural course of disease 
takes decades and so cannot really be replicated over the working lifetime of an interested researcher. 
In the context of chronic systemic inflammation, rodent models of RA such as collagen-induced or 
adjuvant arthritis only last 4 -6 weeks and thus are unlikely to have the time to develop significant 
vascular complications. Lupus-prone mice have longer lasting disease (several months) but develop 
degenerative vascular disease in only around 20% of animals, with the exception of the WBF1 model 
used here[474]. 
Most previous in vivo studies of CVD in SLE or RA and CVD have done so by crossing strains of 
lupus prone or arthritis-susceptible mice with Apo E
-/-
 mice. Apo E
-/-
 mice have grossly deranged 
plasma lipids with low HDL and high total cholesterol and LDL and spontaneously develop 
cholesterol-laden atheromata. Attempts have been made to study the links between RA and CVD 
using CIA-susceptible, Apo E
-/-
 mice. These animals developed more severe arthritis, but no change in 
the severity of atherosclerosis was observed[485]. 
To study CVD in the context of SLE. Aprahamian et al used Gld.apoE
-/-
 animals, deficient in both Fas 
ligand and Apo E as their model to study whether rosiglitazone could ameliorate disease 
manifestations[486]. Others have used Apo E
-/-
 mice crossed with Type I IFN receptor deficient mice, 
or looked at cardiometabolic risk profile or markers of endothelial dysfunction in standard lupus-
prone mouse models[55, 487, 488]. 
The principal problem with all these models is that they either involve measuring indirect surrogate 
markers for vascular disease, or involve using a model with such gross derangement of lipid profile 
that extrapolation to the human situation is difficult. In addition Apo E
-/-
 mice, although they develop 
extensive atheromata, very rarely suffer plaque rupture and vessel occlusion.  
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The WBF1 model that I used is not a model of atherosclerosis but rather of an inflammatory 
vasculopathy in which it is likely that anti-phospholipid antibodies play a pathogenic role. However, 
the vasculopathy is frequently associated with a local inflammatory cell infiltrate, vessel thrombosis 
and occlusion, causing tissue infarction, and thus I felt it was a closer approximation to the vascular 
injury associated with SLE than any other model. 
7.3.2 Characterisation of the WBF1 model 
The initial work presented in this chapter was the original characterisation of the WBF1 model that I 
performed. Cohorts of male and female animals aged 12, 16 and 24 weeks were studied for signs of 
vascular disease: myocardial and bowel infarcts and aortic aneurysms. As expected, female animals 
showed no signs of disease even at 24 weeks, while male animals were affected in low numbers at 12 
weeks and slightly more at 16 weeks. Overall, however, the numbers of affected animals appeared 
lower than the original descriptions of the model suggested, with a smaller proportion suffering MI or 
death[456]. Although the coronary vasculopathy was present in a high proportion of animals, the 
appearances seemed less florid. In particular, large deposits of PAS-positve material in vessel walls 
were very rarely observed, and this meant that the scoring system devised by Berden et al[395] had to 
be modified when I quantified the disease. It is not clear why this would be, but environmental 
influences are likely to be important in modulating the onset and severity of disease, and there are no 
doubt differences in pathogen exposure, diet and bedding material between the conditions the animals 
used in these experiments were housed in and those of the animals in the original reports. 
In addition, I noted aortic disease in a small number of older male animals both in the initial 
characterisation experiments and in those used to study the effects of MTX. Macroscopically these 
appeared to be fusiform and saccular aneurysms, in some cases initiating near branch points where 
intercostal arteries originated. However, although gaining histological sections was extremely difficult 
due to the fragile nature of the tissue, frozen sections through one indicated that it was in fact an 
arterial dissection. It was not possible to study the pathology underlying this aortic disease, but it is 
known that the WBF1 mouse is hypertensive so this could be contributing[480]. Vasculopathy 
affecting the vasa vasorum might also be present. 
7.3.3 MTX treatment of WBF1 
The arterioprotective actions of MTX were explored by treating WBF1 mice with a low dose, once 
disease was established but still early in its course. The intervention was timed to model the treatment 
of early systemic inflammatory disease in patients, and aimed to demonstrate amelioration of the 
vasculopathy and a reduction in end-organ damage due to infarction.Therefore, they were given MTX 
1mg/kg weekly for 4 weeks from 12 to 16 weeks. At 12 weeks disease is detectable in WBF1 
mice[395, 478, 481], while by 16 weeks over 80% would be expected to have developed the 
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vasculopathy and around 40% to have suffered an MI[395]. Thus this seemed a good time point to 
look for disease modification, without causing suffering to a large proportion of animals. 
The dose of MTX was chosen to be as low as possible while still exerting a pharmacological effect. It 
was chosen on the basis of that shown to alter adenosine levels in vivo, and that shown to be effective 
in treating rodent models of inflammatory arthritis[376, 393, 394]. 1mg/kg is higher than the doses 
used to treat inflammatory arthritis in adults (typically 15-25mg weekly), but not dissimilar to those 
used in juvenile idiopathic arthritis, where doses up to 30mg in 30 - 40kg children can be used. 
A previous attempt to treat this model with MTX failed to show any improvement in mortality or 
renal function at 34 weeks[482]. However, this study used three-fold higher doses of MTX, which 
may have contributed to mortality given that MTX accumulates in renal failure, and the end-point was 
a late stage in an unremitting disease where a large percentage of animals would already be expected 
to have died. I studied an early time point, in the hope that this meant disease might be more easily 
modulated, rather than waiting for irreversible damage to set in. This also reflects current clinical 
practice, where we aim to treat as early as possible in the course of disease. 
Using low dose MTX in WBF1 mice resulted in increased vascular expression of phosphorylated 
AMPKα and MnSOD, replicating the major in vitro findings reported in Chapters 5 and 6. These 
changes were observed in lysates prepared from whole aortae and thus represent changes in all cells 
within the vessel wall, of which EC are only a small proportion. However, this increases the 
likelihood that these changes might also occur in patients treated with MTX, as they have now been 
observed in both in vitro cultures of primary human cells and in an animal model of chronic 
inflammatory disease, and at doses compatible with those used in clinical practice. 
7.3.4 WBF1 disease modification with MTX 
Treating WBF1 mice at an early stage in disease with MTX attenuated organ damage and reduced the 
severity of coronary vasculopathy with a reduction in both infiltrating adventitial leucocytes and in 
PAS-positive material in vessel walls. Although fewer animals treated with MTX suffered an MI, and 
those that did suffered smaller infarcts than controls, there were not enough affected animals for this 
difference to be statistically significant. There were a few technical limitations however that may have 
contributed. Measuring cTnI captures myocardial damage at a single time point; the levels fall away 
over a few days after myocardial damage occurs. Using it to quantify MI on post mortem blood 
samples will thus have missed infarcts more than a few days old. Conversely, quantifying infarcted 
tissue histologically was so time consuming that only a single slide cut at the mid-ventricular point 
from each animal could be analysed. Although it had the advantage of capturing both old and new 
infarcts, small lesions elsewhere in the heart will have been missed. Thus both methods used may 
have underestimated the number of MIs suffered by the cohort. 
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However, the multisystem organ damage score did show an effect of MTX on disease progression in 
this model. This too however is subject to some limitations. As I treated animals with MTX only 
once, it was not possible to validate the score in advance on a group of treated animals: instead it was 
composed of those disease features apparent in 16 week old male mice but not in their healthy female 
littermates when I first characterised the model. Secondly, there is a concern about bias given that I 
both treated the animals and carried out the post mortem examination. Although I used a coding 
system to blind myself regarding treatment condition, this will not have been perfect given that I knew 
from which cage each animal I culled came from. However, the myocardial sections were examined 
by second investigator who was blinded, and we agreed on the presence or absence of myocardial 
infarcts and of the vasculopathy together. 
MTX also exerted a specific anti-inflammatory action, reducing expression of aortic endothelial and 
adventitial ICAM-1. The reduction in adventitial ICAM-1 may be of relevance to the mechanism by 
which MTX improved the coronary vasculopathy, as it may have contributed to the reduction in 
adventitial leucocyte infiltration. A reduction in endothelial ICAM-1 is an important observation in 
terms of how MTX retards atherogenesis in general, as increased expression of EC adhesion 
molecules is a central feature of endothelial dysfunction and of critical importance for the recruitment 
of leucocytes into atherosclerotic plaques. MTX has previously been shown to reduce soluble ICAM-
1 in blood samples from patients with early RA and with heart failure, as well as surface ICAM-1 on 
HUVEC in vitro[382, 431, 489]. However, I did not find that treating HUVEC with MTX reduced the 
induction of ICAM-1 stimulated by TNFα (Figure 5.10). This discrepancy between in vitro and in 
vivo findings illustrates the importance of doing both in order to be confident whether the results are 
meaningful.  
I have not been able to show whether AMPK activation and increased expression of downstream 
cytoprotective genes were necessary for the protective effects of MTX in this model. This could have 
been done by, for example, treating animals with an AMPK inhibitor such as Compound C in addition 
to MTX. Unfortunately time constraints did not allow me to investigate this. 
The experiments presented in this chapter have demonstrated therefore that MTX can exert 
arterioprotective effects in vivo, increasing vascular AMPK activation and MnSOD expression and 
reducing ICAM-1. These changes may be important for its ability to modulate the course of a murine 
inflammatory vasculopathy. 
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8 CONCLUDING REMARKS 
8.1 Introduction 
Premature CVD complicates chronic systemic inflammatory disease such as RA and SLE[12]. 
Understanding of the mechanisms that underlie this has progressed but remains incomplete. As a 
result, although treatment for these conditions has improved radically in the last 30 years, we lack 
knowledge of how to prevent or retard the associated vascular injury. 
Atherosclerosis begins with endothelial dysfunction, a state characterised by reduced bioavailability 
of NO, increased expression of cell adhesion molecules and oxidative stress[91]. Endothelial 
dysfunction is clinically detectable by non-invasive means and is reversible whereas established 
atherosclerosis is not[90]. If it were known therefore which drugs, or drug combinations, were best 
able to reverse endothelial dysfunction, it might be possible to construct a pharmacological strategy to 
tackle CVD in chronic inflammation.  
Normal endothelium exists in a quiescent state, with low cell turnover and energy use, a reducing 
intracellular environment and tonic production of NO[11]. This state is promoted by high flow LSS 
and, in some vascular beds, VEGF. If the balance is disturbed by oxidative, inflammatory or 
metabolic insults, cytoprotective pathways operate to counteract these and restore homeostasis. These 
include induction of anti-oxidant enzymes such as MnSOD and HO-1 and anti-apoptotic proteins such 
as Bcl-2 and A1, modulation of mitochondrial metabolism via uncoupling proteins, and enhanced 
protection against complement-mediated injury via DAF. 
One signalling kinase that is capable of responding to cellular stressors is AMPK. AMPK is 
classically activated by metabolic or nutritional stress, and the outcome is conservation of, or 
enhanced efficiency in the use of, cellular energy[261]. In EC, AMPK activation increases NO 
production, protects against oxidative injury and prevents apoptosis[142]. It also has effects on 
mitochondrial metabolism by promoting mitochondrial biogenesis[310]. AMPK can be activated by 
several classes of drugs that have vasculoprotective effects, including statins, metformin and fibrates, 
but these observations are limited largely to in vitro studies using drug concentrations several fold 
higher than those achievable in patients.   
MTX, an anti-inflammatory drug central to the current treatment paradigms for RA, is probably 
prescribed long-term for several hundred thousand people in the UK (by my own estimate). Robust 
evidence shows that its use is associated with a reduction in risk of CVD in RA[79]. Despite such 
widespread use, its anti-inflammatory mechanism of action is not completely understood. The best 
evidence suggests that MTX acts by inhibiting enzymes involved in nucleotide metabolism, resulting 
in increased adenosine levels[369]. However, other nucleotides whose intracellular levels are also 
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altered by MTX include AICAR, ZMP and AMP, all of which are capable of allosteric activation of 
AMPK.  
Thus, the hypothesis I formulated was that MTX acts to protect vascular endothelium against 
inflammatory injury by activating AMPK, and that this leads to enhanced expression of cytoprotective 
genes. If present, such a mechanism might explain why the use of MTX in RA is associated with 
reduced CV mortality, and may provide a pharmacological strategy for the  prevention of 
atherosclerosis in chronic systemic inflammation. 
8.2 Research questions 
The work presented in this thesis sought to explore mechanisms through which endothelial 
cytoprotective pathways might be activated, in order to offer pharmacological protection against 
vascular injury to patients with chronic inflammatory disease. Four questions were addressed: 
The endogenous mediators of endothelial cytoprotection VEGF and high flow LSS regulate many 
similar pathways in EC. Do confluent EC conditioned by LSS react differently to VEGF compared to 
static-cultured cells, resulting in a synergistic induction of cytoprotective pathways? 
Does MTX activate AMPK and enhance cytoprotective gene expression in EC, and does this have a 
functional benefit? 
If it occurs, by what mechanisms does activation of AMPK by MTX lead to changes in gene 
expression? 
Does MTX activate AMPK and enhance cytoprotective gene expression in vivo, and can it improve 
outcome in a murine model of inflammatory vascular disease? 
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8.3 Major findings 
8.3.1 EC responses to VEGF when conditioned by high flow LSS are generally not 
synergistic 
Confluent HUVEC were exposed to high flow LSS using the Cytodyne streamer parallel plate 
apparatus for 16 - 24h, before the addition of VEGF 25ng/ml for periods ranging from 4 to 24h. 
Previous reports had indicated that both VEGF and LSS could induce endothelial expression of the 
cytoprotective enzyme HO-1 and so I looked for a synergistic induction. However, although LSS 
strongly induced HO-1, VEGF did not under static conditions, and a synergistic increase was 
observed only with mRNA, and transiently at a short time point only.  
Synergy was not observed with other proteins whose expression is thought to be regulated by both 
VEGF and LSS such as VEGFR2 and eNOS, while little difference in expression was observed with 
DAF, known to be regulated by VEGF but not LSS. An intriguing effect was noted with the anti-
apoptotic protein A1, whose expression is regulated by VEGF. LSS for 24h strikingly down-regulated 
expression and VEGF added to LSS-exposed cells was able to overcome this and strongly induce 
expression. However, this was a transient phenomenon that had recovered by later time points and 
was probably an artefact related to the process of endothelial equilibration to flow. 
Finally, a phosphokinase array was performed to explore differences in phosphorylation status in 
HUVEC treated with VEGF for 15 minutes after 24h equilibration to high flow LSS. Although VEGF 
was still able to enhance phosphorylation of a small number of kinases, notably AMPK, JNK and p27, 
in most cases kinases that were phosphorylated by VEGF in static conditions or by LSS were 
dephosphorylated when VEGF was added to EC conditioned to LSS. This may reflect homeostatic 
mechanisms, where the effect of two strong drivers of a phenomenon acting together is a reduction in 
its magnitude. Another possible explanation is that VEGF is a growth factor and endothelial mitogen, 
while LSS generally promotes a quiescent state with low cell turnover and thus the two together may 
act in opposition. What is clear, however, is that in general EC responses to VEGF when conditioned 
by high flow LSS are not enhanced compared to those in static culture. 
8.3.2 MTX activates AMPK and induces cytoprotective gene expression in EC, 
resulting in enhanced protection against apoptosis 
One of the few kinases whose phosphorylation state was enhanced by VEGF in HUVEC conditioned 
by LSS was AMPK, and this kinase formed the basis for investigating pharmacological approaches to 
enhance endothelial cytoprotection in patients suffering chronic inflammatory diseases. 
AMPKαThr172 phosphorylation was increased by treating HUVEC with MTX 100nM for 48h. This 
concentration is close to those achieved therapeutically in patients. Cytoprotective gene expression 
was also observed when both 100nM and 10nM MTX were studied; with induction of MnSOD and 
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HO-1 protein and mRNA, and also DAF, A1 and UCP-2 mRNA. Induction of MnSOD protein was 
also demonstrated in HAEC. These changes did not represent a general response to an oxidative insult 
as no change was seen in expression levels of Trx, Trx reductase or NQO-1. Induction of MnSOD and 
HO-1 were preserved if HUVEC were co-treated with folic acid and MTX, and if a dysfunctional 
endothelium was modelled by pre-treatment with TNFα. MTX treatment did not alter the induction of 
cell adhesion molecules by TNFα, but did protect against apoptosis induced by glucose deprivation. 
Consistent with its known actions in inhibiting folic acid metabolism however, it also reduced EC 
proliferation. 
These results suggest that long exposure to MTX at therapeutically relevant concentrations exerts a 
beneficial effect on HUVEC by activating AMPK and inducing cytoprotective gene expression. As 
the responses are preserved in the presence of folic acid and TNFα, they may be of relevance to the 
mechanism of action in patients prescribed MTX. 
8.3.3 MnSOD and HO-1 induction of MTX is dependent on AMPK and CREB 
Although I had demonstrated that MTX activates AMPK in HUVEC and enhances expression of 
cytoprotective genes, whether the changes in gene expression were the result of AMPK activation had 
not been proved. Furthermore the transcription factors involved had not been identified. 
Two different loss-of-function approaches were employed to establish the role of AMPK in the 
induction of MnSOD and HO-1 by MTX. First, AMPK was inhibited using Compound C. This 
reduced the induction of MnSOD and HO-1 mRNA by MTX but not protein; in fact Compound C 
itself induced MnSOD and HO-1 protein and this probably masked any effect of MTX via AMPK. 
Therefore, RNA interference was used to deplete AMPKα1 and/ or AMPKα2. Using this technique it 
was established that inhibiting AMPKα2 signalling prevents MTX inducing MnSOD and HO-1 and 
inhibiting AMPKα1 prevents the induction of HO-1 and may also affect MnSOD. As a further step, 
HUVEC were treated with the AMPK activator AICAR and induction of MnSOD was observed. 
Previous reports indicated that a good candidate for the transcription factor involved in mediating 
induction of MnSOD by AMPK activation was CREB, as this is a direct target of AMPK and it has 
previously been demonstrated to mediate MnSOD expression in cancer cells in response to TPA[200, 
445]. MTX 100nM for 48h resulted in increased CREB
Ser133
 phosphorylation, and this was inhibited in 
HUVEC treated with AMPKα1 or AMPKα2 siRNA, indicating that CREB lies downstream of 
AMPK. CREB depletion by RNA interference abolished the induction of MnSOD and HO-1 by 
MTX, and ChIP demonstrated enhanced binding of CREB, most probably at a known, validated, CRE 
site, to the SOD2 promoter. 
Finally, the role of ROS in the induction of HO-1 and MnSOD by MTX was investigated. MTX itself 
caused a small rise in intracellular ROS. Pre-treatment with NAC to abolish all ROS production 
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completely prevented induction of HO-1 by MTX but had no effect on MnSOD. An attempt to 
explore the effects of mitochondrial ROS using a mitochondrial ROS scavenger did not alter MnSOD 
or HO-1 induction but may represent a technical failure. 
Therefore, the induction of cytoprotective genes in HUVEC by MTX is dependent upon an AMPK 
and CREB pathway. Although MTX does increase intracellular ROS production, whether this is 
restricted to a particular subcellular compartment or is important for the induction of MnSOD and 
HO-1 remains to be determined. 
8.3.4 MTX increases AMPK phosphorylation and MnSOD expression in vivo and 
reduces the severity of an inflammatory vasculopathy 
The experiments reported in the final chapter of this thesis explored the in vivo relevance of the in 
vitro findings regarding the effects of MTX on EC biology that were presented in the earlier chapters. 
The male WBF1 lupus-prone mouse develops an inflammatory vasculopathy of small muscular 
arteries in the heart and GI tract, leading to thrombosis and organ infarction. These animals were 
treated with MTX 1mg/kg weekly for 4 weeks, early in the course of disease, to investigate whether 
MTX could reduce its severity.  
MTX treatment increased vascular expression of phosphorylated AMPKαThr172 and MnSOD, and 
reduced aortic adventitial and endothelial ICAM-1 expression. MTX treatment also attenuated organ 
damage and reduced the severity of the coronary vasculopathy. However, there were not enough 
affected animals for an effect of MTX in myocardial infarct number or size to be seen.  
These results show that MTX is capable of activating AMPK in the vasculature at doses relevant to 
clinical practice in both in vivo and in vitro settings, and also enhancing MnSOD expression. 
Furthermore it can modulate the course of an inflammatory vasculopathy in the setting of a murine 
lupus-like illness, although whether this depends on activation of AMPK or alterations in MnSOD 
expression has not yet been definitively established. 
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8.4 Discussion 
The central finding of the work presented in this thesis is the identification of a new mechanism of 
action of MTX that might explain why patients with RA who are treated with long-term, low dose 
MTX are at reduced risk of CV mortality. I have shown that MTX might exert beneficial effects on 
normal tissue, rather than just precipitating apoptosis in cells that we wish to get rid of. In EC MTX 
activates AMPK, phosphorylates CREB and induces expression of cytoprotective genes with roles in 
mitochondrial function and with anti-oxidant, anti-apoptotic properties. MTX did reduce EC 
proliferation and induced a rise in intracellular ROS levels, but protected against apoptosis induced by 
glucose deprivation. MTX also activated AMPK and increased MnSOD expression in the murine 
vasculature, and ameliorated the severity of vasculopathy in the WBF1 lupus-prone mouse.  
Is MTX beneficial or harmful to the vasculature? 
Although MTX has been in widespread use as a treatment for chronic inflammatory diseases for 
nearly 30 years, it is not completely accepted by practising physicians that MTX offers any benefit to 
normal tissue. Its use at high doses as a cancer chemotherapy and abortifacient drug have perpetuated 
a popular view that MTX is harmful, and is effective in treating inflammatory disease only because it 
kills rapidly dividing cells before normal cells are irreversibly damaged. Many physicians, if asked 
whether MTX might exert beneficial effects on normal tissue such as vascular endothelium, would 
think not. 
There are several ways in which MTX might be harmful. First, it induces apoptosis in malignant cells, 
activated leucocytes, and other actively dividing cell types such as keratinocytes[380, 384]. Secondly, 
it increases ROS levels, and can do so to a degree that promotes apoptosis, again in activated 
leucocytes[380]. More pertinent to the vasculature, MTX can increase plasma homocysteine levels 
and interfere with the production of the eNOS co-factor BH4[388], and has anti-angiogenic 
properties[385]. It might therefore be reasonable to propose that MTX is likely to be harmful to the 
vasculature, and indeed initial studies on MTX and CVD in RA suggested CVD was increased, 
associating this with a rise in plasma homocysteine concentration[357]. 
However, clinical experience of MTX prescribed at 15-20 mg per week in rheumatological practice is 
altering perceptions of this drug and its long-term safety. Co-prescription of folic acid and regular 
monitoring of relevant blood indices has resulted in MTX being taken safely by thousands of patients 
over many years. Although MTX does increase homocysteine concentrations, co-prescription with 
folic acid reverses this[360]. Several studies have now demonstrated that the long-term low-dose 
MTX regimen used in RA is associated with reduced CVD[79, 361]. The use of MTX is also 
associated with improvement in endothelial function[363]. This evidence, combined with the long 
clinical experience supporting its safety, has led to the initiation of a trial of long-term low dose MTX 
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for the secondary prevention of CVD in patients with atherosclerosis but no underlying inflammatory 
condition[15]. 
Improvement in CV mortality with MTX may not solely be due to direct beneficial effects of the drug 
on endothelium. They may also reflect an anti-atherogenic action of adenosine via ligation of its A2A 
receptor which, in addition to an anti-inflammatory action, may induce reverse cholesterol transport 
proteins and prevent foam cell formation[390]. MTX is also a very effective anti-inflammatory drug 
which successfully reduces levels of circulating cytokines and other inflammatory mediators, and the 
reduction in CV mortality could simply be an indirect result of its general suppression of chronic 
inflammation. 
In the work presented in this thesis, no evidence of harm to EC was found using MTX. Although 
MTX did reduce cell proliferation in vitro, this is unlikely to be significant in vivo given the much 
lower rate of turnover of EC. MTX did not induce EC apoptosis at the doses used, and indeed 
protected against it when induced using glucose deprivation. Although an increase in ROS was found 
in cells treated with MTX, it was unclear where in the cell this occurred and whether it was 
physiological or not. In addition, MTX increased expression of cytoprotective genes. However, it 
remains to be determined whether the changes in gene expression occur because MTX promotes a 
more healthy internal cell milieu, or whether they are a response to a stressful effect of MTX on the 
cells. This is entirely possible given that MTX inhibits enzymes involved in many aspects of cell 
metabolism. If so, MTX may be exerting beneficial effects by inducing stress-response hormesis. This 
is a term borrowed from the study of longevity referring to the phenomenon whereby low-level stress, 
by inducing expression of protective pathways, improves resistance to subsequent challenges[89, 
179]. 
Overall, this study supports the notion that MTX is likely to be protective to the vasculature. 
Are the findings relevant to the use of MTX in clinical practice? 
There are several reasons to support the idea that the effects of MTX on EC discovered in the 
experiments presented here may be relevant to the use of long-term low dose MTX in the treatment of 
chronic inflammatory disease. Firstly, phosphorylation of AMPK and changes in downstream 
enzymes were seen in HUVEC at MTX concentrations thought to be achievable in patient sera, and 
moreover increased phosphorylated AMPK and the downstream target MnSOD was observed in 
murine vascular tissue following MTX administration analogous to the long-term, low dose use that is 
so effective in chronic inflammatory disease. Secondly, the effects of MTX on MnSOD expression at 
least were replicated in both HUVEC and HAEC, as well as in murine vascular tissue. Thirdly, 
although I was not able to demonstrate an effect of MTX on pro-inflammatory gene expression in 
vitro, reduction in ICAM-1 expression was observed in vivo, suggesting that the MTX doses and 
administration used were operating as would be expected in terms of effect on inflammatory 
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pathways. Finally, in vitro AMPK phosphorylation and changes in gene expression were only 
observed with MTX after a 48h  delay. Given that MTX, when used as an anti-inflammatory drug, has 
a long onset and offset of action, taking several weeks, a delayed  response  is consistent with an 
effect relevant to the use of MTX in clinical practice. 
Therefore, I think it likely that the MTX-mediated AMPK activation in the vasculature that has been 
demonstrated is likely to be a real phenomenon in patients. 
Could AMPK activation by MTX be part of its anti-inflammatory mechanism of action in 
addition to vascular protection? 
This thesis presents data showing that for the first time that MTX activates AMPK in vascular 
endothelium, both in vitro and in vivo, and at concentrations relevant to clinical practice. AMPK has 
been associated with anti-inflammatory and desirable metabolic changes in many different systems 
and disease settings[261, 266]; the evidence supporting its protective role in EC was discussed in the 
introduction. 
Recent studies have suggested that AMPK activation in cells of the immune system is associated with 
anti-inflammatory changes[266] . The question therefore arises whether MTX may also activate 
AMPK in cells of the immune system as part of its anti-inflammatory mechanism of action. This is 
certainly possible, particularly as the anti-inflammatory mechanism of action of MTX is still a matter 
of some debate. Although there is strong in vitro and in vivo evidence that adenosine accumulation is 
important, there is little evidence in patients of alterations in adenosine levels. In addition, in Chapter 
7 AMPK phosphorylation was demonstrated in murine aortic tissue following MTX treatment. 
Endothelial cells are only a small proportion of the total cell content of the aorta, and so it is likely 
that MTX does activate AMPK in tissues other than the endothelium. 
AMPK activity shifts cellular energy generation towards mitochondrial oxidative phosphorylation, 
which is associated with a quiescent, anti-inflammatory cellular phenotype with low energy turnover 
and reduced cell growth and proliferation. This is thought to be important in mediating AMPK's anti-
cancer effects and is postulated to underlie its anti-inflammatory actions[266]. In particular, AMPK 
activation may discourage use of glycolysis and the pentose cycle for energy generation, as is seen in 
many activated leucocytes, and promote oxidative phosphorylation via mitochondria that generate 
significantly greater ATP per mole of glucose. In addition, AMPK activation may have direct anti-
inflammatory actions, reducing NFκB-mediated transcription and iNOS expression in macrophages. 
Is there evidence to suggest MTX might also promote some of the changes in cell phenotype that have 
been ascribed to AMPK activation? Certainly MTX reduces cell proliferation, although this may be 
due to its effects on folic acid and purine metabolism rather than through AMPK. There is also 
evidence that MTX, albeit at high dose, can inhibit enzymes involved in the pentose phosphate 
pathway[416], an alternative energy source that is used by activated macrophages and which AMPK 
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activation diverts cell metabolism away from. In addition, MTX and AMPK activation share similar 
effects on glycogen metabolism: while MTX increases glycogenolysis in rat liver, AMPK activation 
may promote glycogenolysis through phosphorylation and inactivation of glycogen synthase[305, 
415]. Finally, MTX has broad anti-inflammatory effects in a number of settings, reducing circulating 
levels of cytokines and soluble cell adhesion molecules and potently inhibiting progression of chronic 
inflammatory diseases. Thus, MTX could mimic effects of AMPK activation in other ways as well as 
activating the pathway itself. 
The importance of CREB, MnSOD and HO-1 in vascular protection and potential role in anti-
inflammatory effects of MTX 
I found that, following AMPK activation, MTX treatment increases CREB phosphorylation and 
binding to the MnSOD promoter, and induces MnSOD and HO-1. All three of these proteins are 
known to play roles in endothelial cytoprotection, and can also have anti-inflammatory effects. It is 
possible therefore that their induction by MTX forms part of its anti-inflammatory mechanism of 
action. 
The importance of CREB in vascular protection was discussed in the introduction. Loss of aortic 
CREB is found as an early feature in rodent models of hypertension, atherosclerosis and insulin 
resistance[201], while cardiac-specific expression of dominant-negative CREB increases oxidative 
stress, mitochondrial dysfunction and mortality[202]. In the immune system, CREB is thought to 
exert anti-inflammatory effects by interfering with NFκB-mediated transcription[199]. CREB and the 
RelA component of NFκB compete for the same limited supply of co-activators, CBP and p300, and 
so the relative abundance of NFκB and CREB in the nucleus determines whether NFκB or CREB-
mediated transcription occurs[490]. 
 Induction of MnSOD protects against atherogenesis and ApoE
-/-
 mice deficient in MnSOD exhibit 
accelerated atherosclerosis[226]. Induction of MnSOD by MTX may also be involved in its anti-
inflammatory effect: treating a rodent model of arthritis with MTX as well as a SOD mimetic reduced 
the dose of MTX needed to control disease by 10-fold[394].  
Finally, a wealth of evidence, reviewed in the introduction, demonstrates the role of HO-1 in vascular 
protection. However, its induction is also significantly anti-inflammatory too. Hmox1
-/-
 mice suffer 
more severe versions of a variety of experimental auto-immune diseases[211], while induction of HO-
1 reduces the severity of nephritis in lupus-prone mice and plays a regulatory role in RA synovial 
inflammation[214, 215]. 
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Could MTX modulate mitochondrial function? 
A number of the changes in EC function observed after MTX treatment suggest that MTX affects 
mitochondrial metabolism and possibly mitochondrial ROS production. MnSOD and UCP2, both 
induced in MTX-treated cells, act to control ROS production in mitochondria. The anti-apoptotic 
protein A1, also induced by MTX, is associated with mitochondria and controls apoptosis via the 
mitochondrial pathway. It is also known that AMPK signalling leads to mitochondrial biogenesis in 
EC, and that loss of CREB is associated with mitochondrial dysfunction[202, 310]. Finally, MTX use 
was associated with a rise in intracellular ROS levels, although I was not able to show whether this 
was localised to the mitochondria or was a more generalised phenomenon. 
Mitochondria in EC are not thought to function primarily for energy generation. Instead, they signal 
cell responses to environmental cues, through the regulated production of ROS, for which UCP2 and 
MnSOD are key[124]. MnSOD controls the conversion of superoxide to H2O2, a relatively stable 
moiety that is capable of signalling. UCP2 controls the speed of electron leak by the electron transfer 
chain and thus the rate of ROS production[238]. Perinuclear mitochondria release ROS that can 
diffuse to the nucleus and alter gene expression, and H2O2 also plays regulatory roles in shear-stress 
induced vasodilation, autophagy, and inflammatory activation[124]. Therefore it is possible that 
MTX, by altering levels of MnSOD and UCP2, is altering mitochondrial ROS production and thus 
influences cell biology in other ways downstream.  
AMPK activation and modulation of mitochondrial metabolism might provide a strategy for 
vascular protection and for reduction of inflammation in chronic inflammatory disease 
A recent review of the effects of AMPK on inflammation suggested that it was through its actions on 
cell metabolism in the immune system that AMPK was anti-inflammatory, and proposed that 
modulating cell metabolism could be employed pharmacologically as an anti-inflammatory strategy in 
chronic inflammatory diseases[266]. 
The original function of the AMPK molecular ancestors is energy conservation in response to 
starvation. In accordance with this, AMPK activation in the immune system  mimics the effects of 
starvation and seems to divert metabolism away from rapid glucose uptake and utilisation in 
glycolysis, towards mitochondrial oxidative phosphorylation and fatty acid oxidation. This change in 
metabolic state appears to promote a switch from a pro-inflammatory to anti-inflammatory cell 
phenotype. AMPK activation "tricks" the cell into behaving as if it is at risk of nutrient shortage, 
encouraging it to adopt a quiescent phenotype in order to survive[266]. 
Real starvation, or calorie restriction, is associated with benefits to the whole organism. It has long 
been known that calorie restriction improves longevity in C. elegans and in rodents. AMPK is 
necessary in C.elegans for the extension of lifespan prompted by calorie restriction. Calorie restriction 
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can also improve resistance to inflammatory disease: a reduction in calories by 30% in the WBF1 
mouse, if started at an early age, markedly delays onset of disease and improves survival[484]. 
I discussed earlier the concept of stress-response hormesis: a brief or low level exposure to a stressor 
enhances resistance to future stressors, and at a molecular level, there is an induction by the stressor of 
an adaptive defensive response through alteration in gene expression[179]. Calorie restriction may be 
one such stressor, and there is evidence to suggest that the enhancement of lifespan secondary to 
calorie restriction may be mediated by stress-response hormesis. For example, rats exposed to calorie 
restriction have increased serum corticosterone, suggesting an organism under stress, but are resistant 
to carcinogenesis compared to normal rats. Mechanistically, at a cellular level, calorie restriction may 
operate via increasing mitochondrial ROS production, and AMPK may be involved in mediating 
this[126]. Schulz et al treated C. elegans with 2-deoxyglucose, reducing glucose availability and 
activating AMPK, increasing mitochondrial oxidative phosphorylation , mitochondrial ROS 
production and anti-oxidant enzyme expression, and increasing lifespan[318]. It should be noted 
however that glucose restriction  is not experienced by mammalian cells physiologically due to 
hepatic gluconeogenesis and so this experimental result cannot be extrapolated directly to human 
tissue. However, it is possible that pharmacological activation of AMPK may be able to mimic some 
of these effects, in the vasculature or the immune system. If MTX does indeed exert vascular 
protective and anti-inflammatory effects via AMPK activation, it may be the downstream effects on 
cell metabolism, particularly on  mitochondrial function, that are important. Indeed, altering cell 
metabolism via AMPK activation may represent a new strategy for vascular protection as well as 
reducing inflammation in the treatment of chronic inflammatory disease. 
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8.5 Future work 
The principal novel findings presented in this thesis were of AMPK activation by MTX, leading to 
induction of cytoprotective genes in human EC and in the murine vasculature. To expand these 
findings, the following questions could be addressed: 
1. Do the changes in AMPK and CREB activation and in cytoprotective gene expression 
demonstrated really occur in the vasculature of patients treated with MTX? This is difficult to 
address as it very hard to obtain endothelial cells from patients, let alone the challenges of 
maintaining a MTX-induced phenotype in culture. One way to explore it however would be to 
study blood outgrowth endothelial cells (BOEC) from patients on MTX and those not, or if 
possible from the same patient before and after starting the drug.  
2. The same technique of isolating and culturing blood outgrowth endothelial cells could also be 
used to study those from patients with AMPK disease. As these patients have a constitutively 
active AMPK complex, BOEC from these patients could be used as a model of AMPK over-
expression to study the phenotype this produces in vascular endothelium. 
3. What is the full extent of changes in gene expression in EC treated with low dose MTX? A 
genome-wide array could be performed to investigate this.  
4. The role of CREB in the responses observed has not been fully demonstrated. In order to be 
certain that CREB activation is driving MnSOD expression in MTX-treated cells, a luciferase 
reporter assay should have been performed. 
5. A number of experiments presented here suggest that one of the results of MTX treatment is 
alteration in mitochondrial metabolism. Is MTX altering mitochondrial ROS production and how 
is it doing so? What is the result of this? These questions could be addressed by using specific 
mitochondrial ROS scavengers to block their effects, and using mitochondrial ROS dyes to 
establish whether their levels are changing in vivo 
6. It was not directly established whether AMPK activation and MnSOD expression were required 
for the improvement in disease severity seen in WBF1 mice treated with MTX. This could be 
addressed by using an AMPK inhibitor such as Compound C concurrently. It is also interesting 
that calorie restriction has been reported to improve disease severity. It might be interesting to 
establish whether this too is because of AMPK activation. 
7. Does activation of AMPK and induction of MnSOD by MTX also occur in leucocytes and does 
this lead to anti-inflammatory effects that might explain MTX's disease modifying action in RA 
and other diseases? This could be studied in a number of ways: first by treating cultured 
leucocytes with MTX; secondly by treating rodents with MTX and isolating and analysing their 
monocytes; and finally by analysing monocytes from patients on MTX. 
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8. If AMPK activation and alteration of mitochondrial metabolism do form a significant part of 
MTX's mechanism of action in both vascular protection and in limiting inflammation, why is it 
that alterations in metabolism have these effects and what are the underlying mechanisms? Are 
there other ways of altering cell metabolism by AMPK activation or mimicking its effects that 
could be used as a strategy for preventing atherosclerosis or treating inflammatory disease?  
 
8.6 Conclusion 
The work contained in this thesis set out to explore how best to protect patients suffering from chronic 
inflammatory diseases from premature CVD as a complication of their illness. I investigated the 
effects of VEGF on EC conditioned by high flow LSS, but did not find a consistent cytoprotective 
response elicited by the two together. However, I have established a novel mechanism of action of 
MTX in the vasculature, with activation of AMPK-CREB signalling, leading to the induction of 
cytoprotective genes. This may contribute to the observed benefits of MTX in reducing 
atherosclerotic complications in patients with RA, and move the perception of this drug from toxic to 
protective. MTX was originally designated an "anti-metabolite" drug because of its inhibition of folic 
acid metabolism. Perhaps in fact low-dose MTX is also altering cell metabolism, but to beneficial 
effect, via AMPK, and so this term should be re-thought. 
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10 APPENDICES 
10.1 Recipes for laboratory solutions 
 
HBSS without glucose 8g NaCl 
   0.4g KCl 
   0.14g CaCl2 
   0.1g MgSO4.7H2O 
   0.1g MgCl2.6H2O 
   0.06g Na2HPO4.2H2O 
0.06g KH2PO4 
0.35g NaHCO3 
(1g d-glucose) 
Make up to 1l with ddH2O and sterile filter 
 
5x Krebs solution 40g NaCl  
1g KCl 
4.63g Na2HPO4.2H2O 
1g KH2PO4 
Make up to 1l with ddH2O  
 
1x Krebs solution 200ml 5x Krebs 
 0.85ml 2.8M MgCl2.6H2O (6.9g in 10ml H2O) 
 131mg CaCl2.2H2O 
 Make up to 1l with ddH2O 
 
5x PSS   38g NaCl 
6.25g NaHCO3 
1.38g KCl 
0.82g KH2PO4 
1.47g MgSO4.7H2O 
11.9g HEPES 
Make up to 1l with ddH2O 
 
1x PSS   200ml 5x PSS 
1.88g glucose 
   0.23g CaCl2.2H2O 
Make up to 1l with ddH2O 
 
Stripping Buffer 31.25ml Tris-HCl 0.5M pH6.8 
50ml 10% SDS 
1.77ml β-mercaptoethanol 
167ml ddH2O (for 250ml) 
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5x TAE  54g trizma base 
27.5g boric acid 
20ml 0.5M EDTA 
Make up to 1l with ddH2O 
 
10x TBS-T 10ml Tween-20 
80g NaCl 
24.2g trizma base 
Make up to 1l with ddH2O; adjust to pH 7.8 
 
  
 204 
 
10.2 Presentations and awards 
The work presented in this thesis was funded by a research training fellowship awarded to me by the 
Wellcome Trust. 
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10.3 Word count 
The word count, excluding references, is 57 650. 
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